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ABSTRACT 
Background: The anaesthetic gas xenon provides long-lasting preservation of 
neuronal function when given several hours prior to neuronal injury: this 
phenomenon is described as preconditioning. However, little is known of the 
mechanisms by which xenon preconditioning mediates its protective effect. Interest 
has focused on the involvement of hypoxia-inducible factor-la (HIF-1 a) in 
preconditioning because: 
(i) Hypoxia activates HIF-la and is an effective preconditioning stimulus; 
(ii) HIF-1 a is a regulator of adaptive responses promoting cellular survival; 
(iii) Several genes that have hypoxia-responsive elements (HRE) for HIF-1 in the 
promoter region are capable of mediating preconditioning (e. g., erythropoietin). 
Therefore, this study speculates on the role of HIF-1 a in xenon preconditioning. 
Method: Separate cohorts of male adult C57 / BL6 mice were preconditioned by 
exposure to 75 % xenon / 25 % oxygen for 2 hours and thereafter immediately 
sacrificed for organ harvesting at 0- 24 hours after xenon preconditioning. Semi- 
quantitative study of HIF-1a and EPO protein expression was performed by Western 
blot analysis, and RT-PCR was used as a measure of gene transcription. 
Results: Xenon preconditioning provokes a time-dependent increase in HIF-1a 
protein in brain as well as kidney. Xenon preconditioning also caused a time- 
dependent increase in EPO (a HIF-1 target gene) transcription and protein 
expression in a corresponding time course to xenon-induced HIF-1 a. To elucidate 
the mechanisms of xenon-induced HIF-la accumulation, the effect of xenon 
preconditioning on HIF-la transcription, translation and degradation was studied. 
Xenon preconditioning does not induce a change in HIF-1a mRNA expression, nor 
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does it significantly attenuate the expression of the PHD2 enzyme, required for HIF- 
1a degradation. To explore translation-dependent pathways, mice were treated with 
rapamycin before xenon preconditioning, to inhibit translation of HIF-1 a through the 
mTOR pathway. Inhibition of this pathway prevented the xenon-induced increase of 
HIF-1a protein. To ascertain whether HIF-la is required for xenon preconditioning, 
siRNA was used to knockdown HIF-la expression in the kidney and xenon's 
renoprotective properties were shown to be abolished. 
Conclusions: Over the same time course as xenon's protection against 
subsequent injury in both brain and kidney, xenon preconditioning induces 
expression of HIF-1a. Increased HIF-1a expression is also associated with 
increased activity as evidenced by enhanced transcription and translation of the 
downstream effector, EPO. Xenon preconditioning does not regulate HIF-1 a at the 
transcriptional level, nor does it inhibit HIF-la degradation. However, these results 
suggest that xenon preconditioning upregulates expression of HIF-1a through 
translation-dependent mechanisms. Furthermore, xenon's action on HIF-1a is 
shown to be causally related to its organ protective effect. If these data can be 
extrapolated to the clinical setting, exposure to xenon would be beneficial prior to 
procedures in which organ perfusion is interrupted, preventing hypoxic-ischaemic as 
well as ischaemic-reperfusion injury. 
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CHAPTER 1 
GENERAL INTRODUCTION 
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1.1 HYPOXIC-ISCHAEMIC ORGAN INJURY 
Hypoxic-ischaemic (HI) organ injury results in functional decompensation 
that contributes to major morbidity and mortality. Myriads of human disease states 
collectively converge on this common end-point that may occur through hypoxia, 
ischaemia, reperfusion following ischaemia, or combinations of these. Given that 
oxygen is an absolute requisite to any aerobic organism, living cells are vulnerable 
to HI injury and will respond in fundamentally similar ways; however, the brain, more 
so than other organs, is remarkably susceptible to HI injury. Stroke alone is the 
most common cause of disability worldwide (Murray, Lopez 1997) and the third 
most common cause of death in the UK . Furthermore, neonatal HI brain injury 
occurs with a worldwide incidence rate varying between 0.4 and 4.5 per 1000 live 
births, where 45 % will have permanent neurological disability or die (Finer et al. 
1981, Wu et al. 2004). The indisputable clinical importance of HI injury has, through 
the decades, prompted intensive investigation to precisely identify the underlying 
pathogenic mechanisms in order that effective therapies may be developed. 
Accordingly, the description that follows focuses on the vulnerability of the brain to 
HI injury and those mechanisms that may be plausible targets of therapy. 
1.2 HYPOXIC-ISCHAEMIC CEREBRAL INJURY 
The healthy human brain is the master controller of body functions as 
diverse as bladder control to creative thinking. It derives its energy needs almost 
entirely through oxidation of glucose and, therefore, relies on the cerebral blood flow 
(CBF) to continuously deliver these substrates, for sustaining physiological cell 
function and metabolism (Back 1998). A decrease in CBF, e. g. through arterial 
occlusion, can result in damage distal to the obstruction, where compromises in 
neuronal oxygenation initiates a series of functional, structural and biochemical 
changes that conclude with cell death and brain damage (Bandera et al. 2006). 
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1.2.1 The ischaemic penumbra: an intriguing paradox 
HI injury can result in a structure-less necrotic core of complete infarction 
that is irreversibly damaged. The surrounding peri-infarct area that adjoins dead 
with normal brain tissue receives a limited blood supply and is termed the ischaemic 
"penumbra, " a description also used for the hazy halo of light around a full lunar 
eclipse (Astrup, Siesjo & Symon 1981). 
The ischaemic penumbra presents itself as the more clinically important and 
intriguing area of interest in HI pathophysiology. Non-invasive imaging studies have 
shown that the infarct core, if left unhindered, grows to engulf the penumbra and 
worsen (Hossmann, Hoehn-Berlage 1995). Paradoxically, however, the experience 
of some patients having suffered from an HI insult has shown that incurred 
neurological deficits may sometimes resolve. A well-received postulation for this 
post-injury healing is based on observations that loss of structural integrity occurs 
with more severe hypoxia than that required for loss of function (Astrup, Siesjo & 
Symon 1981); therefore, the penumbral region is regarded as "structurally intact yet 
functionally paralysed" after the HI insult (Hossmann 2006) and may recover 
through plausible mechanisms, such as the restoration of blood flow through 
neighbouring collateral vessels, or modifications in neuronal metabolism that 
accommodates the lowered blood supply (Astrup et al. 1977). Though heavily 
constrained by time, it is the ischaemic penumbra that therapies target to mitigate 
the symptoms of HI injury. 
Furthermore, a linear relationship between CBF and differential thresholds of cell 
viability has been established. Evaluation of perfusion imaging studies in animal 
models estimate that the threshold for the ischaemic penumbra correlates to a 
reduction in CBF to 40 % of normal, a level that corresponds to failure of cortical 
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evoked potentials that indicate loss of electrical function; irreversible brain damage 
from infarction occurs with CBF reduced below 15 % of normal, and is associated 
with a massive elevation in extracellular potassium, indicating membrane failure and 
loss of structural integrity; complete CBF interruption will culminate in cell death 
within only a matter of minutes (Back et al. 1996) (Figure 1). 
1.2.2 The evolutionary phases of hypoxic-ischaemic injury 
The process of HI injury is often described as evolutionary, progressing 
through three main phases. The initial pathogenic insult establishes the acute 
phase, causing immediate injury within minutes, directly inducing energy failure and 
cell membrane depolarisation to form a necrotic infarct core. The sub-acute phase 
lasts for the next 4-6 hours and is characterised by the expansion of the infarct 
core volume to engulf the adjacent ischaemic penumbra. Lastly, injury proceeds to a 
delayed, or reperfusion, phase that occurs during the recovery period lasting for 
days or weeks as injury further progresses, with secondary events such as 
inflammation and delayed cell death (Siesjo 2008) (Figure 2). 
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Infarct 
core Penumbra 
Figure 1. The ischaemic penumbra 
rU 
co 
Infarct Penumbra 
core 
This cartoon (not to scale) illustrates the regions of the infarct core and the ischaemic 
penumbra. Following hypoxic-ischaemic injury, the infarct core forms as a result of a critical 
reduction in CBF, leading to energy failure and cell death. The ischaemic penumbra forms 
as a result of mild to moderate reductions in CBF, which results in structurally intact, but 
functionally paralysed, tissue. Abbreviations: CBF, cerebral blood flow. Modified from (Lo 
2008). 
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Ischaemic penumbra   
Infarct core   
Minutes Hours 
Figure 2. Evolution of the infarct core 
Days and weeks 
This cartoon illustrates the progression of an infarct core after HI injury (not to scale). The 
acute phase occurs within minutes after the initial HI insult. The sub-acute phase occurs 
over the next 4-6 hours, with a rapid increase in infarct core volume, and decrease in 
penumbra volume. The delayed, or reperfusion, phase occurs over the following days and 
weeks, and is marked by inflammation and delayed cell death. 
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1.2.3 The molecular mechanisms of infarct progression 
Numerous interconnected mechanisms take part in the processes of HI 
injury and, therefore, it is appreciated as a complex heterogeneous disorder whose 
development is characterised by the severity, extent and timing of the insult, the age 
of the brain, as well as the nature of the subsequent reoxygenation or reperfusion 
phase (Alvarez-Diaz et al. 2007). Therapeutic strategies addressing this 
heterogeneity are more likely to warrant further investigation, and may be in the 
form of a combination therapy as typified in certain cancer and HIV treatment 
regimes (Aronowski et at. 2003, Lyden et at. 2000), or as a single agent with 
widespread action as exemplified through the phenomenon of preconditioning 
(Ratan et al. 2004). 
1.2.3.1 Excitotoxicity 
At the cellular level, interruption in oxygen and glucose delivery prompts a 
complex cascade of deleterious biochemical events (a simplified diagram of the key 
events that take place is shown in Figure 3). Oxygen deprivation prevents oxidative 
phosphorylation and, therefore, rapidly obliges mitochondria to switch from aerobic 
to anaerobic metabolism, an energy inefficient process that rapidly exhausts 
adenosine triphosphate (ATP) reserves and accumulates lactic acid. This failure in 
energy, or ATP, generation results in cell membrane depolarisation as ATP- 
dependent transcellular sodium-potassium pumps cease to function; with loss of 
membrane polarity, excitatory and inhibitory neurotransmitters are released to act at 
their respective receptors, the most notable of these being glutamate (Shalak, 
Perlman 2004). 
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Glutamate, the principal excitatory amino acid in the mammalian central nervous 
system (CNS), is an agonist at post-synaptic ionotropic glutamate receptors, such 
as the N-methyl D-aspartate (NMDA) receptor. NMDA receptors have regions not 
only of agonist activity, but also of antagonist activity (i. e. magnesium) and are 
cation channels highly permeable to sodium (responsible for depolarisation), and 
calcium (capable of stimulating numerous enzyme systems) (Dirnagl, ladecola & 
Moskowitz 1999). NMDA receptors play a dichotomous role where they are vital for 
brain function and underlie formation of memory and learning (Bliss, Collingridge 
1993) and yet, by contrast, their intense and acutely unrelenting activation results in 
neuropathology and cell death (Lipton, Stamler 1994). 
Glutamatergic neuronal activity has been shown by magnetic resonance 
spectroscopy to be tightly coupled to glucose metabolism (Sibson et al. 1998). 
Therefore, energy failure disables glutamate regulation and its excessive efflux onto 
the NMDA receptor facilitates depolarisation and intracellular calcium overload, 
producing glutamate neurotoxicity, also referred to as "excitotoxicity" (Olney 1971). 
1.2.3.2 Calcium toxicity 
Calcium is a universal intracellular second messenger that activates 
numerous enzyme reactions. Physiological cytosolic calcium concentration is 
extremely low with steep concentration gradients existing between the cytosol and 
the extracellular compartment, as well as between the cytosol and the endoplasmic 
reticulum (Hossmann 2006). During HI injury, cytosolic calcium accumulates to a 
major degree, by glutamate-mediated NMDA receptor stimulation, but also by 
interrupted calcium efflux from energy failure, as well as through mitochondrial and 
endoplasmic reticulum calcium release (Shalak, Perlman 2004). Elevation of 
intracellular calcium leads to a sharp rise in its activity in multiple calcium-dependent 
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effector pathways with formation of oxygen free radicals as by-products; these 
contribute to injury by fragmenting the cell membrane and disrupting DNA, inevitably 
triggering irreversible death of cells (Grow, Barks 2002). 
1.2.3.3 Oxidative stress 
Free radicals play an important role in the physiological control of cell 
function, for example, through participation in redox homeostasis as well as signal 
transduction pathways (Droge 2002). However, oxidative stress is a general term 
referring to pathological oxidative metabolism that, rather than generating ATP, 
produces excessive free radicals and compromise cell survival. 
In physiologically functioning mitochondria, approximately 90 % of oxygen supplied 
to the cell will be involved in the production of ATP via the electron transfer chain in 
the inner mitochondrial membrane. The remainder of the free oxygen will form 
superoxide anions that are reduced to water through antioxidants, such as 
superoxide dismutases and glutathione peroxidase, and rendered non-damaging. 
Following hypoxia-ischaemia, energy failure and consequent calcium toxicity 
interferes with the mitochondrial electron transfer chain that, often with 
accompanying anti-oxidant depletion, results in accumulation of superoxides as well 
as more reactive species, such as the hydroxyl radical, by a Fenton reaction (Inder, 
Volpe 2000). Oxidative stress is pertinent to the reperfusion phase of hypoxia- 
ischaemia. The re-establishment of perfusion to a previously damaged cell does not 
bring back equilbirum but instead the oxygen floods into dysfunctional mitochondria 
and further contributes to free radical accumulation. High concentrations of free 
radicals promote cell damage by DNA fragmentation, lipid peroxidation of the cell 
membrane and intracellular organelles (Saito et al. 2005), and disruption of 
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membrane and pump function that leads to more glutamate efflux and, therefore, 
further perpetuation of excitotoxicity (Grow, Barks 2002). 
1.2.3.4 Nitric oxide toxicity 
Though the various molecular injury pathways in this account have been 
described as isolated entities they are inextricably related, as studies on nitric oxide 
further demonstrate. Nitric oxide (NO), or nitrogen oxide, is one of the few gaseous 
messenger molecules in the body and plays a role in functions such as blood vessel 
homeostasis. NO is produced from the reaction between L-arginine and nitric oxide 
synthases (NOS), of which three isoforms have been identified; neuronal and 
endothelial NOS (nNOS and eNOS, respectively) activation are dependent on 
intracellular calcium concentration, whereas inducible NOS (iNOS) is activated by 
cytokines in neurons and endothelial cells, as well as astrocytes and microglia 
(Samdani, Dawson & Dawson 1997). 
Following hypoxia-ischaemia, NO exhibits physiological and pathological functions, 
acting to promote, as well as protect against, injury; the net effect, therefore, is 
dependent on the various isoforms of NOS activated, and this in turn is dependent 
on the location of insult, a situation that is unpredictable. Injury-mediated production 
of neuronal NO has been shown to modify the NMDA receptor to enhance calcium 
influx and excitotoxic damage (Sorrentino et al. 2004). In addition, the rise in 
intracellular calcium induces further NO generation that, in combination with 
superoxide, generates the potent peroxynitrite radical for further facilitation of 
glutamate release (Shalak, Perlman 2004). Peroxynitrite also undergoes further 
conversion to form the hydroxyl radical and nitrogen dioxide, enhancing oxidative 
stress through oxidation and nitration of DNA, proteins and lipids (Beckman, 
Koppenol 1996). Conversely however, calcium-dependent NO production in 
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endothelial cells via eNOS leads to vasodilation, blood flow, prevention of 
thrombosis and therefore alleviation of injury (Dalkara et al. 1994). Several days 
following reperfusion, iNOS expression has been shown to increase in glia and 
neutrophils with the consequential NO left to flood the ischaemic region and 
rtr tribute to delayed neurotoxicity as well as potentiating pro-apoptotic pathways 
(adecola et al. 1995). 
1.2.3.5 Inflammation 
An inflammatory response has been shown to be evoked by HI injury, with 
iu ýI. rleukin-1 ß and tumour necrosis factor-a messenger RNA (mRNA) expressed 
from one hour after hypoxia-ischaemia in rats (Hagberg et al. 1996). Pro- 
infloýý rimatory cytokines may contribute to injury progression directly, through 
stimulation of iNOS and free radical generation, as well as indirectly, by provoking 
cells to release further glutamate (Shalak, Perlman 2004). However, the role of 
inflammatory mediators is not straight forward and whether inflammation is 
beneficial or deleterious, may depend on the severity and extent of hypoxia- 
. sohaemia, and the timing of the inflammatory response; an early response may 
promote injury and a later response may be beneficial for initiating repair processes 
(Wang, Tang & Yenari 2007). 
1 .2 . 3.6 
Cell death 
The inevitable end fate of unperturbed HI injury occurs through both necrotic 
and apoptotic mechanisms. A higher ratio of necrotic cell death is evident with more 
severe insults and also in the adult brain compared to the neonatal brain (Bonfoco 
et al. 1995) yet, great variability exists from one individual to another. Necrosis and 
apoptosis produce cell death through separate and distinct mechanisms. Necrotic 
,, (-Il death is characterised by passive cell swelling, disruption of cytosolic 
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organelles, loss of internal homeostasis, membrane lysis, release of cell contents, 
and activation of inflammation (Krysko et al. 2008). Apoptosis, by contrast, is an 
active process that is propagated through a well-orchestrated series of events 
defined with specific features such as cell shrinkage, membrane blebbing, nuclear 
pyknosis chromatin condensation and DNA fragmentation, without the occurrence of 
inflammation (Edwards, Mehmet 1996). Early excitotoxicity during the acute phase 
of injury has been shown to result in rapid necrotic cell death to form the initial 
infarct core. The surrounding ischaemic penumbra however, is subjected to milder 
excitotoxicity, oxidative stress and inflammation, resulting in delayed cell death that 
is more characteristic of apoptosis (Mergenthaler, Dirnagl & Meisel 2004). A 
simplified diagram of the key events is illustrated in Figure 3. 
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Figure 3. Simplified schematic representation of molecular injury pathways 
that lead to cell death 
Energy failure from hypoxic-ischaemic injury disables glutamate regulation, where its 
excessive efflux onto the NMDA receptor facilitates depolarisation and intracellular calcium 
overload, resulting in excitotoxicity. Accumulation of intracellular calcium results in activity of 
numerous calcium-dependent effector pathways, which results in the formation of ROS and 
NO, contributing to oxidative stress. Free radicals promote cell damage by DNA 
fragmentation, lipid peroxidation of the cell membrane and intracellular organelles. 
Moreover, free radicals disrupt cell membrane pump function, which results in further 
glutamate efflux and excitotoxicity. An inflammatory response is initiated from 1 hour after HI 
injury and contributes to injury progress by further induction of ROS and NO production, as 
well as glutamate release. Left unperturbed, HI injury results in cell death. Abbreviations: 
[Ca2+]I, intracellular calcium concentration; HI injury, hypoxic-ischaemic injury; NMDAR, N- 
methyl-D-aspartate receptor; NO, nitric oxide; ROS, reactive oxygen species. 
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1.3 THERAPEUTIC STRATEGIES VERSUS HYPOXIC- 
ISCHAEMIC INJURY 
In principle, HI injury is reversible after an insult through replenishment of 
oxygen and nutrient delivery but this is heavily constrained by time (Hossmann 
2007); as such, alternative therapeutic strategies are needed. Endogenous 
counteracting mechanisms that ameliorate injury do exist and these will be later 
discussed. Therapeutic strategies, in general, refer to pharmacological interventions 
that temporarily alleviate the deleterious effects of injury that lead to cell death; this 
is accomplished by increasing the "window of opportunity" prior to restitution of 
blood supply, interfering with expansion of the core infarct as well as preventing 
reperfusion-induced secondary cell death (Ginsberg 1997). Pharmacological 
salvation is beyond the grasp of the necrotic infarct core and is therefore aimed at 
penumbral preservation alone. 
1.3.1 Target-directed therapies 
Elucidation of the molecular entities contributing to HI injury and progression 
to cell death has formed the basis for the development of target-directed therapies. 
Existing evidence demonstrates that the numerous molecular participants of injury 
contribute to cell death through mutually exclusive pathways (Won, Kim & Gwag 
2002). Antagonists, inhibitors and blockers of glutamate, NMDA, calcium, NO, other 
free radicals (or antioxidant therapies), inflammatory mediators, apoptotic factors, as 
well as growth factors and trophic agents such as nerve growth factor (NGF) 
(Chiaretti et al. 2008), insulin-like growth factor-1 (IGF-1) (Hung et al. 2007) and 
brain-derived neurotrophic factor (BDNF) (Han, Holtzman 2000), have all been 
extensively examined as a means to relieve HI injury. The proven neuroprotective 
efficacy of therapies directed against their pathogenic target is regrettably also 
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compounded, with further investigation, to have detrimental effects on the other 
r) thogenic pathways that take part in injury progression to cell death. This 
Nghlights the need for combinatorial therapies, or single agent therapies that exhibit 
multiple actions, for maximal prevention of cell death. Importantly however, 
regardless of therapy efficacy, alone or in combination, these interventions are of 
limited consequence or relevance if the tissue is not adequately reperfused in a 
tiro tlý ly fashion. 
1.3.2 Clinical failure 
Despite substantial experimental evidence of certain therapies acclaiming 
preclinical promise, their performance in the clinical arena has resulted in a litany of 
fru _arating disappointments. These failures further exacerbate the difficulty in the 
hunt to provide therapies relevant to humans, as pharmaceutical industries are 
cautious to offer their financial support without proof of principle for a return on their 
investment. Several plausible explanations have been raised with respect to this 
translational difficulty, from animals to humans, at times even questioning whether 
b-, i: -x understanding of injury concepts may be more fanciful than factual; it seems 
urv kely, however, that over thirty years of rigorous research into HI injury should be 
discounted as invalid. Reflecting on current limitations and flaws displays both 
preclinical and clinical experimental shortcomings; addressing these may offer a 
glimmer of cautious optimism for the long-suffering perseverance required in the 
search to attain future therapeutic success. 
The use of animals, naturally, has its limitations. Findings in the ever popular rodent 
model may not be transferable in its entirety to humans because of interspecies 
variability. Even within the same animal species, the strain will affect outcome from 
the same model of injury; mild, moderate or severe injury is observed in SV129, 
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C57B or FVB mice subjected to the same insult, respectively (Fox, LeVasseur & 
Faden 1999). Therefore for experimental rigour, animals are constrained to be 
identical in strain, genetics and sex, whereas all strata of human population can be 
affected by hypoxia-ischaemia. Furthermore, animals may sometimes be excluded 
from analyses if the prescribed injury has fallen out of the experimental criteria or if 
they generate anomalous results. Anaesthetic use, a legal necessity in animals, can 
compound the action of the test therapy as well as injury-mediated cell death. 
Furthermore, consideration to the pharmacology of therapies has been poor or 
absent altogether, lacking in evaluation of dose response, therapeutic window. 
pharmacokinetics or pharmacodynamics (Wahlgren, Lyden 2000). 
A key issue in human studies has been the delay in delivering therapies after injury. 
Glutamate antagonists, for example, may have been administered after the acute 
injury phase and excitotoxic damage would have already been established (Hoyte et 
al. 2004). Lastly, though by no means exhaustively, the outcome of some human 
trials may have detected a significant response to therapy if patient enrolment had 
been markedly increased for adequate statistical power (Green 2008). 
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1.4 PRECONDITIONING: A THERAPEUTIC STRATEGY 
VERSUS IMPENDING HYPOXIC-ISCHAEMIC INJURY 
In most situations, the onset of injury is unpredictable but in those clinical 
settings in which it can be anticipated, for example, during brain or kidney surgery, 
pre-emptive measures may be considered. It has been proposed from as early as 
1943 that rats subjected to small graded amounts of injury, induced by hypoxia, 
acquired a resistance enabling them to withstand an otherwise fatal degree of 
trauma (Noble 1943). It was not until 1986, however, that the concept of 
"preconditioning" was officially introduced to the scientific community, when Murry 
and colleagues demonstrated through a series of landmark experiments on canine 
hearts that, contrary to traditional and intuitive thinking, ischaemia is not always 
harmful; pre-treatment with repeated brief episodes of ischaemia interwoven with 
reperfusion protected the myocardium from a subsequent, prolonged ischaemic 
insult, able to reduce the size of myocardial infarct by as much as 75 % compared 
to controls (Murry, Jennings & Reimer 1986). In the 20 years since its first 
discovery, Murry's seminal paper is currently the most cited article published by 
Circulation, and a Pubmed search reveals that there are, to date, in excess of 2000 
publications directly attributed to the profound effects of preconditioning. 
Interestingly, however, the experiments of Murry and colleagues somewhat 
overshadowed the work of Schurr, earlier that same year, demonstrating the 
adaptation of adult rat hippocampal slices to anoxia by hypoxia (Schurr et al. 1986). 
Since, the protective effect of preconditioning has been demonstrated in all organs, 
with the first demonstration of cerebral ischaemic preconditioning against ischaemic 
injury by Kitagawa (Kitagawa et al. 1990), as well as all species tested from bacteria 
to mammalian cells (Yellon et al. 1998). 
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1.4.1 Terms and definitions 
1.4.1.1 Preconditioning 
There is no established definition, as such, for preconditioning but it may be 
regarded as the brief presentation of a non-injurious, sub-lethal stressor to induce 
protection against a subsequent prolonged, injurious and potentially lethal stress 
(Gidday 2006). Preconditioning confers "tolerance" to living cells, employing their 
fundamental endogenous capability in resisting recurrent stress through 
evolutionarily conserved, natural adaptive processes (Dirnagi, Simon & Hallenbeck 
2003). 
1.4.1.2 Cross tolerance 
While the original studies involved hypoxia or ischaemia, the early 
elucidation of the molecular mechanisms involved in the process of HI 
preconditioning raised the possibility of manipulating those targets 
pharmacologically. Therefore, a plethora of agents have been investigated; the most 
clinically promising of these are anaesthetic agents because of their possible 
application in elective, high-risk surgical patients. The putative therapeutic utility of 
anaesthetic preconditioning, especially for injury to the CNS, exceeds that induced 
by a strategy involving hypoxia and/or ischaemia because the latter strategy has a 
narrower safety margin. These studies introduced the notion of "cross tolerance, " 
where preconditioning against HI injury may be induced not only by hypoxia or 
ischaemia but also by a diverse variety of metabolic or physical stressors, or 
pharmacological agents (Tauskela et al. 2001). However, the cross-induction of 
pharmacological-induced tolerance may differ in efficacy compared with hypoxic or 
ischaemic preconditioning and the protection is often governed by multiple 
mechanisms. 
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1.4.1.3 Postconditioning 
Postconditioning is a relatively novel concept. Ischaemic postconditioning 
has been mainly experimentally demonstrated in the heart, where intermittently 
obstructing flow following post-ischaemic reperfusion leads to protection (in contrast 
to ischaemic preconditioning, which occurs before the onset of ischaemia). The 
appeal of postconditioning is its increased clinical applicability to patients and 
appears to occur through similar mechanisms as preconditioning. Clinical trials have 
shown postconditioning to be an efficacious therapy in patients with acute 
myocardial infarction (Thibault et al. 2008) and has more recently also been proven 
effective in the brain (Wang et al. 2008b). 
1.4.1.4 Pharmacological preconditioning 
Mizumura and colleagues in 1995 demonstrated that pharmacological 
agents are able to precondition (Mizumura, Nithipatikom & Gross 1995). This form 
of preconditioning generally refers to chemical compounds that mimic hypoxia 
through interference of cellular respiration and oxygen sensing mechanisms; these 
hypoxia mimetics include the respiratory chain inhibitor nitroproprionic acid 
(Wiegand et al. 1999), the HIF-la inducers desferrioxamine and cobalt chloride 
(Jones et al. 2008), as well as mitochondrial potassium ATP channel openers such 
as diazoxide (Mayanagi et al. 2007). Importantly, pharmacological preconditioning is 
distinct from target-directed therapies administered prior to injury; while these 
therapies interfere with specific components of the injury cascade, pharmacological 
preconditioning reduces injury by adapting the whole organism to a more resilient 
phenotype. 
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1.4.1.5 Anaesthetic preconditioning 
A notable form of pharmacological preconditioning is anaesthetic 
preconditioning where certain inhalational anaesthetics, such as halothane, 
isoflurane and sevoflurane, have been demonstrated as effective inducers of acute 
mnd delayed preconditioning (Cason et al. 1997). Anaesthetic preconditioning has 
iIso been successfully trialled in humans and is a promising therapy for surgical 
patients at high risk of developing ischaemic complications. Particularly relevant to 
this study, neuroprotection by preconditioning with xenon has recently been 
demonstrated in our laboratory (Ma et al. 2006), although the underlying molecular 
mechanisms remain to be elucidated. 
I42 Examples of preconditioning in the clinical setting 
Several clinical trials exploring the role of preconditioning as a 
neuroprotectant have shown that transient ischaemic attacks (TIAs) protect the 
brain against stroke (Moncayo et al. 2000). However, these results have been 
challenged by the TIA study in North Carolina (Johnston 2004). In the heart, large 
clinical trials have displayed more robust evidence, where angina has been shown 
to reduce the size of myocardial infarcts, as well as decrease arrhythmias and 
improve left ventricular function, when compared to non-angina patients. 
Furthermore, the clinical exploitation of endogenous protection is demonstrated 
during angioplasty surgery, where brief balloon inflation has been shown to protect 
the heart from further inflations (Faries et al. 2008). The inhalational anaesthetic, 
isoflurane, has also been used during coronary artery bypass graft surgery, and was 
shown to be associated with improved long-term outcome (Yu, Beattie 2006). 
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1.4.3 The phases of preconditioning 
Despite the array of stimuli able to induce preconditioning, certain hallmarks 
exist. Adaptation to a tolerant phenotype is biphasic, occurring as two temporally 
distinct types of preconditioning, namely acute and delayed preconditioning, that 
differ in their mechanisms. Acute preconditioning offers potent protection and occurs 
within minutes and persists for 1-3 hours after introduction of the preconditioning 
stimulus; it is short-lived and provides protection as a result of changes in ion 
channel permeabilities, protein phosphorylation and other post-translational 
modifications (Gidday 2006). Delayed preconditioning, first described by Marber and 
colleagues (Marber et al. 1993) is less potent than the acute form, but corresponds 
to at least a thirty-fold longer duration and broader level of protection (Stein et at. 
2004), manifesting slowly from 4- 24 hours after the preconditioning stimulus and 
protecting cells for up to 72 hours against injury (Marber et at. 1993). This 
phenomenon is best appreciated as one that may require changes in gene 
expression and activation and, in contrast to acute preconditioning, is dependent on 
de novo protein synthesis (Meldrum 1997). Therefore, delayed preconditioning does 
not merely compete to neutralise injury cascades but serves to genetically 
11 reprogramme" the response to HI injury (Gidday 2006). 
1.4.4 The mechanisms of delayed preconditioning 
The endogenous protective processes that mediate delayed preconditioning 
are topical and have been the subject of many reports. The majority of researchers 
are in agreement that there is not one exclusive pathway leading to a 
preconditioned state. Evidence supports that preconditioning requires the concerted 
participation of numerous cell types, molecules and diverse effector mechanisms; 
these fundamentally end in reprogramming the genomic response to injury, from cell 
death to survival, with subsequent translation of proteins that promote oxygen 
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delivery and metabolism as well as cell function, thereby preventing the induction 
and the propagation of injury cascades. Bewildering assortments of molecules have 
been linked to preconditioning but no definitive or systematic understanding 
currently exists. However, it is possible to observe a degree of mechanistic similarity 
required to achieve a phenotype that is more resilient to hypoxia-ischaemia in 
different organs and even across several species. 
The various preconditioning stimuli that have been identified may be loosely 
classified as non-pharmacological, such as hypoxia and ischaemia, or 
pharmacological, through noxious agents like inflammatory mediators; these stimuli 
cause energy and metabolic alterations that result in the generation of triggers, such 
as NO and reactive oxygen species (ROS), alerting the cell to the presence of 
"danger" and putting into action defensive measures that counteract any further 
harm. Triggers activate an exquisitely complex network of intracellular signaling 
pathways with numerous protein kinases and transcription factors, involved in cell 
growth and survival, implicated to play important transduction roles; these include 
protein kinase C (PKC) (Beguin et al. 2007, Weber et al. 2005a), mitogen-activated 
protein kinases (MAPKs) (Bu et al. 2007, Weber et al. 2005b), janus kinases 
(JAKs) (Xuan et al. 2001), signal transducers and activators of transcription (STATs) 
(Butler et al. 2006), nuclear factor-kappa B (NFKB) (Chen et al. 2008, Valen et al. 
2000), and hypoxia-inducible factor-1 alpha (HIF-1a) (Eckle et al. 2008). Many of 
the downstream effector mechanisms of preconditioning directly counteract cell 
death by shifting the excitatory / inhibitory balance toward inhibition and generation 
of ROS scavengers, anti-apoptotic proteins and inflammatory protein antagonists. 
Effectors may also improve energy supply by improving energy metabolism and 
blood supply, through generation of vascular endothelial growth factor (VEGF) 
(Addya et at. 2005), erythropoietin (EPO) (Malhotra et al. 2006) and endothelium- 
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derived NO (Xuan 2007), as well as enhancing survival through growth factors and 
trophins such as BDNF (Lee et al. 2008, Ma et al. 2006). 
Several extensive enquiries have demonstrated that reoxygenation or reperfusion, 
as occurs during hypoxia or ischaemia, with or without preconditioning, naturally 
activates an oxygen and redox sensitive family of transcription factors known 
collectively as hypoxia-inducible factors (HIFs) that may be implicated in ischaemic 
preconditioning. Whether HIFs play a role in xenon-induced preconditioning will be 
explored in this thesis. 
1.5 HYPOXIA-INDUCIBLE FACTORs 
The transcriptional activator HIF-1 is widely appreciated as the master 
regulator of oxygen homeostasis and plays a crucial role in the physiological 
response to counteract hypoxia; accordingly, modulation of its activity is a potent 
way to improve the outcome of a broad range of hypoxia-related pathologies, 
including HI injury. The discovery of HIF-1 arose through the observation that 
hypoxia, anaemia, polycythaemia or cobalt chloride administration induces 
transcription of the EPO gene as well as production of the biologically active protein, 
measured by an increase in serum EPO levels and accompanying elevation in 
oxygen carrying capacity (Goldberg, Dunning & Bunn 1988). Subsequent studies 
coordinated by Semenza et al. (1991) facilitated the identification of 50 base pair 
sites located in the 3'-flanking sequence of the EPO gene (now termed the hypoxia- 
responsive element (HRE)) that were able to bind hypoxia-inducible nuclear factors. 
Today, the hypoxia-inducible nuclear factor is known as HIF-1 (Semenza 1994). 
HIF-1 was later demonstrated not to be unique to the EPO gene but able to 
bind 
DNA and activate gene transcription in non-EPO producing cells, providing the initial 
line of evidence that HIF-1 DNA binding capacity is based on a common recognition 
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sequence of a ubiquitous cell response to hypoxia. HIF-1 transcription factor is 
fundamental to determining the life or death of various cells. It orchestrates not only 
the physiological response to counteract hypoxia, but also normal early embryonic 
vascular development (lyer et al. 1998). 
1.5.1 Molecular structure 
HIF-1 has a heterodimeric structure, composed of a HIF-1a subunit that is 
sensitive to changes in oxygen tension, and a constitutively expressed, 
oxygen-independent HIF-1 ß subunit. Both subunits of HIF-1 are members of the 
basic-helix-loop-helix (bHLH) superfamily of eukaryotic transcription factors; the 
basic domain permits binding to DNA and the helix-loop-helix (HLH) structure, a 
common thread found in many transcription factors, mediates subunit dimerisation. 
HIF-1 also contains a region of amino acid homology termed the per-ARNT-sim 
(PAS) domain found in numerous species including prokaryotes, indicating that HIF- 
1 is highly evolutionarily stable and essential (Wang, Semenza 1995); it may 
function as an auxiliary DNA binding, dimerisation or transactivation domain. The 
acronym PAS represents the first three transcription factors identified in this 
superfamily from the Drosophila melanogaster fruit fly: period (per), a circadian 
rhythm-regulating protein; aryl hydrocarbon receptor nuclear translocator (ARNT), 
the dioxin receptor dimerisation partner; simple minded (sim), a regulator of 
neuronal development (). Incidentally, further elucidation of HIF-1 ß demonstrated it 
to be identical to ARNT differing solely on nomenclature (Semenza 1994). 
In addition to the bHLH-PAS domains localised at the N-terminal half of the HIF-1 
structure, HIF-la also contains two transactivation domains (TADS), one at the N- 
terminus (NTAD) and the second located near the C-terminus (CTAD) of the protein 
structure, required for interaction with the gene transcription co-activators CBP / 
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p300 (Lando et al. 2002). Located between the TADs is the oxygen-dependent 
degradation (ODD) domain that is responsible for the five minute half-life of HIF-1o 
(Salceda, Caro 1997) as it contains "PEST" motifs (sequences rich in proline (P), 
glutamic acid (E), serine (S) and threonine (T)) that are frequently found in proteins 
that display a short half-life, often of less than 2 hours (Rechsteiner, Rogers 1996): 
deletion of the ODD domain results in HIF-1 a stability in the presence of oxygen. 
HIF-la additionally contains a C-terminal nuclear localisation signal (CNLS) that is 
crucial for its transportation into the nucleus (Kallio et al. 1998) (Figure 4). 
HIF-1 a and HIF-1 ß have been found in all human and mouse tissues tested with an 
additional variant of HIF-1 ß, also called ARNT2, found in brain and kidney. Three 
HIF-a isoforms have been identified so far, designated HIF-la, HIF-2a and HIF-3a, 
and all dimerise with HIF-1 p to bind to the hypoxia-responsive element (HRE) of 
target genes. HIF-3a, however, contains an inhibitory PAS domain that lacks 
transcriptional activation capacity and instead acts as a dominant negative regulator 
of HIF-la, by binding to the HIF-la NTAD and inhibiting its DNA binding activity 
(Makino et al. 2001). HIF-2a was discovered from the elucidation of the sequence 
of the human genome; HIF-1a and HIF-2a isoforms share similar amino acid 
identities within the bHLH-PAS and TADs and therefore both dimerise with HIF-1 ß 
and bind to DNA. Despite their structural and regulatory similarities, these two 
isoforms are likely to play unique and non-redundant roles in the organism. The 
HIF-2a structure shows an additional cysteine residue in the basic domain that may 
account for specific redox regulation of DNA binding (Lando et al. 2000), which may 
result in binding to its own unique set of target genes. Evidence suggests that 
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Figure 4. Schematic representation of the domain structures of the hypoxia- 
inducible factor family and sites of regulation in normoxia 
All members of the HIF family of transcription factors contain bHLH and PAS domains, 
required for DNA binding and dimerisation to HIF-1ß. Each of the 3 HIF-a isoforms, contain 
ODDDs and TADs, required for oxygen-dependent degradation and transcriptional activity, 
respectively. However, HIF-3a lacks transcriptional activation capacity, as it contains only 
one TAD and the PAS domain is inhibitory. 
In the presence of oxygen the PHD2 enzyme hydroxylates HIF-la proline residues P402 
and P564, or HIF-2a proline residues P405 and P531, resulting in its degradation. 
Furthermore, asparaginyl hydroxylation by FIH-1 prevents HIF-a subunits from associating 
with transcriptional co-activators, such as CBP/p300. 
Abbreviations: 2-OG, 2-oxoglutarate; A, asparaginyl residue; bHLH, basic helix-loop-helix; 
CBP/p300, CREB binding protein and p300; CTAD, C-terminus transactivation domain; FIH- 
1, factor inhibiting HIF-1; HIF, hypoxia-inducible factor; WAS, inhibitory Per-ARNT-Sim; 
NTAD, N-terminus transactivation domain; ODDD, oxygen-dependent degradation domain; 
P, proline residue; PAS, Per-ARNT-Sim; PHD2, prolyl hydroxylase domain-containing 2 
enzyme. 
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HIF-2a expression is distinct from HIF-1a; whereas HIF-la is ubiquitously 
expressed, HIF-2a is found predominantly in vascular endothelial cells, 
catecholamine producing cells, the kidneys and lungs (Tian, McKnight & Russell 
1997). Although a wealth of knowledge exists for HIF-1 a, the founder of this 
transcription factor family, less is known about HIF-2a but these two isoforms are 
likely to perform some non-overlapping functions. 
1.5.2 Regulation of hypoxia-inducible factors 
Activation of HIF-dependent transcription is chiefly dependent on regulation 
of its HIF-1 a subunit by synthetic and degradative pathways. HIF derives its name 
from hypoxia-mediated induction but many other factors, endogenous and 
exogenous, occurring during both normoxia and hypoxia, are involved in its 
regulation at different junctures. 
1.5.2.1 Transcription of HIF-1 a mRNA 
HIF-1a is encoded by the HIF1A gene located on chromosome 14g21-q24 
(Semenza et al. 1997), with human and mouse HIF-1 a sharing 90 % amino acid, 
and 80 % nucleotide sequence, conservation (Iyer et al. 1998). Sequencing of the 
HIFJA gene has shown the promoter region to be rich in guanine-cytosine (GC) 
content but lacking in thymine-adenine-thymine-adenine (TATA) sequences, and 
the transcription initiation site to contain multiple points for binding of the nuclear 
factor Sp1; these are characteristics frequently observed in ubiquitously expressed 
genes, where Sp1 belongs to a family of transcription factors that maintain basal 
transcription of "house keeping" genes (Samson, Wong 2002). 
HIF-1a mRNA transcription has generally been accepted as constitutively 
maintained regardless of oxygen availability (Kallio et al. 1997). 
More recently 
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however, HIF-1 a mRNA levels have been reported to be transiently increased by 
acute but not delayed hypoxic preconditioning (Shao, Gao & Lu 2005). The reasons 
behind these discrepancies remain unclear but emphasises that though acute and 
delayed preconditioning may utilise similar biochemical components, they occur 
through distinct mechanisms. A possible mechanism for increasing HIF-1a mRNA 
expression may be via the transcription factor nuclear factor kappa B (NFkB), since 
hypoxia is able to activate NFkB (Koong, Chen & Giaccia 1994), and the p50 and 
p65 NFkB subunits have been demonstrated to bind to the promoter region of the 
HIF1A gene, that results in a transient increase in HIF-1a mRNA expression 
(Belaiba et al. 2007). Interestingly however, It has been postulated that the promoter 
region of the HIF1A gene, upstream from the transcription initiation site, may 
contain sequences that activate as well as inhibit its own transcription in a cell type- 
specific manner (Minet et al. 1999); furthermore, hypoxic upregulation may occur 
without stabilisation of the HIF-1 a mRNA into translation (Wenger et al. 1997). To 
date, however, knowledge concerning the effect of anaesthetic preconditioning on 
HIF-1 a mRNA expression is scarce; the use of isoflurane in the hepatoma cell line 
(Hep3B) was shown to induce HIF-1a protein but not HIF-1a mRNA (Li et al. 2006). 
1.5.2.2 Translation of HIF-1 a protein 
Translation of most eukaryotic proteins requires the interaction of its mRNA 
5' CAP sequence with the eukaryotic initiation factor (elF) -4F translation initiation 
complex that on assembly, recruits ribosomal units to commence translation, after 
recognising the AUG initiation codon (Scheper, Voorma & Thomas 1992). eIF-4F 
consists of three components: the CAP binding protein eIF-4E, the scaffold protein 
eIF-4G and the ATP-dependent helicase eIF-4A. The rate-limiting factor of protein 
synthesis is dependent on eIF-4E binding proteins (4E-BPs) that sequester and 
strictly regulate elF-4E availability for the translation initiation complex 
formation. 
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4E-BP phosphorylation is mainly controlled by signalling from the mammalian target 
of rapamycin (mTOR) pathway that lowers its affinity for elF-4E, resulting in 
assembly of elF-4F and facilitation of protein synthesis (Gingras, Raught & 
Sonenberg 2001) (Figure 5). 
In aiming to reduce energy consumption, hypoxia is generally associated with 
inhibition in protein translation, which aims to sustain survival during low ATP 
production. This is achieved through a decrease in mTOR signalling and, therefore, 
hypo-phosphorylation of 4E-BP and associated eIF-4E sequestration (Richter, 
Sonenberg 2005). However, a decrease in HIF-1a mRNA translation is spared 
during hypoxia, through an additional mechanism independent of mTOR and elF-4E 
binding to the mRNA 5' CAP sequence. This alternative mode is through an internal 
ribosome entry site (IRES), a nucleotide sequence located in the 5' untranslated 
region (UTR) that allows for CAP-independent translation; this occurs by allowing 
ribosome binding directly to the mRNA. Few mammalian mRNAs contain IRES 
except for those whose translation is required during stresses, such as hypoxia or 
glucose deprivation (Lang, Kappel & Goodall 2002). 
Stimulation of HIF-la protein translation has been shown to be inducible by growth 
factors, oncogenes and cytokines. Expression of epidermal growth factor (EGF) in 
human prostate cancer cells lacking the phosphatase and tensin homolog (PTEN) 
tumour suppressor has been observed to result in autocrine stimulation of tyrosine 
kinase receptor signalling with downstream induction of HIF-1a protein expression; 
this growth factor-induced HIF-1a is sensitive to the phosphoinositide-3 kinase 
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Figure 5. The mammalian target of rapamycin protein translation initiation 
pathway 
This is a simplified schematic diagram illustrating the mTOR protein translation initiation 
pathway. mTOR-dependent signalling may be regulated by growth factors and nutrients, and 
protein kinase pathways such as the P13K / Akt pathway. Akt activity phosphorylates TSC2, 
which inhibits the TSC1/2 complex and subsequently, disinhibition of Rheb/GTP. Modulation 
of mTOR leads to phosphorylation of 4E-BP and S6K. 4E-BP phosphorylation lowers its 
affinity for the CAP binding protein, elF-4E. Availability of elF-4E leads to the assembly of a 
translation initiation complex, facilitating protein synthesis. Through an independent 
pathway, S6K activity also leads to increased protein translation of 5' TOP mRNAs. HIF-1a 
contains both 5'CAP and 5'TOP sequences. Abbreviations: P13K, phosphoinositide-3 
kinase; TSC, tuberous sclerosis complex; ATP, Adenosine triphosphate; mTOR, mammalian 
target of rapamycin; 4E-BP, eIF-4E-binding protein; eIF-4E, eukaryotic initiation factor-4E; 
S6K, S6 kinase; TOP, 5'-terminal oligopyrimidine-rich tract. 
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(PI"TK) and mTOR inhibitors, LY294002 and rapamycin respectively (Zhong et al. 
2000). Additionally, heregulin and insulin-like growth factor-1 (IGF-1) induce HIF-1 a 
protein expression along with activity of the p70 S6 kinase and elF-4E that are 
known downstream effectors of the PI3K-mTOR pathway, with an increase in HIF-1 
target gene expression also (Semenza 2000). 
1 , 5.2.3 Post-translational degradation of HIF-1 a 
1,5.2.3.1 Prolyl hydroxylation 
HIF-1 a is regulated by oxygen concentration where it is virtually 
undetectable at 21 % oxygen. During normoxia, both HIF-1a and HIF-1ß are 
constitutively transcribed and translated, but HIF-1a is also post-translationally 
r1 , edified to be constitutively degraded, which results in abrogation of HIF-1 
transcriptional activity. Degradation begins by the hydroxylation of two proline 
residues (P402 and 564) (Masson, Ratcliffe 2003) embedded in conserved amino 
acid motifs within the HIF-la ODD domain. This prolyl hydroxylation reaction was 
first unearthed in the model organism Caenorhabditis elegans to be catalysed by 
the egg laying defect-9 (EGL-9) dioxygenase enzyme, where egl-9 mutant worms 
displayed constitutive HIF-la expression (Epstein et al. 2001). Since then, three 
mammalian egl-9 homologues have been identified and named prolyl hydroxylase 
domain containing enzymes 1,2 and 3 (PHD 1,2 and 3) with a fourth PHD recently 
identified (Oehme et al. 2002). These enzymes are members of the 2-oxoglutarate 
(2-GG) -dependent dioxygenase superfamily and share biochemical similarities to 
the collagen prolyl-4-hydroxylases that also utilise molecular oxygen as a substrate 
for hydroxylation, as well as requiring iron and ascorbate as cofactors (Schofield, 
Zhang 1999). However, unlike PHDs, collagen prolyl-4-hydroxylases are unable to 
catalyse HIF-1a proline hydroxylation (Jaakkola et al. 2001). The half-life of HIF-la 
has been shown to be increased by 2-OG analogues that inactivate PHDs with 
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PHD2 demonstrated to be the dominant enzyme controlling HIF-1a (Ivan et al. 
2002), or iron chelators and metal ions that reduce or substitute iron from its binding 
site (Masson, Ratcliffe 2003). The PHD enzymes catalyse the splitting of molecular 
oxygen, transferring one oxygen atom to the HIF-1 a proline residue, and reacting 
the other with 2-OG to generate succinate as a component of the Kreb's cycle, with 
carbon dioxide as a by-product (Masson, Ratcliffe 2003). Ascorbate is also 
important for optimising full PHD enzymatic activity by maintaining iron in the ferrous 
state (Bruick, McKnight 2001) (Figure 6). 
1.5.2.3.2 Polyubiquitination 
The conformational change of proline-hydroxylated HIF-la represents a 
recognition signal to the von Hippel-Lindau (VHL) tumour suppressor protein, whose 
ß-domain interacts directly with the HIF-1a ODD domain, targeting it for destruction 
by the ubiquitin-proteasome system (UPS) (Stolze, Mole & Ratcliffe 2006). 
Mutations of both alleles of the VHL gene are associated with the hereditary von 
Hippel-Lindau disease, a cancer syndrome marked by sporadic development of 
renal cell carcinomas and highly vascularised tumours that display constitutive 
expression of HIF-la and aberrant production of its target genes (Iliopoulos et al. 
1996). On binding to HIF-1a, VHL associates with the proteins elongin B and C, 
cullin-2 and Rbx-1 to form a multi-protein E3 ligase complex, which signals for the 
polyubiquitination of HIF-1 a, irreversibly subjecting it to proteolytic degradation by 
the 26S proteasome (Kallio et al. 1999). To constitutively express and degrade HIF- 
1a is an energy consuming burden on the cell but this mechanism also allows for a 
rapid, energy-efficient response to hypoxia that may occur within minutes and even 
seconds. (Ravi et al. 2000) proposed the existence of a VHL-independent 
Qrýu. 
LoND= 
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Figure 6. Oxygen-dependent post-translational degradation of HIF-1 a 
HIF-1 a is classically regulated by oxygen availability. In normoxia, PHD2 enzymes 
hydroxylate HIF-la proline residues (P402 and P564) (where PHD2 requires oxygen as a 
co-substrate, as well as iron, 20G and ascorbate as cofactors). Hydroxylated HIF-la is 
recognised by the VHL E3 ubiquitin ligase complex, which leads to the polyubiquitination of 
HIF-1 a, irreversibly subjecting it to proteolytic degradation by the 26S proteasome. 
Abbreviations: HIF-1 a, hypoxia-inducible factor-1 alpha; HIF-10, hypoxia-inducible factor-1 
beta; HRE, hypoxia-responsive element; p300/CBP, p300 and CREB binding protein; PHD2, 
prolyl hydroxylase domain-containing 2 enzyme; vHL: von Hippel-Lindau (modified from 
(Gidday 2006)). 
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pathway affecting HIF-1a stability, which depends on another tumour suppressor 
P53 enhancing the murine double minute-2 (MDM2) -mediated polyubiquitination 
and degradation of HIF-1 a, where homozygous deletion of P53 in tumour cells 
enhances HIF-dependent gene transcription and neovascularisation of tumours 
(Ravi et al. 2000). 
1.5.2.3.3 Normoxic HIF-1 a accumulation 
While knowledge regarding HIF-1 has been derived through studies 
following the effects of low oxygen, there is increasing evidence demonstrating 
oxygen-independent accumulation of HIF-1a by a variety of normoxic stimuli; these 
include growth factors (e. g. insulin-like growth factors (Feldser et al. 1999), anabolic 
hormones (e. g. insulin (Stiehl et al. 2002)), neurotransmitters (e. g. acetylcholine 
(Hirota et al. 2004)) and nitric oxide (Sandau et al. 2001) as well as pharmacological 
agents such as desferrioxamine (Wang, Semenza 1993). Although dependent on 
cell-type, signalling pathways shown to stimulate HIF-1a synthesis have involved 
MAPK (Zagorska, Dulak 2004) as well as P13K (Li et al. 2004). Furthermore, many 
of the normoxic stimuli of HIF-1 a are also known to activate other transcription 
factors such as NFKB; furthermore, the HIF-1a promoter contains NFKB binding 
sites, raising the possibility that cross-talk between transcription factors may occur. 
However, the mechanisms for HIF-1a accumulation under those settings are not yet 
fully elucidated. 
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1.5.3 Transcription of HIF target genes 
HIF-1 a accumulation, whether due to changes in synthesis or degradation, 
leads to its translocation to the nucleus for dimerisation to its HIF-10 subunit, 
forming the HIF transcription factor. For transcriptional activity, HIF binds to specific 
hypoxia-response elements (HRE) found in its target genes (5'-RCGTG-3'). This 
binding is necessary yet not sufficient for full transcriptional activity. HIF-1 related 
gene transcription also requires interaction with other transcription factors at 
adjacent DNA-binding sites such as hepatic nuclear factor 4 (Semenza 1994) as 
well as interaction with co-activators CBP / p300 histone acetyltransferases, SRC-1 
and TIF-1, that are themselves regulated by oxygen concentration and redox state 
(Gray et al. 2005). Under normoxia, HIF-1a stability is further regulated by 
hydroxylation of the asparaginyl residue A803 by the asparaginyl hydroxylase factor 
inhibiting HIF-1 (FIH) that prevents its association with CBP / p300 and attenuates 
transactivation of HIF-1-target genes (Lando et al. 2002) (Figure 4). Hypoxia 
attenuates FIH-1 activity that allows for CBP / p300 association with HIF-1o and 
consequent transcriptional activity. Similar to PHDs, FIH-1 also utilises oxygen as a 
substrate and requires 2-OG, iron and ascorbate for enzymatic activity (Figure 7). 
To date, HIF-1 has been reported to control more than one hundred target genes 
with diverse functions that collectively promote cellular adaptation to hypoxia 
(Semenza 2003). These genes may be nominally classified into three categories. 
Firstly, those that lead to cell proliferation and survival (e. g. insulin-like growth 
factors); secondly, those that decrease oxygen consumption within the cell (e. g. 
glycolytic enzymes for anabolic metabolism; and thirdly, those that enhance delivery 
of oxygen to cells, either swiftly through increased erythropoiesis (e. g. 
EPO, 
transferrin) or through angiogenesis (e. g. VEGF) for a more permanent oxygen 
delivery solution. 
Imperial College London Page 52 of 230 July 2008 
Ta Lim 
HIF 1rx 
HIS-trýc 
HIFý tct 
HIF ýu. 
f-j HIF"t target genes 
Pro: eohisis 
p11 regulation 
Glucose rnetaboksm 
Cell proliferation and survf%ral 
Figure 7. HIF-1 a accumulation results in HIF-1 transcriptional activity 
HIF-1 a is classically regulated by oxygen availability. In hypoxia, PHD2 enzymatic activity is 
inhibited due to the absence oxygen as a co-substrate, resulting in HIF-1 a accumulation 
rather than degradation. Accumulated HIF-1 a translocates into the nucleus for 
heterodimerisation to HIF-1 ß. This results in formation of the HIF-1 transcription factor, 
which binds to the HRE of its target genes. Transcriptional co-activators, such as CBP/p300, 
interact with HIF-1, leading to transcription of the target genes. Abbreviations: HIF-1 a, 
hypoxia-inducible factor-1 alpha; HIF-1 ß, hypoxia-inducible factor-1 beta; HRE, hypoxia- 
responsive element; p300/CBP, p300 and CREB binding protein; PHD2, prolyl hydroxylase 
domain-containing 2 enzyme. (Modified from (Gidday 2006)). 
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1.5.4 Organ protective functions of HIF-1 a 
Cerebral ischaemia in post-natal-day (PND) 7 rat pups, induced by 3 hours 
of 8% oxygen with carotid artery occlusion, showed a 40 % reduction in ipsilateral 
hemispheric weight, where HIF-1a was found to be decreased in the ipsilateral 
hemisphere but induced throughout the brain in the contralateral hemisphere. 
However, when PND7 rat pups underwent hypoxic preconditioning (3 hours of 8% 
oxygen) 24 hours preceding cerebral ischaemia, there was a dramatic protection 
against cerebral infarct that correlated with an induction of HIF-la throughout the 
brain (Gidday et at. 1994). In further support to the concept that HIF-1a confers 
tolerance to HI injury, the proven HIF-1 a inducers cobalt chloride or desferrioxamine 
were demonstrated to protect against cerebral HI injury by as much as 76 and 56 %, 
respectively. This protection correlated with induced HIF-la in the brain that 
displayed DNA binding and transcriptional activity with expression of HIF-1 target 
genes (Sharp, Bernaudin 2004). Therefore, HIF-la induction is relevant to both 
hypoxic as well as pharmacological preconditioning. However, iron chelators 
themselves, though effective, are unlikely to be pursued further for stroke therapy in 
the clinical setting, as iron is a cofactor for a host of important cellular functions; its 
inhibition is likely to have side effects that may be too toxic for patients (Ratan et al. 
2004). HIF is believed to regulate the response to hypoxia and other stresses by 
orchestrating the transcription of its target genes where several have already been 
directly shown to protect against HI injury, including EPO and VEGF, which will now 
be discussed as possible mechanisms for the cytoprotective effects of HIF-1 a. 
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1.5.4.1 Erythropoietin 
Hypoxia increases the HIF driven expression of erythropoietin (EPO), a 
glycoprotein initially identified as a haematopoietic growth factor that stimulates the 
production of erythrocytes and oxygen delivery to tissues (Semenza et al. 1991). 
Foetal EPO production occurs in the liver but production in the adult takes place 
mainly in kidneys (Jelkmann 2004). Administration of exogenous EPO has an 
excellent safety profile and is used to treat anaemic patients with renal insufficiency 
in adults as well as infants; it is, however, also misused as a potent performance- 
enhancing drug amongst endurance athletes with the premise that it increases 
oxygen carrying capacity to exercising muscles. A growing body of evidence is 
mounting observing the widespread expression of EPO and its receptor in rodent as 
well as human tissue, including brain, provoking interest in a role for EPO beyond 
haematopoiesis (Chen et al. 2007, Grimm et al. 2006, Noguchi et al. 2007). EPO 
receptors have been found to be present in undifferentiated human embryonic 
neuroepithelial cells and, accordingly, EPO has been found to regulate 
neurogenesis through production of neuronal progenitors from neural stem cells 
(Shingo et al. 2001), as well as promoting progenitor cell differentiation into 
neurons, (Wang et al. 2004b), astrocytes (Lee et al. 2004) and oligodendrocytes 
(Sugawa et al. 2002). The centrality of EPO to successful brain development is 
exemplified when mice lacking EPO receptor expression exhibit severe anaemia 
and widespread neuronal apoptosis with death at embryonic day 13.5 (Yu et al. 
2002). The adult brain displays only a low basal level of EPO expression but upon 
brain insult and hypoxia, a dramatic rise in transcription and translation of EPO and 
its receptor occurs (Digicaylioglu, Lipton 2001) that promote multi-factorial 
beneficial 
effects in the central nervous system, including anti-apoptosis (Masuda et al. 
1994), 
anti-oxidation (Chattopadhyay et al. 2000), and neurotrophic effects 
(Campana, 
Misasi & O'Brien 1998). EPO is a clinically promising neuroprotective candidate 
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because induction of EPO is also found in preconditioned brains (Malhotra et al. 
2006) and exogenous EPO administration is protective against HI injury in vitro 
(Meloni et al. 2006) and in vivo (Sakanaka et al. 1998) as well as being successfully 
used in pilot studies on patients with acute ischaemic stroke (Grasso et al. 2007). 
1.5.4.1.1 EPO beyond haematopoiesis 
The activity of EPO is mediated through its specific cell surface receptor that 
belongs to the superfamily of type 1 cytokine receptors (Ihle 1995). The EPO 
receptor exists as an inactive homodimer complex with the cytoplasmic portion in 
association with the Janus family tyrosine kinase JAK-2 (Tilbrook, Klinken 1999). 
Binding of EPO enables autophosphorylation of the EPO receptor-associated JAK-2 
that consequently cascades to signal transduction pathways including STAT5 (Sola 
et al. 2005), MAPKs (Guillard et al. 2003), NFKB (Digicaylioglu, Lipton 2001)and 
P13K (Zhande, Karsan 2007). EPO-induced activity of these pathways results in 
reduction in infarct volume after middle cerebral artery occlusion (MCAO) in rats 
with a dramatic reduction in apoptosis within the ischaemic penumbra, through 
increased expression of the anti-apoptotic protein BcI-xL (Siren et al. 2001); 
furthermore, infusion of EPO neutralising antibodies after mild ischaemia results in 
apoptosis and neuronal degeneration (Sakanaka et al. 1998) and inhibition of MAPK 
and P13K abrogate the observed EPO-induced survival against HI cell death (Siren 
et al. 2001). Beyond preventing apoptosis, EPO-mediated cytoprotection may 
include effects on transiently increasing intracellular calcium concentration; five 
minute administration of EPO 8 hours prior to injury dose-dependently increased 
neuronal cell viability from glutamate toxicity but this effect was lost on simultaneous 
addition of a calcium chelator, ethylene glycol tetra-acetic acid (EGTA), suggesting 
that calcium influx is a critical event in the mechanism of EPO-enhanced resistance 
to injury (Sakanaka et al. 1998). An anti-oxidant effect of EPO has also been 
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reported through restoration of cytosolic catalase and glutathione peroxidase anti- 
oxidant activity, that detoxify ROS and protect the cell membrane from lipid 
peroxidation (Chattopadhyay et al. 2000). Furthermore, brain endothelial cells have 
been shown to respond to EPO and express EPO receptors with consequent 
neovascularisation and capillary tube formation, that may increase perfusion and 
brain haemodynamics to aid metabolically compromised tissue after experimental 
stroke (Ribatti et al. 1999). Finally, EPO administration after brain injury leads to the 
increased expression of BDNF that may enhance neurogenesis (Wang et al. 
2004a). Therefore, EPO is multi-dimensional in its possible cytoprotective 
mechanisms. 
1.5.4.2 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is a polypeptide belonging to a 
subfamily of angiogenic growth factors that exerts powerful mitogenic activity on 
endothelial cells from arterial, venous and lymphatic vessels (Leung et al. 1989). 
VEGF is well established to specifically stimulate vascular endothelial cell 
microvessel outgrowths and tri-dimensional angiogenesis as demonstrated in an in 
vitro model using rat aortic rings (Nicosia, Nicosia & Smith 1994) and in vivo on the 
rat cornea (Phillips, Knighton 1995), playing an essential role in embryogenic vessel 
formation, as well as physiological angiogenesis associated with metabolism, 
exercise and wound healing. The discovery of VEGF may be traced back to the late 
1800s where tumours were first observed to be highly vascular (Ferrara 2005). The 
provocation of an angiogenic response by implantation of a tumour into a rabbit's 
ear raised the question as to whether tumour-derived vascular growth 
factors may 
exist, a speculation that consequently lead to the identification of vascular 
permeability factor (VPF) in 1983, as a soluble protein that 
induced vascular 
leakage (Senger et al. 1983); this was later cloned and shown to exhibit mitogenic 
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2't v'ty only to endothelial cells and accordingly renamed VEGF (Ferrara 2002). The 
pro-angiogenic mechanism of VEGF involves stimulating expression of plasminogen 
itkvators, collagenases and metalloproteinases that creates a pro-degradative 
environment for migration and tissue remodelling of endothelial cells. VEGF also 
°, it -ceases vascular permeability that induces plasma protein leakage, which 
&, pports endothelial cell growth and energy demands (Ferrara, Davis-Smyth 1997). 
1 ,. 5.4.2.1 VEGF in the nervous system 
As a result of alternative mRNA splicing, there are at least six isoforms of 
Vl-'. GF and two tyrosine kinase VEGF receptors (VEGFR-1 and VEGFR-2) have 
!:, x-on identified to date as the mediators of VEGF biological function (Terman et al. 
`=Y-ý2) Additionally non-tyrosine kinase transmembrane receptors, called 
neuropilins, have more recently been identified as another VEGF binding site; first 
identified in Xenopus tadpoles, these cell-surface glycoprotein receptors are 
important mediators in guiding axonal extension in the developing nervous system 
(He, Tessier-Lavigne 1997), and are expressed in endothelial and tumour cells as 
well as dorsal root ganglion, optic and olfactory nerves and sympathetic neurons 
(Soker et al. 1998). Neuropilins play a role in embryonic development and 
tý. pogenesis; its overexpression leads to morphological anomalies of excessive 
capillary and nerve fibre sprouting and extra digits in mice (Kitsukawa et al. 1995), 
whereas neuropilin-deficient mice display impaired neural vascularisation and 
, ýqenesis of major blood vessels (Kawasaki et al. 1999). Transcripts of VEGF are 
detectable from embryonic day (E) 7.0 in the murine endoderm with accompanying 
VEGF receptor expression, which increases vascular sprouting to the 
neuroectoderm in later development of the CNS from E11.5 (Dumont et al. 
1995). 
Inoually, VEGF is confined almost exclusively to cortical neurons, but as vascular 
i_yeds mature, expression moves to glial cells that are in close proximity 
to vessels 
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(Ogunshola et al. 2002). In the adult, VEGF and its receptors are expressed at a 
minimal basal level throughout the whole organism but expression is inducible in the 
CNS by hypoxia through the activity of kinase signalling pathways, such as PKC 
(Ijichi, Sakuma & Tofilon 1995). Expression of VEGF in the CNS is necessary for 
angiogenesis and subsequent transport of oxygen and nutrients to the developing 
brain and nervous system, where it dose-dependently results in vasculo-genesis 
and branching of vessels, as well as an increase in vessel lumen size (Silverman et 
al. 1999). Beyond vascular effects, VEGF is directly neurotrophic and proliferative 
on neurons and glia throughout the brain, promoting the proliferation of neural stem 
cells and supporting axonal outgrowth, with its effects likely to be mediated through 
multiple signalling pathways, including P13K and PKC (Zhu et al., 2003). 
1.5.4.2.2 Neuroprotective and neurotrophic effects of VEGF 
Interestingly, VEGF is also directly neuroprotective in an in vitro rat 
ischaemia model where its exogenous administration doubles the number of 
surviving cells after 24 hours of oxygen and glucose deprivation, an effect that was 
reversed in the presence of the P13K inhibitors, wortmannin or LY294002 (Jin et al. 
2000). Endogenous VEGF has also been found to rescue hippocampal neurons 
from glutamate-induced excitotoxicity (Matsuzaki et al. 2001) and its increased 
expression is observed after HI injury, with a contiguous increase in voltage-gated 
potassium channel expression also. In a rat model of middle cerebral artery 
occlusion (MCAO), VEGF was observed to attenuate cell death through P13K and 
tyrosine phosphorylation of potassium channels; anti-sense VEGF suppression or 
P13K inhibition during MCAO attenuated potassium channel activity, which was 
subsequently found to also be associated with decreased cell viability 
(Qiu, Zhang & 
Sun 2003). Evidence for P13K-independent mechanisms of VEGF-mediated survival 
also exists. Cell viability of cultured neurons exposed to 24 
hours of hypoxia may be 
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increased to a similar extent by administration of VEGF or a caspase-3 inhibitor: 
VEGF was found to inhibit caspase-3 activation and accordingly anti-sense VEGF 
increased the proportion of caspase-3 expressing neurons, that corresponded with 
an increase in cell death (Jin et al. 2001); as such, VEGF may also be regarded as 
an anti-apoptotic molecule. 
HIF activity on the HRE of the VEGF gene has been shown to be crucial for 
protection against hypoxia-induced toxicity, but it is also critical in motor neuron 
function. Deletion of the VEGF HRE resulted in slow growth, decreased survival and 
impaired hypoxia-induced VEGF, that progressively resulted in motor neuron 
degeneration and muscle atrophy in an adult mouse model, similar to the symptoms 
of the rare neurodegenerative disease amyotrophic lateral sclerosis, alternatively 
known as Lou Gehrig's disease (Oosthuyse et al. 2001). The defects were observed 
to be due to a loss of myelination, caused primarily by a decrease in neural vascular 
perfusion and, therefore, chronic ischaemia. Exogenous administration of VEGF to 
the cerebrospinal fluid of these mice improved motor performance and decreased 
progression to paralysis with a significant increase in survival time also (Storkebaum 
et al. 2005). 
The clear developmental and anatomical associations between the vascular and 
nervous systems naturally raise questions of whether, or how, they may be 
mechanistically coordinated. It remains difficult to resolve whether the stimulatory 
effects of VEGF on embryonic neurogenesis are independent of its angiogenic role 
since inactivation of a single VEGF allele in mice is embryonically 
lethal by day 
E11.0, stemming from severe anomalous vessel formation (Ferrara et al. 1996). 
In 
the adult, however, neurogenesis has strikingly been shown to occur within an 
endothelial cell-mediated angiogenic niche: the subgranule zone of 
the adult 
hippocampus is known to generate new neurons throughout life; proliferation of 
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neural stem cells within this zone were not only observed to be located in dense 
clusters that surrounded the vasculature, but additionally displayed 
immunoreactivity to endothelial cell markers (Palmer, Willhoite & Gage 2000). 
Furthermore, a causal coordination between angio- and neuro- genesis has been 
observed in the adult songbird brain where neurogenesis in the higher vocal centre 
proceeds through life. Testosterone in the brain was shown to induce expression of 
VEGF and its receptor, with associated local endothelial cell-mediated angiogenesis 
that also produced BDNF one week later, where BDNF is known for its neurotrophic 
role and support of neuronal differentiation; in addition, VEGF inhibition substantially 
diminished angio- and neuro- genesis in the songbird's vocal centre (Louissaint et 
al. 2002). 
1.5.4.2.3 VEGF in disease 
The discovery of VEGF is very much linked to its role in oncology where its 
expression is prevalent in many solid tumours including those in lung, breast and 
colon. Tumour cells able to secrete VEGF exhibit greater microvascular permeability 
and neovascularisation, which subsequently promotes tumour growth and 
metastasis (Folkman 1971) and, therefore, the size of a tumour is directly 
proportional to its vascularity. Accordingly, numerous anti-angiogenic agents are 
currently under development as potential treatments against solid tumours. 
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1.6 NON-ORGAN PROTECTIVE FUNCTIONS OF HIF-1 
1.6.1 Critical role of HIF in embryogenesis 
HIF-1a, HIF-2a and HIF-10 are all required for normal mouse development, 
where knockouts of either HIF-1a or HIF-2a are embryonically lethal. Homozygous 
HIF-1a deficient (-/-) mice arrest in development on day E9.0 and die by E10.5 from 
: r(yvere cardiovascular and neural tube defects, with massive and widespread cell 
death within the brain (Kotch et al. 1999). Heterozygous HIF1 a +- mice are, 
however, able to maintain normal development but are unable to respond to hypoxia 
showing impairment in erythrocytosis as well as in pulmonary vascular remodelling 
(Kline et al. 2002). HIF-2a -/- mice are also embryonically lethal (Tian et al. 1998). In 
Me absence of HIF-1 p, mouse development is stunted due to a lack of HIF gene 
tra., r ription (Maltepe et al. 1997). 
1.6.2 Paradoxical role for HIF-1 a 
HIF-la is documented in literature to promote not only survival and 
pr k (. ction of cells but paradoxically may also promote the death of cells. Its 
p '==active role in preconditioning is currently being extensively studied and its ability 
to induce neuronal survival factors, such as EPO and VEGF, is widely documented. 
it plays a pivotal role in metabolism, promoting the transcription of glucose 
transporters as well as glycolytic enzymes. Less documented is the ability of HIF-la 
to promote death of cells. It is reported to mediate hypoxia-induced apoptosis 
through induction of the tumour suppressor P53 (Carmeliet et al. 1998) as well as 
heing able to inhibit the Bcl-2 family member BNIP3 (Bruick 2000). What is unclear 
is whether the net effect of HIF-1 a is to protect or promote infarction. 
Though 
ev Bence is pointing more towards its beneficial role for the organism 
in the context 
of preconditioning, the non-preconditioned ischaemic brain undergoes a 
HIF-1 o 
tc baled ischaemia-induced neuronal death (Halterman, 
Federoff 1999). 
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1.6.3 Role in cancer 
Regions of poor oxygenation are a frequent feature of solid tumours. Chronic 
waypoxic exposure occurs as tumour cells proliferate and increase the distance for 
e)-: _ygen diffusion from a vessel to the tumour cell; acute hypoxia also occurs 
because of the disorganised circulatory system and consequential transient 
changes in blood flow and, as such, tumour survival is dependent on adaptation to 
such stresses. Clinical studies have observed that the degree of hypoxia correlates 
with poor prognosis with increased prevalence of metastasis (Brizel et al. 1997) as 
cells induced to survive in such an environment have adapted to exhibit reduced 
apoptotic potential (Sullivan, Graham 2007). The best described response to 
hypoxia is mediated by HIF-1 a and its over expression is pathophysiologically 
implicated to facilitate tumour adaptation and survival; tumour grade, 
vascularisation, progression and aggressiveness is reported to be correlated to a 
high level of HIF-1 a protein expression. This increased expression is further 
correlated with an increase in HIF-1a activity marked by induction of tumour 
vascularisation, as VEGF controls the angiogenic switch as well as metabolic 
transition to anaerobic glycolysis, through increased expression of glucose 
transporters and glycolytic enzymes. 
The relevance of HIF-1 a to tumour biology is displayed through its relationship with 
tumour suppressors such as P53 and VHL. In normal oxygen tensions, P53 is 
recognised by the ubiquitin protein ligase MDM-2 that results in the proteasomal 
degradation of P53 (Wawrzynow et al. 2007). During hypoxia the accumulation of 
HIF-1 a results in HIF-1 a binding to P53 that inhibits 
MDM2-mediated P53 
degradation. Instead, MDM2 targets HIF-1a to proteasomal degradation, leaving 
P53 free to mediate apoptosis. However, tumours displaying P53 loss-of-function 
result not only in prevention of hypoxia-induced apoptosis 
but also decreased T 1DM- 
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2-mediated HHF-la degradation. With VHL tumour suppressor loss-of-function in 
renal cell carcinomas or cerebellar haemangioblastomas, HIF-la degradation is 
impaired and, therefore, the protein level is over expressed resulting in very well 
vascularised cancers (Kaelin 2007). 
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1.7 XENON 
As mentioned earlier, xenon displays neuroprotective properties through a 
preconditioning phenomenon and before considering the putative role of HIF-1a in 
this action, more needs to be revealed about this noble gas. 
1.7.1 Physico-chemical properties of xenon 
The chemical family of primordial gaseous noble elements-helium, neon, 
argon, krypton, xenon and radon-has always been intriguing in that their most 
characteristic property is, rather, their lack of property in forming no compounds. 
Their choice of name reflects this circumstance as exemplified with xenon, deriving 
its name from the Greek for "strange one". Xenon gas is extremely rare and 
constitutes no more than between 0.00005 to 0.0875 parts per million of the earth's 
atmosphere (at the most, this amounts to 4 mL of xenon in a 50 m3 room) (Marx et 
al. 2000). 
Its discovery was made late in the history of chemistry, in 1898, by Scottish-born 
chemist William Ramsey with his student Travers working to understand the high 
density of atmospheric nitrogen. Deservedly, Ramsey was later awarded the Nobel 
Prize in chemistry, in recognition of his discovery of the noble gases and his 
determination of their position in the periodic table. Xenon is a naturally occurring, 
non-flammable, non-hazardous, colourless and odourless trace gas. It is extracted 
as a by-product of oxygen manufacture, from fractional distillation of liquefied air. 
The energy-intensive extraction process and the associated exorbitant cost required 
to produce xenon reflects on its rarity. 
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1.7.2 Medicinal uses of xenon 
1.7.2.1 Anaesthesia 
Interest in the anaesthetic properties of xenon arose in 1939 when the 
physician Behnke investigated deep sea divers in the United States Navy who 
displayed "drunkenness" from breathing mixtures of gas that had different narcotic 
potencies. Because of xenon's scarcity, Behnke could not demonstrate but, 
nonetheless, calculated that xenon should display anaesthetic effects even at 
normobaric pressure (Marx et al. 2000). In 1941, a Russian named Lahzarev may 
have assessed the effect of xenon in man but the work remained unpublished; the 
first published work was conducted by Lawrence in 1946 showing xenon to be a 
general anaesthetic in mice (Caffee et al. 1999). Five years later, xenon was 
demonstrated to possess anaesthetic properties in humans by (Cullen and Gross 
1951), when they successfully conducted two surgical procedures under xenon 
anaesthesia; an orchidectomy in an 81-year-old male and fallopian tube ligation in a 
37-year-old female. Loss of consciousness and an increased pain threshold was 
evident with inhalation of 50 % xenon and pronounced narcosis occurred with 80 % 
xenon. Despite its success, the prohibitive expense of xenon kept it out of the 
limelight until the development of the first closed-circuit anaesthetic machines made 
it potentially more economically viable. Technical improvements in delivering low 
flow xenon in a closed-circuit system (Dingley et al. 2001) or using xenon recyclers 
and scavengers (Dingley, Mason 2007), based on thermodynamic processes and 
molecular sieves, will further enhance the feasibility of clinically exploiting xenon. 
Xenon displays many favourable properties of the ideal inhalational anaesthetic, 
with investigators noting many advantages over nitrous oxide, a routinely used 
anaesthetic gas; xenon is a small apolar atom with a low 
blood / gas partition 
coefficient, able to easily pass through the blood brain barrier 
for a rapid onset and 
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)'fset of action, which is independent of surgical duration (Goto et al. 1998), an 
vantageous property for an inhalational anaesthetic. It has a minimum alveolar 
Cuº"centration (MAC) of 63 % in humans, or 71 % in mice, with excellent analgesia 
at sub-anaesthetic concentrations. Xenon provides circulatory stability in that it does 
not affect heart rate, mean arterial blood pressure or cardiac contractility (Luttropp 
et al. 1993), nor does it impair the neurohormonal stress response to surgery, 
measured by an unchanged adrenaline level (Burov et al. 1995). Animal studies 
sh )w xenon to be devoid of allergic, mutagenic, carcinogenic or foetotoxic 
properties (Lane et al. 1980). As well as being environmentally sound, by displaying 
ýG: depletion of stratospheric ozone or contribution to the green house effect, its 
safety and efficacy profile in clinical anaesthesia remains unrivalled. Its scarcity in 
th` atmosphere, and hence the substantial expense involved in its purification, is 
i "he only impediment limiting its widespread use (Sanders, Franks & Maze 2003). 
With respect to xenon's mechanism of anaesthesia, a seminal paper by our 
9ab., ýatory demonstrated that xenon is a potent antagonist of the NMDA receptor 
(Franks et al. 1998), activation of which is pivotal in the propagation of acute 
neuronal injury, and this may lead to the inhibition of nociception in spinal dorsal 
horn neurons (Lynch, Guttmann 2002). Xenon has little effect on non-NMDA 
glutamatergic or GABAA receptors, nor is its actions affected by antagonists of a2 
adrenergic or opioid receptors; it seems likely, therefore, that xenon's mechanism of 
analgesia is also through NMDA receptor antagonism. 
The large size of xenon may 
:P tntribute to its anaesthetic potency, where neighbouring molecules 
distort and 
pq ýiarise xenon to induce a dipole that 
facilitates its interaction with proteins (Trudell, 
Roblin & Eger 1998). 
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1.7.3 Possible utility for organ protection 
Remarkably, neuroprotective effects of xenon have been demonstrated in 
various models. A series of in vitro studies showed that xenon reduced injury in a 
mouse neuronal-glial cell co-culture induced by either NMDA, glutamate, oxygen 
deprivation or oxygen-glucose deprivation (OGD) (Wilhelm et al. 2002), a finding 
that has been corroborated by other investigators in a different neural crest cell line 
(Petzelt et al. 2004). Protection by xenon has also been demonstrated in in vivo 
models of acute neuronal injury, involving administration of excitotoxins to rats (Ma 
et al. 2002), anaesthetic-induced apoptotic neurodegeneration in the neonate (Ma et 
al. 2007), cardiopulmonary bypass in rats (Ma et al. 2003), middle cerebral artery 
occlusion in mice (Homi et al. 2003), cardiac arrest in pigs (Schmidt et al. 2005), 
and hypoxia-ischaemia in neonatal rats (Ma et al. 2006). Xenon is a more 
efficacious neuroprotective agent than either gavestinel or dizocilpine (MK801) (Ma 
et al. 2005), two other NMDA antagonists that have been clinically tested, and lacks 
the toxicity that afflicts other NMDA receptor antagonists (Ma et al. 2002). 
Furthermore, the effect of xenon neuroprotection is synergistic with hypothermia 
and is likely to be mediated through inhibition of apoptosis (Ma et al. 2005). 
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1.8 AIMS 
This body of research aims to better understand the mechanisms behind 
xenon's preconditioning capability by exploring whether HIF-la may play a role, at 
least in part, in mediating the organ protection against HI injury that is afforded by 
xenon preconditioning. This research aims to answer the following specific 
questions: 
I. Does xenon preconditioning affect the expression of HIF-1a? 
If xenon preconditioning affects HIF-1a expression, is the xenon-induced 
HIF-1 a functionally active, and about to transcribe its target genes? 
II. What are the mechanisms underlying xenon-induced HIF-1a expression? 
Specifically, does xenon preconditioning affect HIF-1a transcription, 
translation or degradation? 
Ill. Is HIF-1 a causally-related to xenon-induced organ protection against 
ischaemic injury? 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 EXPERIMENTAL MODELS 
2.1.1 ANIMAL MODELS 
This study was approved by the Home Office, United Kingdom, and all 
animal procedures were carried out in accordance with the United Kingdom Animals 
(Scientific Procedures) Act of 1986. Every effort was made to minimise animal 
suffering and the number of animals used. 
Ten-week-old C57BL6 male adult mice weighing 20 - 25 grams purchased from B& 
K Universal Limited (Grimston, Aldbrough, Hull, U. K. ), were housed in a special 
pathogen-free facility at Imperial College London in an automated 12-hour-light / 12- 
hour-dark diurnal schedule colony room, in a temperature (20 - 22 °C) and humidity 
(23 %) controlled isolated ventilated chamber. Mice were given free access to 
irradiated food and sterile water ad libitum before the start of experimentation and 
allowed to familiarise to their new housing environment for three days. 
2.1.2 CELL MODELS 
2.1.2.1 Solutions 
Media Stock (1 L) 
100 mL 1 OX Minimum essential medium (MEM) (Sigma Aldrich) 
83 mL Glucose bicarbonate stock 
Top up to 1L with dH2O 
Glucose bicarbonate stock (1 L) 
44 g D-glucose 
26.3 g NaHCO3 
Top up to 1L with dH2O 
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2,1 2.2 Neuronal-glial cell co-culture 
The mixed cortical co-cultures containing both neuronal and glial elements 
were derived from foetal and early postnatal BALB/c mice, respectively. Whole 
cerebral neocortices were removed from post-natal-day (PND) 1-2 BALB/c pups. 
After trypsination and resuspension, cells were plated at a density of 6.25 x 104 cells 
/ cm2 on 4-multiwall plates (Costar, Cambridge, MA). These glia cells were grown in 
a culture medium of PM5,5 (media stock with 5% foetal bovine serum, 5% horse 
serum, 2 mM L-glutamine, 100 U/mL anti-biotic anti-mycotic solution (Sigma 
Aldirch)) until reaching confluence, approximately one week after plating. Cortical 
neuronal cells were obtained from foetal BALB/c mice at gestation day 14 - 16 and 
i. bated at a density of 1.25 x 105 cells / cm2 on the confluent monolayer of glia cells, 
derived from the corresponding genetic mouse strain. Neuronal-glial co-cultures 
+-F ýre maintained in medium until reaching confluence one week after plating. 
2.1.2.3 Human kidney-2 cell culture 
Human kidney-2 (HK-2) cells (European Cell Culture Collection) are derived 
from a primary culture of human adult male kidney proximal tubular epithelial cells, 
immortalised by transfection with the E6 / E7 genes of a human papilloma virus-16 
that does not change its phenotype or function. The E6 / E7 genes bind to its host's 
DNA regulatory proteins that promote cell proliferation, but without malignant 
transformation, as growth of the host's cells remain dependent on anchorage and 
under normal regulatory control (Ryan et al. 1994). HK-2 cells were maintained in a 
75 cm2 tissue culture flask at 37 °C in RPMI 1640 medium (Invitrogen) 
,, Ljpplemented with 10 % foetal bovine serum (FBS) (Invitrogen), 2 mM L-glutamine 
(Invitrogen), and 100 U/ mL penicillin-streptomycin (Invitrogen) in a humidified air 
with 5% carbon dioxide atmosphere. After reaching confluence, cells were 
ä4; tached from the flask with 0.05 % trypsin / 0.6 mM EDTA solution (Invitrogen) for 
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%? rt Minutes and activity stopped with the addition of RPMI 1640. The cell suspension 
as centrifuged at 1300g for 5 minutes, resuspended in supplemented RPMI 1640 
and plated in 60 mm Petri dishes. Cells were used soon after reaching 80 % 
confluent. 
2.11.2.4 Renal cell carcinoma cell culture 
RCC4- and RCC4+ (kindly donated by Professor Patrick Maxwell) refer to 
ter% o derivatives of the von Hippel-Lindau (VHL)-defective renal cell carcinoma (RCC) 
cell line RCC4. RCC4+ is stably transfected with an expression plasmid encoding 
the wild-type VHL tumour suppressor, and RCC4- is stably transfected with an 
empty vector. Both cell lines were cultured in parallel at 37 °C in RPMI 1640 
medium supplemented with 10 % foetal bovine serum, 2 mM L-glutamine, and 100 
/ mL penicillin-streptomycin (Invitrogen) in a humidified air and 5% CO2 
atmosphere. They were used soon after reaching 80 % confluence. 
2. .3 GAS EXPOSURE 
2,1.3.1 In vivo 
C57BL6 male adult mice were preconditioned by exposure to 75 % xenon 
baha. nced with 25 % oxygen for 2 hours in a purpose-built closed circuit anaesthetic 
chamber (3 L volume) connected to a3L reservoir bag, a gas pump, a xenon 
monitor (439XE Analyser, Air Products, Surrey) and an oxygen monitor (Datex, 
Capnomac Ultima). A gas mixture of 75 % xenon and 25 % oxygen was delivered at 
a rate of 2L/ minute for 3 minutes to the air-tight 3L gas chamber containing no 
more than 4 mice on a gridded platform, with silica gel and soda lime placed 
underneath to eliminate moisture and carbon dioxide, respectively. 
Any residual 
room air present in the circuit was then further displaced by emptying the 
3L 
,: ervoir bag 3 times. The circuit was then closed 
but replenished with fresh gas 
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mixture every 30 minutes. A thermometer was placed in the chamber with the mice 
and temperature maintained at 37 °C +/- 0.5 °C by the use of a heating pad. 
Negative control mice were exposed to 75 % nitrogen balanced with 25 % oxygen 
for 2 hours. Positive control mice underwent hypoxic preconditioning through an 
already established paradigm (Gidday et al. 1994) by exposure to 8% oxygen 
balanced with nitrogen for 3 hours (Figure 8). 
2.1.3.2 In vitro 
Experimental medium was prepared by first bubbling gas mixtures of 75 % 
xenon, 20 % oxygen and 5% carbon dioxide through fine sintered glass bubblers in 
Dreschel bottles for 45 minutes with continual stirring at 37 T. The pre-bubbled 
experimental medium was used to replace the existing medium on the cell cultures 
that were then subsequently placed in an air-tight purposed-built gas exposure 
chamber set to 37 °C, equipped with inlet and outlet valves and an internal electric 
fan to evenly distribute gases over the cultures. Gases were delivered at a rate of 
100 mL / minute and when connected to calibrated flow-meters, the desired gas 
composition could be obtained. After 45 minutes of gas equilibration, the gas circuit 
was closed to begin the preconditioning paradigm using gas concentrations of 75 
xenon, 20 % oxygen and 5% carbon dioxide for 2 hours. Negative control cultures 
were bathed in experimental medium pre-bubbled with 75 % nitrogen, 20 % oxygen 
and 5% carbon dioxide and then exposed to the same gas concentrations in the 
gas exposure chamber for 2 hours. Positive control cultures were bathed in 
experimental medium pre-bubbled with 1% oxygen and 5% carbon dioxide 
balanced with nitrogen and then exposed to these same gas concentrations for 4 
hours, using an established paradigm for hypoxic preconditioning in cells (Gidday et 
al. 1994). Immediately after gas treatments, experimental medium was removed 
and replaced with standard supplemented growth medium. 
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Figure 8. Schematic illustration of in vivo gas exposure circuit 
A purpose-built closed circuit gas chamber was used for exposing mice to various gas 
preconditioning paradigms. The gas chamber (with a volume of 3 L) was connected to a 3L 
reservoir bag, an air pump, a xenon monitor and an oxygen monitor. Soda lime and silica gel 
were placed in the gas chamber, to absorb carbon dioxide and moisture, respectively. 
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2.1.4 ORGAN HARVESTING IN MICE 
Following gas exposure, organs were harvested. Mice were sacrificed by 
cervical dislocation at the following time intervals of 0,2,4,8 and 24 hours after gas 
exposure. Immediately after sacrifice, the mouse was decapitated and an incision 
along the sagittal plane was made, across the length of the skull that allowed for it 
to be peeled back to reveal the brain. The brain was dissected out, separated into 
its two hemispheres and immediately frozen in liquid nitrogen. A midline incision 
was made along the length of the body of the mouse and other organs including the 
heart, liver and kidneys were harvested and also immediately frozen in liquid 
nitrogen. Dissected organs were then archivally stored at -80 °C until required for 
further experimentation. 
2.2 REVERSE TRANSCRIPTION-POLYMERASE 
CHAIN REACTION 
2.2.1 Purification of total RNA 
2.2.1.1 In vivo 
Total RNA was extracted from frozen organs using DNA- and RNA- free 
equipment and the RNeasy Mini Kit (Qiagen), according to the manufacturer's 
protocol. Briefly, after cleaning the work area with RNase erase (Qiagen) tissue was 
collected from archival storage at -80 °C, weighed and completely submerged in 
RNAlater solution with at least 1 mL of solution to 1 mg of tissue, to stabilise RNA 
expression in a small RNA-free Petri dish. The tissue was cut into small pieces of 
approximately 2 mm3 each. 600 pL of RLT lysis buffer was added to a plastic mortar 
to which 30 pg of sample was added and then disrupted with a plastic pestle. 
Once 
the tissue was well homogenised, it was transferred to the QlAshredder 
homogeniser column, which was placed in a2 mL collection tube and spun for 3 
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minutes in a microcentrifuge at maximum speed (6000g). The QlAshredder was 
removed and 600 pL of 70 % ethanol was slowly dripped into the collected 
homogenised lysate and then mixed well by pipetting. The sample was pipetted into 
a genomic DNA eliminating spin column placed in a collection tube and centrifuged 
for 30 seconds at 6000g. The flow-through was discarded and 700 µL of RW1 was 
pipetted into the spin column to wash it and centrifuged for 30 seconds at 6000g. 
the flow-through was again discarded and 500 pL of RPE was pipetted into the spin 
column to wash it and centrifuged for 3 minutes at 6000g. To elute the RNA, the 
spin column was then placed in a new collection tube and 50 pL of RNase-free 
water was pipetted in and centrifuged for 1 minute at 6000g. The extracted RNA 
may be stably stored for 1 year at -80 °C. 
2.2.1.2 In vitro 
The RNeasy Mini Kit (Qiagen) was used according to the manufacturer's 
instructions. Briefly, the cell culture medium was completely aspirated from the 
treated cell cultures and RLT lysis buffer was added directly to the Petri dish. Cells 
were then disrupted using a rubber cell scraper and pipetted up and 
down to 
remove visible cell clumps. The cell mixture was then transferred 
to the 
QlAshredder homogeniser column and subsequently processed using the same 
protocol as for animal tissues, described above. 
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2.. 2.2 Determination of RNA concentration, purity and 
kntegrity 
The concentration of the total purified RNA was then quantified by 
measuring its ultraviolet (UV) absorbance at 260 nm wavelength in a 
spectrophotometer, where an absorbance reading of 1.0 corresponds to 44 pg / mL 
of HNA. The purity of RNA was also determined at the same time, by the ratios of 
the wavelengths at 260 nm and also at 280 nm, where 280 nm is the absorbance 
peak for protein contaminants. A ratio of 2: 1 (260: 280 nm) indicates the absence of 
proiein contamination, with ratios above 1.7: 1 deemed acceptable. The integrity and 
size distribution of the harvested RNA was checked by denaturing agarose gel 
efr trophoresis with ethidium bromide staining. Briefly, a2% agarose gel, made 
+_ it. h 1 .2g agarose in 60 mL of TAE buffer with 5 µL of the fluorescent dye ethidium 
bromide, was poured into a casting tray and set for 60 minutes at 4 °C. The gel was 
placed in an electrophoretic tank that was filled with Tris-acetate EDTA (TAE) buffer 
to cover the surface of the gel. Loading dye was mixed with RNA samples in a 1: 5 
ratio, respectively, and loaded into the gel for electrophoresis at 100 V for 25 
,,,,,,, Mutes. The fluorescent bands were visualised using a 
Flour-S Multi-Imager 
Imaging system (Bio-Rad). Good RNA integrity should give 2 sharp bands 
con esponding to the 28S ribosomal RNA and 18S RNA in an approximate ratio of 
2: 1 respectively. Smeared bands are an indication that the RNA sample is likely to 
have been degraded during extraction (Figure 9). 
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Figure 9. RNA integrity in the mouse brain and kidney 
An RNA preparation from the mouse brain and kidney was electrophoretically 
separated on a2% agarose gel to assess its integrity. Crisp bands indicate intact 
RNA. Abbreviations: B, brain; K, kidney; 28S, 28S ribosome; 18S, 18S ribosome. 
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2.2.3 Reverse transcription 
Reverse transcription is the synthesis of single-stranded complementary 
DNA (cDNA) using the isolated RNA as a template. The oligo dT primer (Promega) 
anneals to mRNA at its optimal temperature and the mRNA is subsequently 
reverse-transcribed into cDNA, in the presence of a reverse trancriptase enzyme 
(SuperScript II, Invitrogen). RNA samples were reverse-transcribed based on the 
manufacturer's (Invitrogen) guidelines. Briefly, olido dT primer and deoxynucleotide 
triphosphate (dNTP) mix (Promega) were added to a collection tube containing 
normalised amounts of RNA sample (approximately 1 pg of RNA per sample). In a 
PCR thermal mastercycler (Eppendorf), the mixture was heated to 65 °C for five 
minutes to denature RNA secondary structures and then quickly chilled to 4 °C for 
one minute, allowing the primer to anneal to the RNA. At this point, an RNase 
inhibitor (Superase-in, Ambion) and 5X first-strand buffer (Invitrogen) were added to 
the samples. Subsequently, the reaction was heated to 42 °C for two minutes before 
Superscript reverse transcriptase was added. The mixture was incubated at 42 °C 
for 50 minutes, allowing for the reverse transcription extension reaction, followed by 
70 °C for 15 minutes to inactivate the reaction. The cDNA product was then kept at 
4 °C for further use or storage at -80 °C. 
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2.2.4 Polymerase chain reaction 
The following primers (Table 1) were designed and made by (MWG Biotech, 
Ebersberg, Germany) for use in PCR: 
Primer Ta Product 
name Sequence (5' to 3') (°C) size (BP) 
ß-ACTIN AGCCATGTACGTAGCCATCC 57 228 
CTCTCAGCTGTGGTGGTGAA 
EPO CCACCCTGCTGCTTTTACTC 57 166 
CTCAGTCTGGGACCTTCTGC 
HIF-1a TCAAGTCAGCAACGTGGAAG 57 198 
TATCGAGGCTGTGTCGACTG 
HIF-ß TGCCTCATCTGGTACTGCTG 57 179 
GAACATGCTGCTCACTGGAA 
Table 1. List of PCR primers and amplification conditions used to analyse the 
expression of genes in this study 
The internal control, HIF-1 ß or ß-actin, was required to verify that similar levels of 
RNA was used in reverse transcription, allowing for comparison of gene expression 
between multiple samples. PCR amplification of the required cDNA was performed 
in 3 mM magnesium chloride, 0.2 pM primers, 0.25 U Taq DNA polymerase 
(Promega) and 0.8 mM deoxynucleotide mix (Promega) in a PCR thermal 
mastercycler (Eppendorf). The PCR program consisted of an initial incubation at 96 
°C for two minutes that preceded 30 cycles of denaturation (96 °C for 30 seconds), 
annealing (57 °C for 1 minute), and extension (72 °C for 3 minutes). A final 
extension period of 7 minutes at 72 °C was also included. PCR products were 
subsequently separated by electrophoresis on a2% agarose gel containing the 
fluorescent dye ethidium bromide and visualized using a Fluor-S Multi-imager 
imaging system (Bio-Rad). 
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2.3 WESTERN BLOTTING 
2.3.1 Solutions 
Tris-Hcl solution (500 mL) 
12.1 g Trizma base 
0.5 L dH2O 
Titrate to pH 8.0 with Hcl 
Tris-buffered saline (TBS) (1 L) 
8.8 g NaCI 
50 mL Tris-HCI 
Top up to 1L with dH2O 
Tris-buffered saline with 0.05 % Tween-20 (1 L) 
8.8 g NaCI 
50 mL Tris-HCI 
Top up to 1L with dH2O 
0.5 mL Tween-20 (very viscous so add after dH2O) 
2.3.2 Protein extraction 
2.3.2.1 In vivo 
Once mice were sacrificed, organs were rapidly excised and harvested and 
immediately fast frozen in liquid nitrogen prior to archival storage at -80 °C. The 
frozen tissue was subsequently weighed and bathed in cell lysis buffer (Cell 
Signalling Technology) at a concentration of 0.2 g/ mL. Samples were immediately 
mechanically homogenised (Polytron Homogenise, Kinematica) on ice in short 3 
second bursts interspaced with 3 second gaps for 30 seconds before centrifugation 
at 3000g for 10 minutes at 4 °C to remove cell debris. The supernatant was carefully 
pipetted out and removed into a new 1.5 mL collection tube and aliquoted to avoid 
multiple freeze-thaw cycles. Aliquoted samples were stored at -80 °C and thawed on 
ice when ready for use. 
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2.3 2.2 In vitro 
On ice, growth medium was removed from the treated cell cultures and 
, sa sequently dissolved and homogenized in cell lysis buffer (Cell Signalling 
T1 c hnology). Samples were then sonicated on ice in short 3 second bursts 
1r 'ierspaced with 3 second gaps for 30 seconds before centrifugation at 10 000g for 
10 minutes at 4 °C to remove cell debris. The supernatant was carefully pipetted out 
, ýý id removed into a new 1.5 mL collection tube and aliquoted to avoid multiple 
uze-thaw cycles. Aliquoted samples were stored at -80 °C and thawed on ice 
when ready for use. 
. .3 Protein quantification using the Bradford assay 
Bradford dye concentrate (Bio-Rad) was diluted with double distilled water 
yiýiH2O) in a 1: 4 ratio respectively, following manufacturer's instructions. To make 
protein standard samples, a known concentration of bovine serum albumin (Bio-rad) 
was serially diluted with ddH2O to range in concentration from 1000,500,250,125, 
12.5 and 1.25 pg / mL. On ice, 10 pL of protein samples and 10 pL of protein 
standard samples were loaded in triplicate into a 96-microwell flat-bottomed clear 
p! aao. Triplicates of cell lysis buffer (10 µL) were also loaded to remove its possible 
contribution to total protein concentration, and ddH2O was used as blanks. Bradford 
dye (20 pL) was pipetted into each well and left to incubate for 5 minutes. The plate 
was then placed in a spectrophotometer to measure the optical density of each 
sample at 595 nm. The standard curve created from the protein standard samples 
allowed for determination of the protein sample concentration and their subsequent 
normalisation to each other. 
imperial College London Page 83 of 230 
July 2008 
Ta Lim 
2.3.4 Electrophoretic protein separation 
Based on the Bradford assay determination of protein concentration, protein 
samples were normalised to the same concentration and volume. Denaturing 
sample buffer concentrate containing a tracking dye (Invitrogen) was added to the 
normalised protein samples in a1: 3 ratio respectively and subsequently heated at 
70 °C for 10 minutes. 4- 12 % gradient Bis-Tris gels (Invitrogen) were positioned in 
a gel holder and assembled into a Western blot tank that was then filled with 
running buffer (Invitrogen). Equal volumes of normalised protein samples were then 
loaded into the wells of the gel using a long fine-tipped pipette. Each well may hold 
a maximum of 25 pL of sample; 10 pL of mouse brain or kidney with sample buffer 
was loaded per well and this contained approximately 100 pg of total protein, where 
as 20 pL of cells with sample buffer were loaded per well and this contained 
approximately 60 pg of total protein. 5 µL of a biotinylated protein ladder (Cell 
Signalling Technology) was also loaded in an additional lane. The gel-loaded 
proteins were then fractionated by electrophoresis at 200 V for 35 minutes which 
was when the dye front had nearly reached the bottom of the gel. 
2.3.5 Electrotransfer 
The proteins separated by electrophoresis were then transferred onto a 
nitrocellulose membrane that acts as a solid support. Pre-cut nitrocellulose 
membranes, filter papers and sponges were soaked in 10 
% methanol transfer 
buffer (Invitrogen) for 5 minutes before the end of the electrophoretic run. According 
to the manufacturer's instructions, a gel and membrane sandwich was 
then created 
from negative to positive (Figure 10). 
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Figure 10. Electrotransfer of proteins, from gel to nitrocellulose membrane 
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As air pockets hinder the flow of electrical current, air bubbles were smoothed out of 
between the gel and nitrocellulose membrane by gently pressing and rolling 
together with a Pasteur pipette. The gel-membrane sandwich was then placed in a 
transfer box which was assembled into the Western blot tank. The transfer box was 
filled with transfer buffer and cool water was used to fill the rest of the tank to aid in 
heat dissipation. The transfer of proteins from gel onto membrane was run at 30 V 
for 60 minutes. 
2.3.6 Immunodetection 
After electrotransfer, the nitrocellulose membrane was incubated with a 
blocking solution composed of 5% non-fat dry milk in Tween-20-containing Tris 
buffered saline (TBS-T) for 3 hours on a gyrating shaker (Fisher Scientific) at room 
temperature. Subsequently, the blocked membrane was incubated overnight for 16 
hours at 4 °C on a gyrating shaker with the relevant primary antibodies directed 
against either HIF-la (120 kDa) (rabbit polyclonal antibody, 1: 500 (Novus 
Biologicals); or mouse monoclonal antibody, 1: 1000 (Novus Biologicals); or rabbit 
polyconal antibody, 1: 1000, (BD Biosciences)), EPO (34 kDa) (rabbit polyclonal 
antibody, 1: 250 (Cell Signalling Technology); or rabbit polyclonal antibody, 1: 500 
(Santa Cruz)), PHD2 (46 kDa) (rabbit polyclonal antibody, 1: 5000 (kindly donated 
by Professor Patrick Maxwell)), mTOR (289 kDa) (rabbit polyclonal antibody, 1: 
1000 (Cell Signalling Technology)), HIF-1 ß (87 kDa) (rabbit polyclonal, 1: 1000 
(Cell Signalling Technology)) or a-tubulin (55 kDa) (mouse monoclonal antibody, 1: 
5000 (Cell Signalling Technology)) (Table 2). The primary antibodies were 
incubated at optimised dilutions in 5% non-fat dry milk solution. After removing the 
antibody, 4 washes in TBS-T lasting 5 minutes each were performed at room 
temperature on a rapidly moving gyrating shaker. The membrane was then 
incubated with the appropriate goat-derived horseradish peroxidase-conjugated 
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secondary antibody (Cell Signalling Technology) directed against the rabbit-derived 
primary antibodies at room temperature for 1.5 hours on a gyrating shaker. The 
secondary antibody was then removed and 5 washes in TBS-T lasting 5 minutes 
each were performed at room temperature on a rapidly moving gyrating shaker with 
an additional sixth wash for 5 minutes in TBS without Tween-20, as this detergent 
interferes with the chemiluminescent reaction. To maximise the visualising of 
immunoreactive bands, the enhanced chemiluminescent (ECL) reagent was mixed 
with the accompanying peroxidase reagent (Lumiglo kit (Cell Signalling 
Technology)) only at the very last minute. The membrane was then incubated for 1 
minute in the ECL solution and then placed protein-side up between two transparent 
acetate sheets, with trapped air bubbles gently rolled out using a Pasteur pipette. 
The acetate-covered membrane was then placed inside a film cassette and in a 
completely dark room exposed to radiographic film (ECL Hyperfilm (Amersham 
Biosciences)) for optimised lengths of time (HIF-1 a, 3-5 minutes; EPO, 5- 10 
minutes; PHD2,5 - 10 minutes; mTOR, 3-5 minutes; a-tubulin, 15 - 30 seconds). 
After radiographic film capture of the immunoreactive bands, the membrane was 
removed from the acetate and washed 3 times in TBS-T lasting 5 minutes each at 
room temperature on a rapidly moving gyrating shaker. The membrane was then 
subjected to the same protocol as outlined above for detection of the house-keeping 
protein, a-tubulin: it was re-blocked in blocking solution before incubation with the 
anti-a-tubulin antibody, washed, incubated with the secondary antibody, washed 
and visualised using the ECL system capture on radiographic film. The results were 
then quantified by densitometric analysis using Adobe Photoshop Elements 2.0 
software, scaled relative to the control sample, and normalised with the 
house- 
keeping protein a-tubulin. A schematic representation of the steps involved in 
Western blotting is depicted in Figure 11. 
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Antigen 
EPO 
HIF-la 
HIF-1 ß 
mTOR 
PHD2 
cx-tubulin 
Primary antibodies Dilution MW (kDa) Supplier 
Rabbit PAb 1: 250 34 CST 
Rabbit PAb 1: 500 34 Sc 
Rabbit PAb 1: 500 120 NB 
Mouse MAb 1: 1000 120 NB 
Rabbit PAb 1: 1000 120 BD 
Rabbit PAb 1: 1000 87 CST 
Rabbit PAb 1: 1000 289 CST 
Rabbit PAb 1: 5000 46 PM 
Mouse MAb 1: 5000 55 CST 
ii a ale 2. List of primary antibodies used in Western blot immunodetection of 
protein expression 
Abbreviations: BD; BD Biosciences; CST, Cell Signalling Technology: EPO, erythropoietin; 
HIF-1a, hypoxia-inducible factor-1 alpha; HIF-1p, hypoxia-inducible factor-1 beta; kDa, 
kilodaltons; MAb, monoclonal antibody; mTOR, mammalian target of rapamycin; MW, 
r nlecular weight; NB, Novus Biologicals; PAb, polyclonal antibody; PHD2, prolyl 
hyddo : glase domain-containing 2 enzyme; PM, Professor Patrick Maxwell (a kind donation); 
SC -, f, ta Cruz. 
jrT, f, crial College London 
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Figure 11. Western blotting 
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This cartoon illustrates the main steps involved in Western blotting. Protein samples, loaded 
onto a4- 10 % Bis-Tris gel, were electrophoretically separated. Proteins were then 
electrotransferred, from the gel to a nitrocellulose membrane. After blocking for nonspecific 
antibodies, the membrane was probed with a primary antibody, followed by a secondary 
antibody conjugated to horse radish peroxidase (HRP). The membrane was then incubated 
with chemiluminescent reagents and the protein of interest detected on radiographic film. 
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2.4 IMMUNOHISTOCHEMISTRY 
2.4.1 Solutions 
0.2 M Phosphate buffer (PB) (2 L) 
46 g Na2HPO4 
9.1 g Na2H2PO4 
2L dH2O 
0.1 M Phosphate-buffered saline (PBS) (2 L) 
1L 0.2MPB 
1L dH2O 
18 g NaCI 
0.1 M Phosphate-buffered saline with 0.3 % triton (PBS-T) (2 L) 
2L PBS 
6 mL Triton X-100 (Promega) 
0.1 M Phosphate-buffered saline with 0.3 % H202 / 70 % methanol (30 mL) 
9 mL 0.1 M PBS 
21 mL Methanol 
300 pL 30% H202 
Heparinised phosphate-buffered saline (PBS-Hep) (2 L) 
2L PBS 
2 mL (1000 UI mL) heparin sodium solution (Sigma) 
10 % paraformaldehyde (2 L) 
Prepare under fume hood and store at 4 °C 
1.6 mL dH2O (heat to -70 °C) 
200 g paraformadehyde (dissolve in water) 
1 mL NaOH (to aid dissolution) 
2L dH2O 
Cool solution to room temperature 
Titrate to pH to 7.4 with HCI and/or NaOH 
Filter and store at 4 °C 
4% Paraformaldehyde (2 L) 
Prepare under hood, make immediately before use and store at 4°C 
1L 0.2MPB 
0.8 L 10 % paraformaldehyde 
Top up to 2L with dH2O 
30 % Sucrose solution (2 L) 
600g sucrose 
2L 0.1 MPBS 
1M Sodium hydroxide (NaOH) (2 L) 
50 g sodium hydroxide pellets 
Dissolve to 2L with dH2O 
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2.4.2 Tissue fixation by transcardial perfusion 
Transcardial perfusion is a common method for tissue fixation in 
immunohistochemical (IHC) techniques. This method uses the circulatory system to 
deliver the fixative solution throughout the body. Fixation is required to preserve the 
structure of tissues and polypeptides so that antibodies used during immunostaining 
can recognise the conformation of their antigen sites. Paraformaldehyde (PFD) is a 
commonly used and reliable fixative agent because it minimises non-specific 
staining and does not interfere with fluorescent dyes, allowing for optimal 
visualisation of the samples. 
After gas exposure, mice were swiftly sacrificed by cervical dislocation and 
dissected to remove skin from the abdomen and chest. The thoracic cavity was 
opened by cutting the diaphragm from one lateral aspect to the other lateral aspect, 
and cutting through the lateral aspects of the rib cage, then horizontally below the 
neck to expose the heart. 
The perfusion needle (blunted 15 gauge hypodermic needle) was inserted through 
the base of the apex (Figure 12) into the left ventricle and gently followed through 
into the ascending aorta. The right atrial chamber was lacerated to make a break in 
the circulatory system, allowing for effluent flow-out of blood and perfusion liquid. 
The heart and circulation were then transcardially perfused with 100 mL of 
heparinised normal saline, at a steady flow rate of approximately 25 mL / minute, to 
stop blood coagulation and to blanch the tissues of blood, followed by perfusion with 
200 mL 4% paraformaldehyde (PFD) in 0.1 M phosphate-buffered saline (PBS) 
solution to preserve the tissues (approximately 10: 1 ratio of 
fixative : tissue); 
evidence of spontaneous "dancing" and tremors in the animal's extremities 
indicated 
that aldehyde had cross-linked with nerves and muscles and that the tissue was 
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Figure 12. Schematic diagram of the transcardial perfusion method 
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`IXtA. Mice were then decapitated and whole brains removed and immersed in 4% 
I' in 0.1 M PBS solution overnight for 16 hours at 4 °C. This was followed by 
ilcubation in 30 % sucrose solution for 24 hours, or until the tissue sank, at 4 T. 
The brain was then coronally cryosectioned at -20 °C into 30 pm sections, collected 
eýýý°r sterile plastic dishes containing 0.1 M PBS and then mounted onto slides. 
2.4.3 Immunostaining 
The mounted sections were washed in PBS (washing was performed 3 
times for 5 minutes). Endogenous peroxidase activity may be found in many tissues, 
ý5 example, due to the presence of red blood cells and, therefore, sections were 
quenched of peroxidase activity by pre-treatment in 0.3 % hydrogen peroxide / 70 
: -9ethanol in 0.1 M PBS for 30 minutes, and subsequently washed in PBS. 
Sections were then incubated with a3% blocking solution for 30 minutes to 
suppress non-specific binding, followed by washing. Sections were incubated with 
the primary antibody directed against HIF-1 a (rabbit-derived polyclonal antibody, 1 
11'z 00 (New England Biolab) diluted in 1% goat serum in PBS-T) overnight for 16 
hours at 4 °C, followed by washing. To test for the specificity of the antibodies used, 
r, o , -cal slides were incubated with 1% goat serum in PBS-T only, without a primary 
antibody present. Sections were then incubated with a biotinylated secondary 
antibody (goat-derived anti-rabbit IgG antibody, 1: 200 (New England Biolab) for 1 
hour at room temperature and washed in PBS-T. This indirect method employing a 
p °rtiary and a secondary antibody is used because signal from the protein of 
interest (HIF-1 a) may be amplified through several secondary antibodies reacting to 
one primary antibody displaying several antigen binding sites. Subsequently, 
samples were incubated with avidin-biotin-peroxidase complex (ABC) solution 
(Vector Lab, Orton Southgate, Peterborough, United Kingdom) for 1 hour, followed 
r)y washing in PBS. Avidin, labelled with peroxidase, is a large glycoprotein that has 
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a high affinity for the biotin found conjugated to the secondary antibodies. The 
peroxidase reaction was developed by incubating the section in 0.02 % 3,3 
diaminobenzidine tetrahydrochloride (DAB) solution (Sigma) containing 0.003 % 
hydrogen peroxide for 6 minutes, that results in a brown precipitate at the antigen 
site. Sections were washed with PBS and transferred to poly-lysine coated slides 
and allowed to dry overnight for 16 hours in darkness at room temperature. 
2.5 RAPAMYCIN ADMINISTRATION 
2.5.1 In vitro 
Rapamycin (Tocris) was dissolved to a concentration of 40 mM in DMSO 
solvent and serially diluted in supplemented RPMI 1640 medium to the final 
concentrations of 100,50 and 25 nM with the end volumes containing 0.0025 % 
DMSO. Supplemented RPMI 1640 medium containing rapamycin was incubated 
with the RCC4+ cell cultures for 30 minutes at 37 °C in humidified air containing 5% 
carbon dioxide, after which it was removed and replaced with experimental medium 
pre-bubbled with pure gas mixtures of 75 % xenon, 20 % oxygen, and 5% carbon 
dioxide, and preconditioned by exposure to the same gas concentrations for 2 hours 
at 37 °C, as previously described above. Experimental medium was then removed 
and replaced with supplemented RPMI 1640 culture medium and placed in the 
humidified air containing 5% carbon dioxide incubator at 37 °C for 24 hours. Cells 
were then lysed, harvested and subsequently analysed by Western blotting. 
Harvesting at 24 hours after xenon preconditioning was chosen as HIF-1 a protein 
expression was earlier demonstrated to occur maximally at this time point. 
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2.5.2 In vivo 
Rapamycin (Tocris) was dissolved to a concentration of 40 mM in DMSO 
solvent and diluted in normal saline (0.9 % sodium chloride) to contain a final DMSO 
concentration of less than 0.1 %. C57BL6 male adult mice were then administered 
rapamycin by intraperitoneal injection at doses of 0.25 mg / Kg or 1.5 mg / Kg, 30 
minutes prior to preconditioning by gas exposure to 75 % xenon balanced with 25 % 
oxygen for 2 hours. Mice were subsequently rested back in their cages for 24 hours 
in room air and then sacrificed by cervical dislocation. Organs were collected, frozen 
and subsequently analysed by Western blotting as described in the sections above. 
Figure 13 illustrates the time course and experimental groups of these rapamycin 
studies. 
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Figure 13. Time course and groups of rapamycin experiments 
This schematic cartoon depicts the experimental groups and time course (not drawn to 
scale) of the rapamycin experiments. C, controls received volume-matched DMSO- 
containing medium (in vitro) or normal saline (in vivo) and were exposed to nitrogen; R, the 
rapamycin alone group received rapamycin and were exposed to nitrogen; X, the xenon 
alone received volume-matched DMSO-containing diluent and were exposed to xenon; XR, 
the xenon with rapamycin group received rapamycin and were exposed to xenon. 
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2.6 GENE SUPPRESSION THROUGH RNA 
INTERFERENCE 
HIF-1a knockout mice are lethal mutants because HIF-1 is required for 
embryonic development. RNA interference (RNAi) is a relatively new method that 
results in "knockdown" rather than "knockout" of a specific gene and is afforded by a 
naturally occurring mechanism. Studies in Caenorhabditis elegans and the 
h rosophila melanogaster fruit fly have shown that RNAi is triggered when double 
stranded RNA (dsRNA) containing sequence homology to an endogenous mRNA is 
into Qduced into the cell (Fire et al. 1998). In the cell, an enzyme termed Dicer 
cleaves the dsRNA into 21 - 23 base pair fragments, termed small interfering RNAs 
(s. ^RNAs) (Elbashir et al. 2001). siRNAs are then incorporated into a cytoplasmic 
nbünucleoprotein complex known as dsRNA-induced silencing complex (RISC) 
(Martinez et al. 2002). RISC uses the antisense strand of siRNA to associate with 
endogenous mRNA that displays sequence homology. The targeted mRNA is then 
cleaved and degraded by non-specific Rnases (Gaudy et al. 2003). The result is 
post-transcriptional suppression of target mRNA expression (Figure 14). 
In mammalian cell cultures, however, exposure to long dsRNA results in non- 
'specific mRNA degradation and translation inhibition, through activation of 
iý,, irrferons, and RNAi may only be achieved through administration of siRNAs 
directly (Elbashir, Lendeckel & Tuschl 2001). In mammals, delivery of siRNA into 
the cytoplasm of the target tissue has been a major hurdle because siRNAs, like all 
nucleic acids, are rapidly degraded by extracellular and intracellular nucleases. 
They are also not readily taken up by cells because they are not able to naturally 
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Figure 14. RNA interference in mammalian systems 
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This cartoon illustrates the mechanism of RNA interference (RNAi) in a mammalian cell. 
RNA may enter the cell in one of three ways. DNA vectors that express long double- 
stranded RNA may be introduced into the cell (left red arrow), or double-stranded RNA may 
directly enter the cell (centre red arrow). The double stranded RNA is then processed by the 
Dicer complex to form small interfering RNAs (siRNAs). Alternatively, siRNAs may be 
directly delivered into the cell (right red arrow). The siRNAs are then incorporated into a 
cytoplasmic ribonucleoprotein complex known as dsRNA-induced silencing complex (RISC). 
RISC uses the antisense strand of the siRNA to associate with the complementary target 
mRNA that results in its cleavage and destruction. (Reproduced from (Aigner 2006)). 
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cross cell membranes. Despite significant technical challenge, naked siRNA has 
been delivered to mice by a high pressure, or hydrodynamic, injection technique 
through the tail vein, that resulted in an 8-fold knockdown of target gene expression 
in the liver (Song et al. 2003), although more typical reduction is usually 20 - 40 % 
(Giladi et al. 2003, Lewis et al. 2002, McCaffrey et al. 2002). 
The hydrodynamic injection technique, through the tail vein, involves the rapid 
delivery of a large volume of siRNA-containing solution into the vasculature, 
typically 2 mL of siRNA-containing solution is delivered within 7 seconds. This rapid 
increase in volume exceeds the capacity of the heart and instead, increases 
pressure in the vena cava that leads to retrograde flow and extravasation of fluid 
(Zhang, Hua 2004). This results in hepatocyte transfection and a smaller degree of 
transfection in other organs including the kidney (Zhang, Budker & Wolff 1999). This 
is also associated with a transient liver toxicity (measured by a rise in serum alanine 
aminotransferase (ALT)), but histological examination does not reveal significant 
pathology. The mechanism of siRNA uptake after hydrodynamic injection is not 
understood. Other macromolecules, such as proteins, may also be delivered by 
hydrodynamic injection and so the mechanism of cellular entry is likely to be non- 
specific. Although siRNA is dependent on delivery efficiency and siRNA efficacy, 
other gene suppression techniques, for example, small molecule inhibitors or 
antisense DNA oligonucleotides, may result in variable specificity or non-specificity 
of target gene suppression. 
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2.6.1 Preparation of the siRNA solution 
Deprotected and annealed high quality (> 90 % pure) HIF-1a siRNA for 
mouse was predesigned and synthesised by Qiagen with the following sequences 
(NCBI accession number NM010431): 
5'-GCUCAAUUUAUGAAUAUUAdTdT-3' (sense) 
5'-UAAUAUUCAUAAAUUGAGCdGdG-3' (antisense) 
siRNAs were designed using standard siRNA design guidelines, to avoid 5' or 3' 
untranslated regions (UTRs), in case other proteins bound to these regions 
prevented siRNA binding. A BLAST search was used to check that this sequence 
was not complementary to other non-target mRNAs, and was synthesised with a 
dTdT overhang. A scramble, or nonsense, siRNA without specific gene silencing 
activity was also provided by Qiagen as a negative control. A dose of 50 µg of HIF- 
la siRNA was used for each animal, as recommended by the manufacturer. This 
was dissolved in siRNA suspension buffer (Qiagen) and added to RNase-free PBS, 
to a total volume of 2 mL, approximately equivalent to 10 % of the weight of the 
mouse. The siRNA solution was warmed to room temperature prior to delivery. 
2.6.2 Preparation of the mouse for surgery 
Animals were placed in a sealed gas chamber where anaesthesia was 
induced with 5% isoflurane and maintained with 2% isoflurane. Endotracheal 
intubation was performed with a 20 G cannula and tubings were connected to a 
mechanical ventilator set to 200 breaths / minute. Body temperature was measured 
by a temperature sensing probe inserted behind the left ear, and maintained at 
37 
°C +/- 0.1 °C by using a heated bed and a heating 
lamp. The lack of response to 
pain, by pinching the foot, indicated sufficient depth of anaesthesia. 
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2.6.3 Hydrodynamic tail vein injection in mice 
A small incision was made midway in the dorsal aspect of the mouse tail, 
optimising visualisation of the tail vein. Upon exposure of the tail vein by blunt 
dissection, it was isolated with fine silk suture slings passed underneath, at the 
proximal as well as the distal end of the vein. The distal sling was tied to reduce the 
loss of injection substance distally. A cannula was then inserted for the 
administration of treatment. Back flow of blood into the cannula established that it 
was properly positioned for a clear injection pathway. The complete volume of 
siRNA solution was then rapidly dispensed into the vein within 10 seconds at a 
constant flow rate. Following closure of the wound, the mouse was emerged from 
anaesthesia and rested for 24 hours (Figure 15). The mouse was then 
preconditioned by gas exposure with 75 % xenon (or 75 % nitrogen as a control) 
balanced with 25 % oxygen for 2 hours as previously described. Twenty-four hours 
after gas exposure, mice were either sacrificed for kidney harvesting for Western 
blotting, or subjected to renal ischaemic-reperfusion injury (IRI) surgery (described 
below). Figure 16 illustrates the siRNA preconditioning experimental groups. 
2.7 RENAL ISCHAEMIC-REPERFUSION INJURY 
Twenty-four hours after gas exposure to either 75 % xenon or nitrogen with 
25 % oxygen, mice were anaesthetised with 1-2% isoflurane. Midline laparotomy 
was performed and renal IRI was induced by right renal pedicle clamping for 25 
minutes, or by right renal pedicle clamping for 40 minutes with left nephrectomy in 
renal failure experiments. Renal ischaemia was confirmed by observing the change 
in colour of the kidneys from red to blanched. Sham-operated mice were dissected 
as above but with no occlusion of the renal vasculature. The intra-abdominal 
temperature was maintained at 37 +/- 0.1 °C with a heating pad which was servo- 
adjusted by a temperature controller (Engineering Inc, 
Stamford, CT, USA) 
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throughout the experiment. The wound was closed with sutures and the skin treated 
with topical iodine solution. Twenty-four hours of reperfusion took place before 
animals were sacrificed and kidneys harvested for Western blotting, or fixed in 4% 
PFD (Figure 17). For survival experiments in the model of renal failure, mice were 
not sacrificed after the reperfusion period, but monitored on a daily basis, for 7 days, 
with a scoring assay based on body weight, activity and general appearance. Any 
animals that scored >7 were euthanized (Table 3). 
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Figure 15. Photograph of tail vein injection in mice 
Photograph of tail vein injection in mice, as seen through a light microscope to optimise 
visualisation. 
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Figure 16. Time course and groups of HIF-la siRNA in xenon preconditioning 
experiments in mice 
This schematic cartoon depicts the experimental groups and time course (not drawn to 
scale) of HIF-1a siRNA in xenon preconditioning experiments in mice. Mice received a single 
hydrodynamic tail vein injection (50 pg siRNA in 2 mL PBS). Twenty-four hours later, they 
were exposed to 75 % xenon, or nitrogen, for 2 hours. After 24 hours, mice were sacrificed 
for analysis of gene and protein expression. Abbreviations: PBS, phosphate-buffered 
saline; NsiR, nonsense siRNA; HsiR, HIF-1a siRNA. 
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Figure 17. Time course and groups of renal ischemia-reperfusion experiments 
in mice 
This schematic cartoon depicts the experimental groups and time course (not drawn to 
scale) of the renal ischaemic-reperfusion experiments. Mice received a single hydrodynamic 
tail vein injection (50 pg siRNA in 2 mL PBS). Twenty-four hours later, they were exposed to 
75 % xenon, or nitrogen, for 2 hours. After 24 hours, renal ischaemia was induced by 
clamping the renal pedicle for 25 minutes (or for 40 minutes and left nephrectomy in the 
renal failure model). This was followed by 24 hours of reperfusion. Abbreviations: PBS, 
phosphate-buffered saline; NsiR, nonsense siRNA; HsiR, HIF-1a siRNA. 
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Post-operative assessment Score 
Body weight 
Greater than pre-operative score 0 
90-100 % pre-operative score 1 
80-90 % pre-operative score 2 
Less than 80 % pre-operative score 4 
Activity 
Normal 0 
Moves spontaneous in cage, but reduced 1 
Moves to stimulus, but not spontaneously 2 
No movement to stimulus, huddled 5 
General appearance 
Normal 0 
Evidence of poor grooming 2 
Animals to be killed if score >7 
Table 3. Post operative assessment scoring assay for renal failure survival 
experiments 
The severe renal ischaemic-reperfusion injury model of renal failure was induced with 40 
minutes of right renal pedicle clamping for 40 minutes and left nephrectomy. Mice were 
subsequently monitored daily over 7 days with a scoring assay based on their body weight, 
activity and general appearance, and immediately euthanized if they scored more than 7. 
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2.8 HISTOLOGICAL ANALYSIS OF RENAL 
ISCHAEMIC-REPERFUSION INJURY 
Kidneys were fixed in 4% PFD as previously described and dehydrated with 
an automated dehydrator for 24 hours before embedding in paraffin wax. Coronal 
sections, 5µm thick, were cut at regular 500 µm intervals with a microtome, and 
hen placed on glass slides (Super Frost). Samples were then dewaxed and 
Dehydrated by running slides through xylene, 100 % ethanol, 90 % ethanol and 75 % 
ethanol and then water. Slides were then immersed in haematoxylin for 1 minute for 
-raining of nucleic acid components, rinsed with water, and immersed in eosin stain 
for 1-2 minutes, for staining of cytoplasmic cell components, and rinsed again. 
Sections were dehydrated again by running slides through ascending ethanol 
washes and then cleared with xylene. Glass cover slips were then placed over the 
sections using mounting solution. For each kidney sample, 10 photomicrographs 
were taken from representative areas of the renal cortex with a digital camera 
(Olympus C 2020) attached to a light microscope (Zeiss Stemi 2000-C) with x 20 
magnification. For each photomicrograph, arranged in a random order, ten cortical 
tubule cross-sections were chosen at random and scored 0-3 by a scorer who was 
unaware of the treatment groups, using a pathological scoring system modified from 
(Hamar et al. 2004), to obtain a maximum score of 300 per treatment group (Figure 
18) and (Table 4). 
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Figure 18. Method of single-blinded histopathological analysis for renal 
schaemic-reperfusion injury experiments 
Above, are photomicrograph examples of cross-sections of the normal and injured renal 
-ýIf. x, with scores from 0-3 assigned to 10 randomly chosen tubules. For each kidney, 10 
photomicrographs were taken from the renal cortex. For each photomicrograph, 10 renal 
were chosen at random by the scorer, who was unaware of the treatment groups. 
w renal tubule chosen, a score of 0-3 was assigned, based on criteria described in 
ifahle 4, giving a maximum score of 300 per kidney. Mean scores were then calculated for 
iiq(-. -itment group (magnification x20). 
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Histopathological scoring criteria 
0- No damage 
Normal renal tubular cells 
1- Mild damage 
Slight dilatation of tubular lumen (50 % 
increase in diameter compared to normal) 
2- Moderate damage 
Flattening of epithelial cells, or partial loss of 
nuclear staining, or moderately dilated lumen 
(50-100 % increase in diameter compared to 
normal) 
3- Severe damage 
Flattening of epithelial cells and lacking 
nuclear staining or severely dilated lumen 
(>100 % increase in diameter compared to 
normal) 
Photomicrograph (x20) 
. TJ 
j 
i 
it7p 
Table 4. Histopathological scoring system for renal ischaemic-reperfusion 
injury experiments 
This histopathological scoring system, based on a system devised by Hamar and colleagues 
(Hamar et al. 2004), assessed the degree of renal tubular dilatation, nuclear staining, and 
the presence of flattened epithelial cells, after renal ischaemic-reperfusion injury. The scorer 
was unaware of the treatment groups. 
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2.9 ANALYSIS OF RENAL FUNCTION 
Blood samples from mice subjected to renal IRI were collected and 
centrifuged at 3000 rotations / minute for 10 minutes to obtain blood serum. As 
surrogate markers of renal function, creatinine and urea levels were measured in 
100 pL of serum with an Olympus AU640 analyzer (Diamond Diagnostics, Watford, 
UK). 
2.10 TUNEL STAINING 
Apoptosis of renal tubular epithelial cells was detected by in-situ terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, a method that 
detects DNA fragments by labelling the terminal end of nucleic acids. The assay 
was performed according to the manufacturer's (Obiogene) instructions. Briefly, 
rehydrated 4% paraformaldehyde-fixed cryostat sections were washed with 0.1 M 
PBS, twice for 5 minutes each, and then pretreated with 20 pg / mL proteinase K at 
room temperature for 15 minutes. For positive controls, sections were treated with 
nuclease (R&D system) at 37 °C for 15 minutes. The sections were first quenched 
in 3% hydrogen peroxide in 0.1 M PBS for 5 minutes. The quenched sections were 
then labelled with terminal deoxynucleotidyl transferase (TdT) enzyme at 37 °C for 1 
hour in a humidified chamber and subsequently incubated with anti-digoxygenin- 
dUTP, conjugated to horseradish peroxidase for 30 minutes at room temperature. 
They were then stained with DAB, followed by counterstaining with methyl green. 
The sum of TUNEL positive cells in an objective grid from ten areas of randomly 
selected renal cortex was counted under a 40x objective lens, by an investigator 
who was blinded to the experimental protocol. 
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2.11 STATISTICAL ANALYSIS 
The results were analysed with Instat software and expressed as means +/- 
standard deviation of the mean. Statistical comparison was determined by one-way 
analysis of variance (ANOVA) followed by post hoc Student-Newman-Keul's 
multiple comparison test for parametric data, and Mann Whitney U test for non- 
parametric data. Survival was analysed by Kaplan-Meier test. Values with p<0.05 
were considered as statistically significant. 
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3.1 REGULATION OF HIF-1 a BY XENON 
PRECONDITIONING 
3.1.1 Nitrogen does not affect HIF-1 a protein expression 
In establishing a suitable control for evaluating HIF-1a protein expression, 
is sensitive to oxygen concentrations, a gas exposure paradigm of 75 % 
i u, i r)gen balanced with 25 % oxygen for 2 hours was used and compared to mice 
xposed to normal room air, in order to be consistent with the 25 % oxygen used in 
the xenon preconditioning paradigm previously employed (Ma et al. 2006). 
6 ok ýuwing exposure to either room air or 75 % nitrogen, mice were sacrificed over a 
time course of 0,2,4,8 and 24 hours, and brains and kidneys harvested. Western 
blortii dti was performed to determine whether these two experimental groups 
ditfeY (, ntially expressed HIF-1 a. 
HlF -1a protein expression was low and remained unaltered over the 24 hour time 
coic:, e in the mouse brain exposed to 75 % nitrogen with 25 % oxygen. These 
1l gigs were comparable to mice exposed to room air. Results were normalised to 
ký loading control, a-tubulin, to confirm that each sample contained equal 
concentrations of total protein. Similar findings were observed in kidney samples. 
'Thereafter, control mice were exposed to 75 % nitrogen with 25 % oxygen for 2 
hours, and sacrificed 24 hours after. This was to minimise the number of animals 
p ýýd in further experiments and to remain consistent with the xenon preconditioning 
paradigm previously established. There were no apparent signs of oxygen toxicity or 
distress to the mouse at 25 % oxygen exposure and this also avoided any risk of 
hypoxic exposure to mice, which would affect HIF-1 a expression (Figure 19). 
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Figure 19. Nitrogen exposure does not affect HIF-la protein expression in the 
mouse brain or kidney 
In the 24 hours following exposure to 75 % nitrogen and 25 % oxygen for 2 hours, HIF-1a 
protein expression was not altered in the mouse (A) brain or (B) kidney, compared to mice 
exposed to room air. Western blots of HIF-1a were normalised to the internal control, a- 
tubulin, and expressed relative to the air control (n=3 per group). 
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3.1.2 Hypoxia increases HIF-1 a protein expression 
Oxygen regulates HIF-la at the post-translational level, through oxygen- 
dependent activity of PHDs and subsequent HIF-la degradation. Hypoxia inhibits 
activity of the PHDs that causes HIF-1 a protein accumulation. For positive controls, 
male adult mice were exposed to a previously established hypoxic preconditioning 
paradigm of 8- 10 % oxygen balanced with nitrogen for 3 hours. During exposure, 
mice were observed to reduce their spontaneous movements and were tachypneic. 
Within seconds of reoxygenation, the normal behaviour characteristics were 
displayed, such as grooming and exploration of their environment. Immediately 
following the end of hypoxic exposure, mice were sacrificed and brain and kidneys 
rapidly harvested. As expected, Western blot for expression of HIF-la protein was 
significantly increased in hypoxia treated mice compared to nitrogen controls, in 
both the mouse brain (3.6 +/- 1.6 fold increase versus 1.0 of control (mean +/- SD)) 
and kidney (4.3 +/- 1.4 fold increase) (n =3 per cohort) (Figure 20). 
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Figure 20. Hypoxic exposure increases HIF-la protein expression in the 
mouse brain and kidney 
Exposure to 3 hours of hypoxia (8 % oxygen) resulted in a striking increase in HIF-1a protein 
expression, the oxygen-sensitive subunit of the HIF-1 transcription factor, in the mouse (A) 
brain (3.6 +/- 1.6 versus 1.0 of control p<0.01) and (B) kidney (4.3 +/- 1.4 versus 1.0 of 
control, p<0.01). Western blots of HIF-1 a were normalised to a-tubulin, and expressed 
relative to the control (75 % nitrogen). Data are presented as means +/- SDs. ** p<0.01 vs. 
control (n=3 per cohort). Abbreviations: C, control; H, hypoxia; HIF-1a, hypoxia-inducible 
factor-1 alpha; SD, standard deviation. 
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Subsequently, HIF-la expression over the time course of 0,2,4,8 and 24 hours 
after hypoxic preconditioning was determined. HIF-la was induced immediately 
following hypoxic preconditioning in both the brain (3.9 +%- 1.5 fold) and kidney (4.3 
+/- 1.6 fold) but strikingly declined to baseline levels by 2 hours after hypoxia (n=3 
per group) (Figure 21). These observations corroborate with the findings of other 
investigators (Jewell et al. 2001). 
The duration of hypoxic exposure was 3 hours rather than 2 hours as used with 
xenon, nitrous oxide or nitrogen exposure. Less than 3 hours of hypoxic exposure 
has not been shown to protect against the noxious effect of subsequent HI injury, 
whereas 3 hours of hypoxia was able to provide robust protection against 
experimental stroke (Gidday et al. 1994). This paradigm also lacks detectable 
damage to the hippocampus or cortical neurons at the histological level (Prass et al. 
2003). 
3.1.3 Xenon increases HIF-1 a protein expression 
To ascertain the effect of xenon preconditioning on HIF-la expression, mice 
were exposed to the xenon preconditioning paradigm of 75 % xenon balanced with 
25 % oxygen for 2 hours, and sacrificed over a time course of 0,2,4,8 and 24 
hours after. Western blots in brain and kidneys of mice were performed for detection 
of HIF-la. In the brain, xenon preconditioning increased HIF-la protein expression 
after 2 hours (1.80 +/- 0.2 versus 1.0 of control, p<0.05) in a time-dependent 
manner, with further upregulation and maximal expression after 24 hours (2.91 +/- 
0.62 versus 1.0 of control, p<0.01). Similarly in the kidney, HIF-1 a expression was 
increased 4 hours after xenon exposure (1.90 +/- 0.59 versus 1.0 of control, p< 
0.05), with further upregulation and maximal expression after 24 hours (3.92 +/- 
0.89 versus 1.0 of control p<0.001) (n=4 per cohort) (Figure 22). This sustained 
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='aqure 21. Hypoxic exposure transiently increases HIF-1a protein expression 
in the mouse brain and kidney 
the time course of 0,2,4,8 and 24 hours after exposure to hypoxia (8 % oxygen), an 
increase in HIF-1a protein expression was detectable immediately following hypoxia, at 0 
hnuº 
, 
in the (A) brain (3.9 +/-1.5 fold increase) and (B) kidney (4.3 +/- 1.6 fold increase). Its 
, ý) - sinn was transient and declined to baseline levels by 2 hours after hypoxia. Western 
blots of HIF-1 a were normalised to a-tubulin, and expressed relative to the control (75 % 
nitrogen). Data are presented as means +/- SDs. ** p<0.01 vs. control (n=3 per group). 
Abbreviations: C, control; H, hypoxia; HIF-1 a, hypoxia-inducible factor-1 alpha; SD, 
standard deviation. 
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Figure 22. Xenon exposure increases HIF-l a protein expression in the mouse 
brain and kidney 
Exposure to 75 % xenon and 25 % oxygen for 2 hours time-dependently increased HIF-1a 
protein expression in the mouse (A) brain after 2 hours (1.80 +/- 0.2 versus 1.0 of control, p 
< 0.05) in a time-dependent manner, with further upregulation and maximal expression after 
24 hours (2.91 +/- 0.62 versus 1.0 of control, p<0.01). In the (B) kidney, HIF-1a expression 
was increased 4 hours after xenon exposure (1.90 +/- 0.59 versus 1.0 of control, p<0.05), 
with further upregulation and maximal expression after 24 hours (3.92 +/- 0.89 versus 1.0 of 
control p<0.001). Western blots of HIF-1 a were normalised to a-tubulin, and expressed 
relative to the control (75 % nitrogen). Data are presented as means +/- SDs. *p<0.05, ** p 
< 0.01, *" p<0.001 versus control (n=4 per group). Abbreviations: HIF-1 a, hypoxia- 
inducible factor-1 alpha; SD, standard deviation. 
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expression of HIF-la occurs in the presence of oxygen, and is in contrast to the 
immediate and transient elevation observed after hypoxic exposure. These results 
indicate that xenon is an anaesthetic gas with HIF-la inducing capability and 
suggest that the mechanism is different from that of hypoxic HIF-la induction. 
To confirm and extend the finding that xenon increases HIF-la expression, 
immunohistochemistry was performed for HIF-1 a in the mouse brain. While little or 
no nuclear expression of HIF-1a was observed in nitrogen-exposed control animals, 
xenon exposure resulted in nuclear accumulation of HIF-la after 6 hours, in brain 
regions that are rendered tolerant by xenon preconditioning in acute neuronal 
hypoxic-ischaemic injury (Ma et al. 2006) (Figure 23). Additionally, primary 
neuronal-glial co-cultures were exposed to xenon. There was a trend towards an 
increase in HIF-la expression from 4 hours after xenon exposure, with significant 
expression occurring after 8 hours (2.2 +/- 0.28 versus 1.0 of control, p<0.05) (n=3 
per group) (Figure 24). Human kidney 2 (HK2) cells were also exposed to xenon, 
where HK2 is a well characterised human kidney proximal tubular epithelial cell line. 
HK2 cells exhibited HIF-1 a activation with similar kinetics to those observed in the in 
vivo mouse kidney. HIF-1a expression was increased after 4 hours (2.2 +/- 0.59 
versus 1.0 of control, p<0.05) with maximal expression after 24 hours (3.8 +/- 0.63 
versus 1.0 of control, p<0.001) (n=3 per group). Therefore, xenon preconditioning 
activates HIF-1 a in isolated human renal epithelial cells (Figure 25). 
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Figure 23. Immunohistochemistry examples of xenon-induced HIF-1a 
expression in the mouse brain 
Above are representative immunohistochemical sample images, immunostained for HIF-1a. 
Panel (A) shows a section of the neuronal cortex from a control mouse, 6 hours after 
treatment with 75 % nitrogen and 25 % oxygen for 2 hours. Panel (B) shows a section of the 
neuronal cortex, 6 hours after treatment with 75 % xenon and 25 % oxygen for 2 hours. 
More HIF-1a positive cells were detected in xenon-treated mice, compared to controls. Scale 
bar represents 100 pm. 
Imperial College London Page 121 of 230 July 2008 
Ta Lim 
A ö3 L 
C 
0 
U 
u2 > 
Q) 
(ü 
v1 
c_ 
ö 
XO 
Cý 
HIF-la . ý,. "ý "-~ 
iiIi 
248 24 
a-tubuIin ,,, q OF, 
C0248 24 
Hours after xenon exposure 
NG 
Figure 24. Xenon exposure increases HIF-la protein expression in primary 
raN-liional-glial co-cultures 
lo protein expression was time-dependently increased in neuronal-glial co-cultures 
->E d to 75 % xenon, 20 % oxygen and 5% carbon dioxide for 2 hours. Maximal xenon- 
induced HIF-1a expression occurred after 8 hours (2.2 +/- 0.28 versus 1.0 of control, p< 
0 05) Western blots of HIF-1 a, were normalised to a-tubulin, and expressed relative to the 
a..,: mtiol (75 % nitrogen). Data are presented as means +/- SDs. *p<0.05 (n=3 per group). 
Abbreviations: HIF-1a, hypoxia-inducible factor-1 alpha; NG, neuronal-glial co-culture; SD, 
standard deviation. 
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I ijure 25. Xenon exposure increases HIF-1a protein expression in human 
kidney-2 cell cultures 
`, )sure to 75 % xenon, 20 % oxygen and 5% carbon dioxide for 2 hours time-dependently 
°=: ý;, ed HIF-1a protein expression in HK2 cell cultures from 4 hours (2.2 +/- 0.59 versus 
1.0 of control, p<0.05) with maximal expression after 24 hours (3.8 +/- 0.63 versus 1.0 of 
control, p<0.001). Western blots of HIF-1 a, were normalised to a-tubulin, and expressed 
relrflive to the control (75 % nitrogen). Data are presented as means +/- SDs. `p<0.05. ** p 
o 01, and *** p<0.001 versus control (n=3 per group). Abbreviations: HIF-1 a, hypoxia- 
inducible factor-1 alpha; HK2, human kidney-2 cells; SD, standard deviation. 
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3.1.4 Xenon increases expression of erythropoietin and 
vascular endothelial growth factor 
In order to ascertain whether xenon-induced HIF-la was redundant or 
indeed biologically active, the effect of xenon preconditioning on expression of the 
HIF target gene EPO was examined in the mouse brain and kidney. In the kidney, 
RT-PCR revealed a time-dependent increase in EPO mRNA expression from 2 
hours after xenon exposure (3.8 +/- 0.79, p<0.05), with striking maximal 
expression occurring 24 hours after (6.32 +/- 1.98, p<0.01) (n=3 per group) (Figure 
26). Evidence of EPO mRNA translation was observed when Western blots for EPO 
protein detected a significant increase in expression 24 hours after xenon exposure 
(2.3 +/- 0.74 versus 1.0 of control, p<0.01). In the brain, xenon-induced expression 
of EPO protein after 24 hours (2.23 +/- 0.60 versus 1.0 of control, p<0.05) was also 
observed, occurring in a comparable fashion to that in the kidney (n=3 per group) 
(Figure 27). 
It is not known whether xenon's effects are exclusive to EPO alone or more 
widespread, and therefore protein expression of another canonical HIF target gene, 
vascular endothelial growth factor (VEGF), in the mouse kidney was evaluated. 
Western blot detected an elevation in VEGF expression from 8 hours (1.9 +/- 0.22 
versus 1.0 of control, p<0.05) to 24 hours following xenon exposure (2.05 +/- 0.25 
versus 1.0 of control, p<0.05), in a similar manner to xenon-induced EPO. The 
time course of EPO mRNA elevation (occurring from 2 hours and preceding the 
protein expression of EPO and VEGF from 24 hours) is relevant to xenon-induced 
HIF-1a, where accumulation begins after 2 hours with maximal expression after 24 
hours (Figure 28). 
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Figure 26. Xenon exposure increases erythropoietin mRNA transcription in 
the mouse kidney 
RT-PCR experiments showed that exposure to 75 % xenon and 25 O, / oxygen for 2 hours 
time-dependently increased EPO mRNA expression in the mouse kidney from 2 hours after 
xenon exposure (3.8 +/- 0.79, p<0.05), with maximal expression occurring 24 hours after 
(6.32 +/- 1.98, p<0.01). EPO mRNA results were normalised to HIF-1ß mRNA and 
expressed relative to the control (75 % nitrogen). Data are presented as means +/- SDs. *p 
< 0.05, and ** p<0.01 versus control (n=3 per group). Abbreviations: EPO, erythropoietin; 
HIF-1 ß, hypoxia-inducible factor-1 beta; SD, standard deviation. 
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Figure 27. Xenon exposure increases erythropoietin protein expression in the 
mouse brain and kidney 
Exposure to 75 % xenon and 25 % oxygen for 2 hours increased EPO protein expression in 
the mouse (A) brain after 24 hours (2.23 +/- 0.60 versus 1.0 of control, p<0.05). Similarly, 
in the (B) kidney, xenon increased EPO protein expression after 24 hours (2.3 +/- 0.74 
versus 1.0 of control, p<0.01). Western blots of EPO were normalised to a-tubulin, and 
expressed relative to the control (75 % nitrogen). Data are presented as means +/- SDs. *< 
p<0.05, ** p<0.01 versus control (n=3 per group). Abbreviations: EPO, erythropoietin; 
SD, standard deviation. 
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Figure 28. Xenon exposure increases VEGF protein expression in the mouse 
kidney 
Exposure to 75 % xenon and 25 % oxygen for 2 hours increased VEGF protein expression 
in the mouse kidney from eight hours onwards (1.9 +/- 0.22 versus 1.0 of control, p<0.05). 
Western blots of VEGF were normalised to a-tubulin, and expressed relative to the control 
(75 % nitrogen). Data are presented as means +/- SDs. *p<0.05 versus control (n=3 per 
group). Abbreviations: VEGF, vascular endothelial growth factor; SD, standard deviation. 
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3.1.5 Nitrous oxide does not affect HIF-1 a protein expression 
The experiments above demonstrate that xenon preconditioning increases 
expression of HIF-la and its target genes, EPO and VEGF. But whether xenon's 
preconditioning effect is related to its anaesthetic properties is not known. Xenon 
exerts its anaesthetic effects through antagonism of the excitatory NMDA receptor, 
thereby reducing downstream excitatory transmission. Nitrous oxide, also known as 
laughing gas, is another NMDA receptor antagonist that is routinely used in 
anaesthetic practice. To ascertain whether HIF-la is regulated by anaesthetic 
NMDA receptor antagonism, mice were exposed to 75 % nitrous oxide for 2 hours 
and HIF-1 a expression determined in the kidney from 0,2,4,8 and 24 hours after. 
Western blot for HIF-1a revealed no effect of nitrous oxide on HIF-1a expression at 
any of the time points studied, compared to controls (n=4) (Figure 29). This 
suggests that the capability of xenon to induce HIF-1a is not simply due to its 
anaesthetic properties, and is independent from its blocking activity at the NMDA 
receptor. 
Imperial College London Page 
128 of 230 July 2008 
Ta Lim 
A2 
C 0 U 
Lplilil 
0248 24 
HIF -1a . 490 _ ,. ý... _ý-. º _ ý.. 
-- 7M ML 
a-tubulin 
C0248 24 
Hours after nitrous oxide exposure 
B 752 C 0 U N 
(n 1 c0 
0 
U 
C_ 
0 
0 
X 
HIF-1a 
pill' 
48 24 
a-tubulin ,, 
C 
41- -, --, ft ýII-- 
0248 24 
Hours after nitrous oxide exposure 
Brain 
Kidney 
Figure 29. Nitrous oxide exposure does not affect HIF-1 a protein expression 
in the mouse brain or kidney 
Exposure to another NMDA receptor antagonist, 75 % nitrous oxide and 25 % oxygen for 2 
hours, did not affect expression of HIF-1a over the 24 hour time-period studied, in the mouse 
(A) brain or (B) kidney, compared to control mice exposed to 75 % nitrogen. Western blots 
of HIF-1 a were normalised to the internal control a-tubulin, and expressed relative to the 
nitrogen control (n=4 per cohort). Abbreviations: HIF-1 a, hypoxia-inducible factor-1 alpha; 
NMDA, N-methyl D-aspartate. 
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3.2 MECHANISM OF XENON-INDUCED HIF-l a 
PROTEIN EXPRESSION 
3.2.1 Xenon increases HIF-1 a through a degradation- 
independent mechanism 
Hypoxia stabilises HIF-la through inhibition of its degradation in a PHD2 and 
VHL -dependent pathway. To answer whether xenon regulates HIF-1 a by impairing 
its destruction via this pathway, parental VHL-negative renal cell carcinoma-4 cells 
(RCC4-), and an otherwise isogenic sub-line stably transfected with pcDNA3-VHL 
(RCC4+) were used. Both RCC4 sub-lines were simultaneously exposed to 75 % 
xenon for 2 hours and harvested at 0,2,4,8 and 24 hours after for Western blot 
analysis. As expected, RCC4- (without VHL) cells expressed a higher level of HIF- 
la compared to RCC4+ (with VHL) cells. However, xenon time-dependently 
increased HIF-1 a protein expression in both cell sub-lines to the same order of 
magnitude, with a comparable rate of increase evident at all time points; twenty-four 
hours after xenon exposure, HIF-la expression was increased in RCC4- by 3.31 +/- 
0.89 fold, and in RCC4+ by 3.15 +/- 1.10 fold, versus 1.0 of control, p<0.01 (n=4 
per group). Therefore, xenon-induced increase in HIF-la expression occurs through 
a VHL-independent mechanism (Figure 30). 
The effect of xenon preconditioning on HIF-1a degradation was also investigated by 
measuring the expression of PHD2 protein by Western blot analysis. Mice were 
preconditioned with xenon and sacrificed at 0,2,4,8 and 24 hours after. Xenon did 
not affect PHD2 protein expression compared to controls in the brain or kidney (n=3 
per group) (Figure 31). Although HIF-1 a is typically regulated through degradation, 
xenon's actions are not dependent on components of the canonical HIF-la 
destruction pathway. 
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Figure 30. Xenon exposure increases HIF-1a through a VHL-independent 
mechanism 
RCC4- and RCC4+ cells were simultaneously exposed to 75 % xenon, 20 % oxygen and 5 
% carbon dioxide for 2 hours, and expression of HIF-1 a protein determined by Western blot 
analysis. RCC4- cells expressed a constitutively higher level of HIF-1a compared to RCC4+ 
cells in the controls and at all time points after xenon exposure. Xenon exposure time- 
dependently increased HIF-1a protein expression in both cell sub-lines, to the same order of 
magnitude. Twenty-four hours after xenon exposure, HIF-1a expression was increased in 
RCC4- by 3.31 +/- 0.89 fold, and in RCC4+ by 3.15 +/- 1.10 fold, versus 1.0 of control, p< 
0.01. Western blots of HIF-1 a were normalised to a-tubulin, and expressed relative to the 
control (75 % nitrogen). Data are presented as means +/- SDs. ** denotes p<0.01, versus 
control (n=4 per group). Abbreviations: HIF-1a, hypoxia-inducible factor-1 alpha; RCC4-, 
parental VHL-negative renal cell carcinoma-4 cells; RCC4+, renal cell carcinoma-4 cells with 
stable pcDNA3-VHL transfection; SD, standard deviation. 
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Figure 31. Xenon exposure does not affect PHD2 protein expression in the 
mouse brain or kidney 
In the 24 hours following exposure to 75 % xenon and 25 % oxygen for 2 hours, expression 
tiGie PHD2 enzyme, required for HIF-1a prolyl hydroxylation, was not altered in the mouse 
(Af ', -)! ain or (B) kidney compared to nitrogen controls. Western blots of PHD2, were 
normalised to the internal control a-tubulin, and expressed relative to the control (75 % 
nitrogen) (n=3 per group) Abbreviations: PHD2, prolyl hydroxylase domain-containing 2 
enzyme, 
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3.2.2 Xenon does not affect HIF-1 a mRNA transcription 
HIF-1a abundance may be regulated at the level of its gene transcription or 
mRNA translation. RCC4+ cells were preconditioned to explore the effect of xenon 
on HIF-1 a transcription over a 24 hour time course. Although xenon increases HIF- 
la protein expression, no significant changes in HIF-la mRNA expression were 
detectable over the same period. Further in vivo studies in the mouse brain and 
kidney corroborated these findings that xenon did not affect HIF-1a mRNA 
expression (Figure 32). 
3.2.3 Xenon increases HIF-1 a protein expression through a 
translation-dependent mechanism 
Next, the role of xenon in modulating the translational efficiency of HIF-1 a 
mRNA was explored. The effect of xenon exposure on mTOR expression was 
studied by Western blot in RCC4+ cells, where mTOR is the best described 
regulator of protein translation, including HIF-1a synthesis. Interestingly, a 
detectable increase in mTOR protein expression could be observed from 2 hours 
after xenon exposure (1.48 +/- 0.39 fold increase versus 1.0 of control, p>0.05), 
but striking and maximal expression occurred at 24 hours after xenon exposure 
(5.93 +/- 1.36 versus of control, p<0.001) (Figure 33). 
To explore the significance of the xenon-induced increase in mTOR protein 
expression, the specific mTOR inhibitor, rapamycin (25,50 or 100 nM, dissolved in 
0.00025 % DMSO), was administered 30 minutes prior to xenon or nitrogen 
exposure in RCC4+ cells. Cells were subsequently harvested 24 hours after, for 
detection of HIF-1a protein. Control cells received volume-matched culture medium 
containing 0.00025 % DMSO. Rapamycin alone did not affect HIF-1 a expression; as 
expected xenon exposure increased expression of HIF- I a. 
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(Figure 32, legend overleaf) 
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Figure 32. Xenon exposure does not affect HIF-l a mRNA transcription 
Over the same 24 hour time period that exposure to 75 % xenon increases HIF-1a protein 
expression, xenon does not affect HIF-1a mRNA expression in the mouse (A) brain or (B) 
kidney, nor in (C) the RCC4+ cell sub-line, compared to nitrogen controls. RT-PCR results of 
HIF-1a mRNA were normalised to HIF-1ß mRNA, and expressed relative to the control (75 
% nitrogen) (n=3 per group) Abbreviations: RCC4+, renal cell carcinoma cell sub-line with 
stable pcDNA3-VHL transfection. 
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Figure 33. Xenon exposure increases mTOR protein expression in RCC4+ cell 
culture 
The involvement of mTOR in xenon-induced HIF-1a protein expression was investigated by 
Western blot analysis. Exposure to 75 % xenon and 25 % oxygen for 2 hours induced a 
detectable, but not significant, increase in mTOR abundance after 2 hours. A striking 
increase occurred after 24 hours (5.93 +/- 1.36 versus of control, p<0.001). Western blots 
of mTOR were normalised to a-tubulin, and expressed relative to the control (75 % nitrogen). 
Data are presented as means +/- SDs. 'p<0.05, "' p<0.001 versus control (n=5 per 
group). Abbreviations: mTOR, mammalian target of rapamycin; RCC4+, renal cell 
carcinoma cell sub-line with stable pcDNA3-VHL transfection; SD, standard deviation. 
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However, the administration of rapamycin prior to xenon exposure significantly 
'' ibited xenon-induced HIF-1a, with greatest HIF-la inhibition occurring at the 
highest concentration of rapamycin tested (lOOnM; 0.89 +/- 0.21 compared to 2.89 
+/- 0.93 of xenon alone, p<0.01) (n=4 per group) (Figure 34). 
Next, the effect of rapamycin was determined in vivo. Rapamycin (0.25 mg / Kg or 
`d 50 mg / Kg), in 0.1 % DMSO-containing normal saline, was administered by a 
single intraperitoneal (IP) injection thirty minutes prior to xenon exposure; HIF-1a 
expression was determined after 24 hours by Western blot analysis. In the brain, 
llý la expression was not altered in mice treated with rapamycin alone at either 
doses and, as expected, xenon alone significantly increased HIF-1a protein 
F Pression. A rapamycin dose of 0.25 mg / Kg, IP, did not attenuate the xenon- 
,, ii aced expression of HIF-1 a, but a dose of 1.50 mg / Kg, IP, did significantly 
attenuate HIF-1 a (1.21 +/-0.58 versus 2.9 +/- 0.68 of xenon alone, p<0.01). 
Similarly in the kidney, rapamycin 1.5 mg / Kg, IP, significantly attenuated the 
Expression of xenon-induced HIF-la (0.85 +/- 0.48 versus 2.86 +/- 0.58 of xenon 
'wbne, p<0.01) (n=4 per group). Therefore, the inhibitory effects of rapamycin, in 
vitro and in vivo, provide further evidence that xenon increases HIF-la protein 
expression through an mTOR-mediated pathway (Figure 35). 
[Jimethyl sulfoxide (DMSO) is a commonly used solvent, that dissolves both polar 
and apolar compounds, and is required in the preparation of rapamycin. A search of 
the open literature reveals no publications detailing its effect on HIF-1a. However, 
control experiments conducted as part of these rapamycin experiments showed that 
DMSO is able to increase expression of HIF-la in a concentration-dependent 
manner. RCC4+ cell cultures were incubated in cell culture medium containing 
0.0001 - 1.0 % DMSO (control cells received volume-matched medium without 
[)MSO) for 30 minutes. After this time, the medium was removed and replenished 
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we 34. Rapamycin inhibits xenon-induced HIF-1a protein expression in 
RrC-4+ cell culture 
lo determine the effect of rapamycin (25,50, or 100 nM in 0.00025 % DMSO cell culture 
medium) on xenon-induced HIF-1a protein expression, RCC4+ cells were pre-treated with 
rapamycin (or volume-matched 0.00025 % DMSO medium) thirty minutes prior to 75 % 
xenon exposure (or 75 % nitrogen) for 2 hours, and HIF-1a protein expression determined 
24 hours later. Rapamycin alone did not alter HIF-1a protein expression, compared to 
ontrol cells, whereas xenon exposure increased HIF-1a by 2.89 +/- 0.93 fold (versus 1.0 of 
nntrol, p<0.01). Pre-treatment with each of the concentrations of rapamycin tested 
Mýobited the induction of HIF-1a by xenon, with greatest HIF-1a inhibition occurring after 100 
eM rapamycin pre-treatment (0.89 +/- 0.21 versus 2.89 +/- 0.93 of xenon, p<0.01). Western 
blots of HIF-1 a were normalised to a-tubulin, and expressed relative to the control. Data are 
oted as means +/- SDs. Single crosses denote p<0.05, and double crosses p<0.01 
o,, xenon alone (n=4 per group). Abbreviations: C, control; DMSO, dimethyl sulfoxide; 
HIFela, hypoxia-inducible factor-1 alpha; R, rapamycin; RCC4+, renal cell carcinoma cell 
.: ý dine with stable pcDNA3-VHL transfection; SD, standard deviation; X, xenon; XR; xenon 
, _irid rapamycin. 
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Figure 35. Rapamycin inhibits xenon-induced HIF-l a protein expression in the 
mouse brain and kidney 
In both the mouse (A) brain and (B) kidney, rapamycin (0.25 mg / Kg, IP) thirty minutes prior 
to xenon exposure did not attenuate the expression of xenon-induced HIF-1 a, assessed at 
24 hours after xenon exposure. However, a higher dose of rapamycin (1.50 mg / Kg, IP) 
significantly inhibited the expression of xenon-induced HIF-1o in both the brain (1.21 +/- 0.58 
versus 2.90 +/- 0.68 of xenon alone, p<0.01) and kidney (0.85 +/- 0.48 versus 2.86 +/- 0.58 
of xenon alone, p<0.01). Western blots of HIF-1 a were normalised to a-tubulin, and 
expressed relative to the control. Data are presented as means +/- SDs. *p<0.05, ** p< 
0.01, versus 1.0 of control. tt p<0.01 versus xenon alone (n=4 per group). Abbreviations: 
C, control; HIF-1a, hypoxia-inducible factor-1 alpha; R, rapamycin; SD, standard deviation; 
X, xenon; XR, xenon and rapamycin. 
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with DMSO-free medium. Cells were harvested 24 hours later for Western blot 
analysis of HIF-1 a protein. DMSO concentrations greater than 0.1 % significantly 
increased HIF-a. However, the same DMSO concentration was used between 
different treatment groups and these effects do not appear to have confounded the 
results obtained in the experiments with rapamycin (Figure 36). 
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Figure 36. DMSO increases HIF-la protein expression in RCC4+ cell culture 
DMSO (0.0001-1.0 %) increased the expression of HIF-1a in a concentration-dependent 
manner in RCC4+ cell culture. Cells were incubated in DMSO-containing cell culture 
medium for 30 minutes. The medium was then removed and replenished with new DMSO- 
free medium for 24 hours. Western blots of HIF-1 a were normalised to a-tubulin, and 
expressed relative to the control. Data are presented as means +/- SDs. *p<0.05 versus 
1.0 of control (n=3 per group). Abbreviations: C, control; DMSO, dimethyl sulfoxide; HIF-1 a, 
hypoxia-inducible factor-1 alpha; RCC4+, renal cell carcinoma cell sub-line with stable 
pcDNA3-VHL transfection; SD, standard deviation. 
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3.3 NECESSITY OF HIF-1 a IN XENON 
PRECONDITIONING VERSUS RENAL ISCHAEMIC- 
REPERFUSION INJURY 
3.3.1 Delivery of siRNA intro the renal parenchyma by 
hydrodynamic tail vein injection 
Delivery of synthetic double-stranded 3' fluorescein-labelled nonsense 
, aiRNA (50 pg in 2 mL PBS) into mouse tubular epithelium was verified, in 
urriparison to volume-matched PBS injection in control mice. Intracellular 
fluorescent signals were detected in kidney tubular cells 24 hours after injection with 
scramble siRNA, while no such fluorescence was found in control mice 24 hours 
after PBS injection. This result corroborates with previous data that hydrodynamic 
sIRNA injection is capable of accumulating in the kidney (van de Water et al. 2006) 
(Figure 37). 
3.3.2 The functional effect of HIF-la siRNA 
The functional effect of HIF-1a siRNA delivery was verified. Twenty-four 
hours after hydrodynamic tail vein injection of HIF-la siRNA, nonsense siRNA or 
PBS, mRNA expression in mouse kidney of HIF-la and EPO was studied, and 
compared to an uninjected control mouse. RT-PCR detected no difference in HIF-1a 
or EPO mRNA expression in mice treated with scramble siRNA or PBS, compared 
to control. However, an attenuated expression of both HIF-1a and EPO mRNA was 
observed in mice treated with HIF-1a siRNA, indicating knockdown of HIF-la and 
H! F-dependent EPO. Results were normalised to HIF-1 ß which is constitutively 
expressed. However, the effect of HIF-la siRNA did not achieve complete 
imperial College London Page 142 of 230 July 2008 
Ta Lim 
Figure 37. Verification of in vivo delivery of 3' fluorescein-labelled siRNA into 
the mouse renal parenchyma 
Volume-matched (A) phosphate-buffered saline (PBS) or (B) 3' fluorescein-labelled 
nonsense siRNA (50 pg in 2 mL PBS) was hydrodynamically injected into the tail vein of 
mice, to verify its delivery into the renal parenchyma. Renal tubular cells took up the 
nonsense siRNA 24 hours after hydrodynamic injection, as shown by intracellular 
fluorescent signals, while no marker was found in PBS-injected control animals. Scale bar 
represents 100 pm. 
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knockdown, with faint bands for HIF-la and EPO mRNA still visible; this may 
indicate that not all cells were transfected. Consistent with other laboratories, in vivo 
siRNA delivery does not result in 100 % uptake (McCaffrey et al. 2002) (Figure 38). 
3.3.3 The necessity of HIF-l a in xenon-induced 
erythropoietin expression 
Next, we investigated whether xenon-induced expression of EPO is 
dependent on the transcriptional activity of xenon-induced HIF-1a. Mice were 
injected with HIF-1 a siRNA, scramble siRNA or PBS, 24 hours prior to xenon 
preconditioning (75 % xenon with 25 % oxygen for 2 hours). Control mice received 
PBS injection 24 hours before exposure to 75 % nitrogen for 2 hours. Mice were 
sacrificed 24 hours after, and expression of renal HIF-1a and EPO protein were 
detected by Western blot and compared to controls. HIF-la expression in the 
kidney was increased 24 hours after xenon exposure in mice pretreated with PBS 
(2.11 +/- 0.42 versus 1.0 of control, p<0.05, or nonsense siRNA injection (2.23 +/- 
0.51 versus 1.0 of control, p<0.05). However, xenon preconditioning failed to 
induce HIF-la expression in mice pretreated with HIF-la siRNA (Figure 39). 
Similarly, EPO expression was increased 24 hours after xenon preconditioning in 
mice pretreated with PBS (2.01 +/- 0.37 versus 1.0 of control, p<0.05) or nonsense 
siRNA (1.9 +/- 0.49 versus 1.0 of control). EPO expression was not induced 
following xenon preconditioning in mice pretreated with HIF-1a siRNA (n=5 per 
group) (Figure 40). 
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Figure 38. Functional effect of HIF-la siRNA in the mouse kidney 
Reverse transcription-polymerase chain reaction (RT-PCR) was used to assess the 
functional effect of in vivo HIF-la siRNA delivery into the renal parenchyma. Twenty-four 
hours following a single hydrodynamic tail vein injection of HIF-1a siRNA (50 pg in 2 mL 
PBS, or volume-matched nonsense siRNA or PBS), expression of both HIF-1a mRNA and 
EPO mRNA were decreased, confirming the functional efficacy of HIF-1a siRNA. Results 
were normalised to the loading control, HIF-1ß mRNA, which is constitutively expressed. 
Abbreviations: EPO, erythropoietin; HIF-1 a, hypoxia-inducible factor-1 alpha; HIF-1 ß, 
hypoxia-inducible factor-1 beta; PBS, phosphate-buffered saline; siRNA, small interfering 
RNA. 
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Figure 39. HIF-1a siRNA attenuates xenon-induced HIF-1a protein expression 
in the mouse kidney 
Western blotting was used to determine the effect of HIF-la siRNA on xenon-induced HIF- 
1a protein expression in the mouse kidney. Twenty-four hours following a single 
hydrodynamic tail vein injection of HIF-1 a siRNA (50 pg in 2 mL PBS, or volume-matched 
nonsense siRNA or PBS), mice were exposed to 75 % xenon, or nitrogen, for 2 hours. 
Twenty-four hours following gas exposure, HIF-1a siRNA attenuated the protein expression 
of xenon-induced HIF-1 a (0.78 +/- 0.36 versus 2.1 +/- 0.42 of xenon alone, p<0.05). 
Western blots of HIF-1a were normalised to the internal control HIF-1ß, and expressed 
relative to the control (PBS-injected mice exposed to 75 % nitrogen). Data are presented as 
means +/- SDs. *p < 0.05 versus control (n=5 per group). Abbreviations: HIF-1 a, hypoxia- 
inducible factor-1 alpha; HIF-1 ß, hypoxia-inducible factor-1 beta; PBS, phosphate-buffered 
saline; SD, standard deviation; siRNA, small interfering RNA. 
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Figure 40. HIF-l a siRNA attenuates xenon-induced erythropoietin protein 
expression in the mouse kidney 
Western blotting was used to determine the effect of HIF-1 a siRNA on xenon-induced EPO 
protein expression in the mouse kidney. Twenty-four hours following a single hydrodynamic 
tail vein injection of HIF-1a siRNA (50 pg in 2 mL PBS, or volume-matched nonsense siRNA 
or PBS), mice were exposed to 75 % xenon for 2 hours (or 75 % nitrogen). Twenty-four 
hours following gas exposure, HIF-1a siRNA attenuated the protein expression of xenon- 
induced EPO (1.1 +/- 0.29 versus 2.01 +/- 0.37 of xenon alone, p<0.05). Results were 
normalised to the internal control HIF-1 ß, and expressed relative to the control (PBS-injected 
mice exposed to 75 % nitrogen). Data are presented as means +/- SDs. 'p < 0.05 versus 
Lantrol (n=5 per group). Abbreviations: EPO, erythropoietin; HsiR, HIF-1 a siRNA, NsiR, 
-ioresernse siRNA; PBS, phosphate-buffered saline; SD, standard deviation; 
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13.4 The necessity of HIF-1 a in xenon preconditioning 
versus renal ischaemic-reperfusion injury 
Previous experiments established the capability of xenon preconditioning to 
piutect against cerebral HI injury (Ma et al. 2006). This study investigated xenon in 
the kidney, and aimed to determine the necessity of HIF-1a for xenon 
w-vres. r, nditioning against renal ischaemic-reperfusion injury (IRI) in mice, using an 
injury model of unilateral clamping of the renal pedicle for 25 minutes. Having 
k. >ý rd the efficacy of HIF-la siRNA at abrogating xenon-induced HIF-la 
tra. ,, _ýcnption, expression and downstream activity, it was investigated whether the 
ren Fr. rotective effect of xenon could be abolished by knocking down HIF-1a. As 
lf-. r. ribed previously, mice were hydrodynamically injected with HIF-1a sIRNA (50 
R. ig in 2 mL PBS), nonsense siRNA or PBS. Twenty-four hours later, mice were 
exposed to 75 % xenon or nitrogen for 2 hours. Twenty-four hours later, mice were 
, nrured by unilateral clamping of the renal pedicle for 25 minutes, or sham-operated 
without injury. Twenty-four hours after renal IRI, kidneys were harvested for 
histological assessment, and blood collected for determining serum creatinine and 
yea levels as a measure of renal function. Morphological evidence of renal IRI was 
assessed using a histopathological scoring assay of cortical tubular damage by an 
pnvvestigator who was unaware of the experimental protocol. Controls (PBS-injected, 
rotr ogen-exposed, sham-operated) showed normal histology. Following IRI, 
histology revealed massively dilated tubular lumen, flattened epithelial cells that 
.t,, - r 
lacked nuclear staining or exhibited nuclear chromatin condensation 
(histological score was 259 +/- 17). Renal ischaemic-reperfusion damage was 
attenuated in xenon preconditioned mice, injected with PBS (54 +/- 19, p<0.01) or 
is sense siRNA (69 +/- 20, p<0.01). However, HIF-la siRNA with xenon 
preconditioning resulted in abrogation of the previously observed renoprotection 
6, p>0.05) (Figure 41). 
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Figure 41. Histological assessment of HIF-1a in in vivo xenon preconditioning 
versus renal ischaemic-reperfusion injury 
Morphological evidence of renal IRI injury was assessed from the analysis of 10 H&E- 
stained cortical tubular cross-sections per kidney, by using a histopathological scoring 
system ranging from 0 (no damage) to 3 (severe damage). The maximum score per kidney 
was 300 (severe damage). Photomicrographs from (A) uninjured controls displayed normal 
histology. (B) Renal IRI histology revealed dilated tubular lumen and flattened epithelial cells 
that lacked nuclear staining or chromatin condensation (histological score 259 +/- 17). (C) 
However, xenon preconditioning reduced the damage induced by renal IRI (54 +/- 19, p< 
0.01 versus IRI), an effect that was not lost by (D) nonsense siRNA prior to xenon 
preconditioning (69 +/- 20, p<0.01 versus IRI) . 
(E) HIF-1a siRNA however, attenuated the 
protective effect of xenon preconditioning (284 +/- 6, p>0.05 versus IRI). Data are 
presented as means +/- SDs and ** denotes p<0.01 versus IRI (n=6 per group). 
Abbreviations: IRI, ischaemic-reperfusion injury; HsiR, HIF-1 a siRNA, NsiR, nonsense 
siRNA; SD, standard deviation. Scale bar represents 100 µm. 
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Qualitatively, similar changes were noted in renal function following IRI; notably, the 
plasma creatinine increased following renal IRI (162 +/- 18 pM / litre) compared to 
controls (35 +/- 1.2 pM / litre). With xenon preconditioning before renal IRI, 
creatinine levels showed no significant difference from mice not subjected to renal 
injury. When xenon preconditioning was preceded by HIF-la siRNA injection, 
creatinine was significantly higher (91 +/- 58, p<0.05) than that seen in the 
uninjured mice. Similar changes were observed in plasma urea (Figure 42). 
3.3.5 The necessity of HIF-1 a in xenon-mediated attenuation 
of apoptosis in renal tubular cells 
In order to evaluate kidney damage at the cellular level, TUNEL staining was 
used to detect apoptotic tubular cells. TUNEL positive cells were almost 
undetectable in uninjured mice but were easily noted in every field in non- 
preconditioned mice following IRI (297 +/- 32); this was attenuated following xenon 
preconditioning and PBS (82 +/- 27, p<0.01) or nonsense siRNA (155 +/- 16, p< 
0.01) pretreated mice. In contrast, TUNEL positive cells in mice pretreated with HIF- 
la siRNA injection followed by xenon preconditioning were as frequently observed 
as in renal IRI animals not exposed to xenon (272 +/- 28, p>0.05) (Figure 43). 
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versus renal ischaemic-reperfusion injury 
Renal function of IRI was reflected by (A) plasma creatinine and (B) plasma urea. Serum 
creatinine in uninjured mice (group A, 35 +/- 1.2 pM/L) increased after IRI (group B, 162 +/- 
1`ý pM / L). However, xenon (with PBS or nonsense siRNA) prior to IRI decreased creatinine 
(group C and D, p<0.01 versus IRI) to levels that were not significantly different from 
uninjured controls. HIF-1a siRNA attenuated the protective effect of xenon against IRI, 
e l. -cited by an increased in creatinine (group E, 91 +/- 58, p<0.05 versus control). Similar 
dvi eyes were seen in plasma urea. Data are presented as means +/- SD. *p<0.05, ** p< 
001, versus IRI (n=6). Abbreviations: C, control; HsiR, HIF-1 a siRNA; NsiR. nonsense 
siRNA; X, xenon. 
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Figure 43. TUNEL + cells in the renal cortex after IRI 
Apoptotic renal tubular cell death, following IRI was prevented by xenon preconditioning, as 
reflected by TUNEL staining. Photomicrographs from (A) uninjured controls showed no 
TUNEL+ cells. (B) Following renal IRI TUNEL+ cells were detected in the renal cortex (297 
+/- 32). (C) Xenon preconditioning reduced the number of TUNEL+ cells (82 +/- 27 versus 
IRI, p<0.01), an effect that was not lost by (D) nonsense sIRNA prior to xenon 
preconditioning (155 +/- 16 versus IRI, p<0.01). (E) HIF-1a siRNA, attenuated the 
protective effect of xenon (272 +/- 28 versus IRI, p>0.05). Data are presented as means +/- 
SDs. ** p<0.01 versus IRI (n=6 per group). Abbreviations: IRI, ischaemic-reperfusion 
injury; HsiR, HIF-1 a siRNA, NsiR, nonsense siRNA; SD, standard deviation; TUNEL, 
terminal deoxynucleotidyl transferase biotin - dUTP nick end labelling. 
Imperial College London Page 154 of 230 July 2008 
Ta Lim 
3.3.6 The necessity of HIF-l a in xenon preconditioning 
versus renal failure 
Following unilateral renal injury, the other kidney remained uninjured so mice 
did not suffer from the consequences of renal failure. To assess whether xenon 
preconditioning was also effective in the context of a more severe insult to renal 
function, further experiments were performed in which the right renal pedicle was 
clamped for 40 minutes and the left kidney was removed. Long-term survival (no 
signs of illness at 7 days) was noted in 75 % of mice exposed to xenon prior to 
severe renal IRI. In contrast, mice not exposed to xenon, or exposed to xenon 
combined with HIF-1 a siRNA fared much worse. Within 2 days, 38 % of these mice 
had died (either spontaneously or euthanised because of severe ill health measured 
against defined criteria) and no mice survived beyond 5 days after renal IRI (p < 
0.001 versus xenon preconditioning) (Figure 44). The mean value of plasma 
creatinine and urea rose more than 10-fold at day 2, just prior to termination, 
following renal IRI. Mice pretreated with xenon exhibited normal creatinine and urea 
values even at 7 days after IRI. 
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Figure 44. Kaplan-Meier survival curve 
The effect of HIF-1 a in xenon preconditioning in long-term survival was assessed in the 
more severe injury model of renal failure, with 40 minutes of ischaemia to the right kidney as 
well as left nephrectomy. In the injury alone group, only 62 % of mice survived beyond day 2 
after injury, with no mice surviving beyond day 5. Xenon preconditioning with PBS or 
nonsense siRNA improved the survival (75 % and 62 % at day 7, respectively). The 
protective effect of xenon was lost in HIF-1 a siRNA- treated mice, with 62 % surviving 
beyond day 2, but none surviving beyond day 6 (n= 8 per group). Abbreviations: IRI, 
ischaemia reperfusion injury. 
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4,1 REGULATION OF HIF-1 a BY XENON 
PRECONDITIONING 
Xenon, derived from the Greek for "strange one, " is so called to denote its 
rarity in the atmosphere, and its inability to take part in chemical reactions which 
rE: nders it a noble gas in the periodic table of chemical elements. Of great 
a1_, cination, however, is that although chemically inert, xenon exerts physiological 
, ý1ects of anaesthesia and analgesia, displaying many of the hallmarks of the ideal 
inhalational anaesthetic agent (Sanders, Franks & Maze 2003), for example, a rapid 
ý_, riset and offset of action and lack of haemodynamic and cardiovascular side 
' , cts (Sanders, Ma & Maze 2005). Further to this, there is increasing experimental 
c,,, Oence of the salutary effects of xenon in mediating organ protection, against 
nute neuronal injury (Homi et al. 2003, Ma et al. 2006) and against myocardial 
infarct (Weber et al. 2005a) through the phenomenon of preconditioning. Similarly, 
certain other inhalational anaesthetics display preconditioning capabilities, such as 
II soflurane (Raphael et al. 2008). However, the mechanisms of preconditioning 
reg-main to be unequivocally elucidated; in particular, the mechanism of xenon 
preconditioning is not known and has been little studied. 
l here is growing recognition for the importance of HIF-la expression in the 
mechanism of hypoxic or ischaemic preconditioning against hypoxic-ischaemic or 
ischaemic-reperfusion injury, in the brain, heart, and kidney, as well as in other 
organs and tissues (Bernhardt et al. 2007). In these settings, HIF-1 a appears to be 
the master controller of the endogenous adaptation to a more hypoxia-resilient 
phenotype orchestrating critical cell processes of survival signalling, glucose 
metabolism and transport, metabolic adaptation, vascularisation and increasing 
oxygen transport capacity. This occurs through the transcription of at least 100 
target genes that alleviate the effects of hypoxia. Indeed, hypoxic preconditioning 
Imperial College London Page 158 of 230 July 2008 
Ta Lim 
induces expression of HIF-1 a, where the level of expression positively correlates 
with the degree of protection afforded. Furthermore, several HIF-1 target genes are 
themselves capable of mediating the cytoprotective responses of preconditioning, 
such as EPO (Joyeux-Faure 2007). 
4.1.1 Xenon preconditioning regulates HIF-1 a protein 
expression 
The molecular mechanisms at play in xenon-mediated adaptation to 
hypoxia-ischaemia, and the contribution of HIF-1a to xenon preconditioning have, 
so far, remained unknown. Therefore, this is the first study to provide evidence that 
xenon exposure increases HIF-1a protein expression. Firstly, hypoxia was 
demonstrated to increase HIF-la protein expression in all experimental models 
used, a finding that is in line with that of other laboratories; this, therefore, 
necessarily validated the results obtained thereafter. Next, it was demonstrated that 
xenon exposure could increase HIF-1a protein expression, and this increase 
occurred in vitro as well as in vivo, which is of greater clinical relevance. The effect 
of xenon was not tissue-specific, inducing expression of HIF-la in both of the 
organs tested, the brain and the kidney. Xenon exposure increased HIF-la 
expression in a time-dependent manner, with maximal expression occurring after 24 
hours. Importantly, the xenon-induced increase in HIF-1 a occurred without hypoxia 
or ischaemia, and is sustained even after removal of xenon stimulation. This is 
dissimilar to hypoxic induction of HIF-1 a, where expression is immediate but 
transient, disappearing upon reoxygenation. Furthermore, xenon increased 
expression of the HIF target genes EPO and VEGF, at the transcriptional and 
translational level, over a time course relevant to HIF-1 a induction by xenon. In 
addition, these findings are not an effect of anaesthesia per se, since exposure to 
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another anaesthetic gas, nitrous oxide, did not induce changes in HIF-la 
expression. 
4.1.2 Normoxic regulation of HIF-1 a 
Interestingly, there is growing evidence displaying induction of HIF-1 a by 
normoxic stimuli, in a cell-specific manner (Semenza 2005), and this occurs to a 
comparable degree to hypoxia-induced HIF-1a. These data reveal that xenon is a 
reliable and robust normoxic stimulator of HIF-la protein expression, where 
induction of HIF-1a by xenon is applicable to different organs, including the brain 
and kidney. Although xenon preconditioning has been demonstrated in the rat heart, 
xenon-induced HIF-1 a in the heart of mice or rats has not been studied. 
4.1.3 Mechanisms of regulating HIF-1 a protein expression 
Although no other laboratories have investigated the effects of xenon 
preconditioning on HIF-1a induction, evidence of plausible mechanisms for 
induction of HIF-la may be gleaned from other normoxic HIF-la inducers, such as 
IGF-1 (Fukuda et al. 2002), insulin (Treins et al. 2002) and human epidermal growth 
factor receptor 2 (HER2) (Laughner et al. 2001). Another inhalational anaesthetic 
with preconditioning properties, isoflurane, has more recently also been 
demonstrated capable of inducing HIF-1a, in a hepatoma cell line, Hep3B (Li et al. 
2006) and in the hearts of rats (Wang et al. 2006) and rabbits (Raphael et al. 2008). 
Evidence from these and other studies suggest the involvement of HIF-la 
translational pathways, including mTOR-dependent (Raphael et al. 2008) and P13K- 
dependent growth signalling pathways (Laughner et al. 2001, Uchiyama et al. 
2004). Other studies on xenon preconditioning have suggested the involvement of 
MAPK signalling (Weber et al. 2005a, Weber et al. 2006a) in reducing myocardial 
infarct size in the rat. However, Weber and colleagues have not explored the 
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possible involvement of the MAPK pathways in the brain or kidney, nor looked at 
HIF-la expression in their paradigms. Further investigation will be required to 
explore the relationship between xenon-induced HIF-1 a and MAPK activity, and 
whether these pathways may cross-talk to exert their protective effects. A more 
detailed discussion on the mechanisms of xenon-induced HIF-la may be found in 
discussion 4.2. 
4.1.4 HIF isoforms 
It should be stipulated that the effect of xenon on HIF-2a or HIF-3a has not 
been assessed in these studies. At the time of starting these experiments, the 
important role of HIF-1 a for protection against hypoxia was apparent and, therefore, 
the investigation into its possible relevance to xenon preconditioning. However, the 
contribution of HIF-2a or HIF-3a at that time remained to be further elucidated. HIF- 
1a was the original HIF isoform identified, through its ability to regulate oxygen- 
sensitive EPO gene transcription. HIF-2a and HIF-3a were later identified, through 
homology screening for putative HIF-1 ß partners (Wiesener et al. 1998) (Talks et al. 
2000). HIF-3a differs in function and expression pattern to either HIF-la or HIF-2a; 
it appears to antagonise, rather than promote, HRE-dependent gene expression 
and, although it is believed to be present in all tissues, is expressed to a lesser 
degree (Makino et al. 2001). HIF-2a is closely related to HIF-1a, and interestingly, 
inactivation of each of these isoforms results in a distinctly different phenotype, 
indicating that they play non-redundant roles. Both isoforms are expressed in all 
tissues and are now believed to each have distinct transcriptional targets but, at this 
current point in time, remains to be more fully understood. 
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Additionally, it must be noted that a number of experiments conducted later in this 
thesis have employed HIF-1ß as an internal control, rather than the more commonly 
. 1sed control, a-tubulin. Both HIF-1 ß and a-tubulin are suitable internal controls, as 
both are ubiquitously expressed by all cells and remain unchanged by experimental 
conditions. Therefore, the switch to using HIF-1 ß does not affect or jeopardise the 
reliability of the results but was intended to add to the completeness of the HIF 
Story 
4.1.5 Anaesthetic regulation of HIF-1 a 
This current study observed no changes in HIF-1 a expression after nitrous 
oxide exposure and similarly, previous experiments demonstrated that nitrous oxide 
dd p s" not protect against acute neuronal injury (Ma et al. 2006). This result is not 
unexpected, but rather, concurs with the hypothesis that HIF-la expression 
contributes to protection. Other laboratories have also reported on the inability of 
nitrous oxide to protect, where it may even exacerbate injury (Pagel, Warltier 2006). 
Frw anaesthetic properties of both xenon and nitrous oxide are attributed to their 
antagonism of the excitatory NMDA receptor. They share certain characteristics; 
both are gases that have low blood / gas partition coefficients (Goto et al. 1998) and 
Misplay good analgesic properties. Yet, the physiological effects of xenon have long 
been observed as markedly different from other NMDA receptor antagonists. For 
example, xenon is a more potent narcotic agent (1.48-fold higher) than nitrous 
oxide, in mice and in humans; rapid induction and emergence is achievable with 
xenon, and it is non-toxic and does not undergo biotransformation (Preckel et al. 
2006). As a further exemplification of the differential effects of xenon compared to 
other inhalational anaesthetics, where xenon increases HIF-1 a, halothane is found 
to block HIF-1 a protein expression (Itoh et al. 2001). Overall, these differences 
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indicate that normoxic regulation of HIF-la is not a general property of anaesthetics. 
but is dependent on the anaesthetic molecule used. 
4.1.6 Sites of action of xenon 
It becomes increasingly clear that xenon does not act at the NMDA receptor 
alone. Other xenon sites of action have been reported that may contribute to its 
anaesthetic and analgesic, as well as its protective properties, although their 
relationship to xenon-induced HIF-la is not known. Xenon may additionally reduce 
excitatory neurotransmitter release through AMPA and kainate receptors (Dinse et 
al. 2005); it favourably affects the ratio of pro-apoptotic and anti-apoptotic proteins 
(Ma et al. 2007); it is capable of opening potassium channels, including the recently 
described two-pore potassium channel; and decreases calcium influx (Weber et al. 
2006b). Xenon is also able to affect cAMP-response element binding (CREB) 
protein expression (Ma et al. 2006). Furthermore, post-treatment with xenon is also 
able to reduce neuronal damage (Dingley et al. 2006), and sub-anaesthetic doses of 
xenon are able to mediate protection in neonatal rat models, when combined with 
hypothermia (Ma et al. 2005). However, in those clinical setting where the potential 
for injury may be pre-empted, for example, in a variety of elective surgical 
procedures in which the cessation of blood supply is inevitable, protection by xenon 
preconditioning is an attractive option, in that the tolerance of the tissue may be 
raised, endogenously equipped and prepared, rendering the forthcoming insult less 
damaging. 
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4.1.7 Xenon preconditioning in human-derived cells 
Xenon neuroprotection by preconditioning of the neonatal rat brain 
demonstrated that most protection was afforded 24 hours after exposure (Ma et al. 
2006). Although the in vivo model described in this thesis is in the male adult 
mouse, the time course of xenon protection correlates with maximal xenon-induced 
HIF-1 a expression, and HIF-1 responsive genes. Other studies have demonstrated 
that the effects of preconditioning may last for up to 72 hours (Pagliaro et al. 2001). 
However, the current study did not explore the expression of HIF-1a beyond 24 
hours after xenon. Furthermore, although the mouse is an excellent experimental 
model, the results obtained from them cannot be directly extrapolated to humans. Of 
interest however, is that a further experiment demonstrated xenon to reliably 
increase HIF-1 a expression in HK2 cells, which are normal human kidney tubular 
cells, immortalised by transfection with the E6 / E7 genes of a human papilloma 
virus-16 that does not change its phenotype or function (Ryan et al. 1994). Again 
this cannot be considered equivalent, but suggests for the clinical potential of 
xenon-induced HIF-1 a effects. 
4.1.8 Xenon preconditioning regulates erythropoietin 
expression 
A mechanism of acquiring tolerance may be achieved through HIF-1 activity 
and transcription of HIF-1 responsive genes, such as EPO. The current study 
demonstrated the capability of xenon to firstly induce EPO transcription, followed by 
translation at 24 hours after xenon. These data are in agreement with different 
models; ischaemic preconditioning induced EPO transcription and translation after 
24 hours (Malhotra et at. 2006) and hypoxic preconditioning induced EPO at 48 
hours (Jones, Bergeron 2001, Bernaudin et at. 2002). Previously, EPO produced by 
the kidney was thought unable to penetrate the uninjured blood brain 
barrier (Marti 
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et al. 1997), but more recent studies have demonstrated it may do so but at 
exceedingly inconsequential levels (Banks et al. 2004). Interestingly however, brain- 
derived EPO expression has been observed, and is thought to be produced in both 
neurons and astrocytes (Bergeron et al. 2000, Bernaudin et al. 2000). This current 
study demonstrated xenon-induced EPO in the brain, but did not look specifically at 
the sites of expression. 
4.1.9 Mechanisms of erythropoietin-mediated protection 
There is a growing appreciation for the multi-potential properties of EPO. 
Numerous in vitro and in vivo studies demonstrate that the detrimental sequelae of 
hypoxic-ischaemic injury may be ameliorated by administration of EPO (Semenza et 
al. 1991). As further evidence, administration of EPO receptor inhibitors reverses 
the protective effects of EPO (Ruscher et al. 2002). Binding of EPO to its receptor 
causes receptor homodimerisation and autophosphorylation of JAK-2 (Tilbrook, 
Klinken 1999), which initiates a cascade of downstream events through several 
pathways. Firstly, the PI3K-Akt pathway is activated by EPO, and is believed to 
participate in survival after injury through inhibition of Bad and suppression of 
apoptotic cell death (Noshita et al. 2001). P13K signalling is generally considered 
necessary to EPO-mediated protection; inhibition of P13K with exogenous 
administration of wortmannin partially inhibited EPO protection (Yano et al. 2001) 
and TUNEL staining revealed the reversal of P13K-mediated reduction in apoptotic 
mechanisms (Siren et al. 2001). Secondly, the JAK2-STAT pathway is another 
means whereby EPO may be able to exert protection, through STAT5-mediated 
transcription of anti-apoptotic genes Bcl-2 and BcI-xL (Siren et al. 2001), and 
differentiation of neural progenitor cells in the brain (Wang et al. 2004b). STAT5 
knockout mice embryos are found to be severely anaemic, combined with increased 
apoptosis of erythroid progenitor cells (Socolovsky et al. 2001). 
Thirdly, EPO has 
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been demonstrated to protect against excitotoxin and nitric oxide-induced injury and 
apoptosis, through a JAK2 and NFkB cross-talking mechanism (Digicaylioglu, Lipton 
2001); EPO-mediated activation of JAK2 was shown to result in phosphorylation of 
the NFkB inhibitor, IkB, and this was associated with NFkB-mediated transcription of 
protection genes. Additionally, inhibition of JAK2, or NFkB, attenuated the EPO- 
induced protection against apoptosis (Digicaylioglu, Lipton 2001). Finally, the ERK 
pathway may possibly be under EPO control, but its role in providing protection is 
uncertain. Ruscher and colleagues determined the unimportance of ERK in 
mediating brain protection (Ruscher et al. 2002); yet, Kilic demonstrated 
neuroprotection through activation of both Akt and ERK (Kilic et al. 2005) (Figure 
45). 
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Figure 45. Possible mechanisms of erythropoietin-mediated protection 
This cartoon illustrates several EPO-mediated signalling pathways that may contribute to 
protection against hypoxic-ischaemic injury. This includes EPO-mediated activation of the 
P13K, ERK, STAT5 and NFkB pathways, which promote cell survival through increasing 
expression of anti-apoptotic factors as well as transcription of protective genes. 
Abbreviations: ERK, extracellular signal-related kinases; IKB, inhibitor of transcription 
factor NFKB; Jak2, Janus tyrosine kinase-2; NFKB, nuclear factor kappa B; P13K, 
phosphatidylinositide-3 kinase; STAT-5, signal transducers and activators of transcription 5. 
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!; ýrthermore, xenon preconditioning in the rat heart may occur through ERK (Weber 
ei al. 2006a). Interestingly, in the same way that xenon increases HIF-1a 
expression in the presence of oxygen and after removal of xenon stimulation, EPO 
is able to induce protection without its sustained expression; once EPO has initiated 
signalling through its downstream pathways, EPO may be withdrawn and protection 
=, c ý! afforded. 
4 1.10 Xenon preconditioning regulates vascular endothelial 
growth factor expression 
The current study also demonstrated the capability of xenon to induce the 
time-dependent expression of VEGF, a critical angiogenic factor and another HIF-1 
re,,, . nsive gene. Although identified as a regulator of proliferation, migration and 
permeability of endothelial cells, VEGF may also contribute to organ protection 
(flosthuyse et al. 2001). Systemic hypoxia induces VEGF expression in all organs 
of the mouse, with greatest induction in the brain, followed by the kidney (Marti, 
sau 1998). Ischaemia also induces VEGF, in the ischaemic penumbra (Leker et 
ale 2001). Similar to EPO, VEGF signalling is associated with the P13K / Akt 
(g-' man et al. 1999) as well as the ERK pathway (Kilic et al. 2006) and may exert 
protection through activation of these pathways. However, the promoter region of 
the VEGF gene contains additional sites to the hypoxia-responsive element; this 
mclude sites for early growth response factor-1 (Egr-1) (Vidal et al. 2000), Sp1 
(, i; ama et al. 2002), mothers against decapentaplegic homolog-3 (SMAD3) (He, 
Chen 2005) and activator protein-1 (AP-1) (Shih, Claffey 2001), among others. 
VEGF is therefore inducible by various molecules. In light of this, although xenon- 
°nduces expression of two target genes of HIF-1 a over a time course relevant to 
xenon-induced HIF-1a, it cannot be ruled out that their induction is through a HIF-1- 
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independent mechanism. However, later experiments in this thesis investigated this 
query with the use of HIF-1 a siRNA in the mouse model of xenon preconditioning. 
4.2 MECHANISM OF XENON-INDUCED HIF-1a 
PROTEIN EXPRESSION 
This next study investigated the mechanism of HIF-la protein induction by 
xenon preconditioning, exploring the effects of xenon on HIF-la transcription, 
translation and degradation. The results show that in contrast to hypoxia, which is 
the classical HIF-1a inducer, xenon does not regulate PHD2 protein expression, 
and induces HIF-1a at a similar rate, in the presence or absence of VHL, implying 
that xenon does not affect HIF-la through post-translational degradative 
mechanisms. Neither does xenon affect transcription of the HIF-la gene. Instead, 
xenon increases expression of mTOR, a regulator of HIF-1a protein translation. 
Additionally, HIF-la expression is abrogated by rapamycin, the specific mTOR 
inhibitor, when it was administered 30 minutes prior to xenon exposure. This 
demonstrates that xenon induces HIF-1 a through mTOR-mediated translation- 
dependent mechanisms. 
4.2.1 Xenon preconditioning and HIF-1 a gene transcription 
The possibility that xenon may induce HIF-1 a expression through 
transcription was discounted, because of the lack of effect of xenon on HIF-1a 
mRNA expression in RCC4+ cells as well as in the mouse brain and kidney. This 
finding is not surprising considering that exposure to another anaesthetic 
preconditioner, isoflurane, does not affect HIF-1a mRNA either (Li et al. 2006). 
Furthermore, although there is discrepancy as to whether hypoxia, the major 
inducer of HIF-1a protein expression, may or may not induce HIF-1a mRNA 
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expression, it primarily regulates HIF-la through degradative mechanisms (Huang 
et al. 1998). 
4.2.2 Xenon preconditioning and HIF-1 a post-translational 
degradation 
Xenon was found not to affect the expression of PHD2, the prolyl 
hydroxylase believed to be the main contributor to HIF-1a degradation (Berra et al. 
2003). As a caveat, PHD2 hydroxylation activity was not assessed. However, it is 
well explored that molecular oxygen is a critical co-substrate that results in PHD2 
enzymatic activity, and this would allow for the degradation of HIF-1a during xenon 
exposure, as well as in the time period following removal of xenon. Furthermore, the 
PHDs are described as non-equilibrium enzymes, in that they do not catalyse the 
reverse reaction; the abundance of non-equilibrium enzymes is often reported as an 
important determinant of its activity (Schofield, Ratcliffe 2005). In light of this, and 
the lack of xenon-induced HIF-1a mRNA transcriptional effects, the rate of increase 
of HIF-1 a protein expression may directly reflect the rate of its protein synthesis, 
induced by xenon. Nonetheless, it is still inappropriate to reject the possibility that 
xenon may increase expression and activity of other proteins that inhibit HIF-la 
degradation, including other members of the prolyl hydroxylase family, PHD1 and 
PHD3. 
4.2.2.1 PHD2-mediated HIF-1 a degradation 
The PHD enzymes belong to the non-haem iron (Fe (II)) and 2-oxoglutarate- 
dependent dioxygenease superfamily (Bruick 2001). To date the mammalian 
genome is found to encode three related proteins, termed PHD1,2, and 3, although 
these are represented by a single gene in both Caenorhabditis elegans and 
Drosophila melanogaster (Epstein et al. 2001). Small interference RNA studies have 
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revealed a dominant role for PHD2 in regulation of HIF-1a degradation in normoxia, 
where PHD2 siRNA fully prevented HIF-la degradation in the presence of oxygen, 
with little or no effect on HIF-1a expression observed with PHD1 or 3 siRNA (Berra 
et al. 2003). Additionally, PHD2, but not PHD1 or 3, contains an N-terminal zinc 
finger `MYND' that is also found in the Caenorhabditis elegans PHD equivalent, 
EGL-9 (Taylor 2001). Interestingly, PHD2 is strongly induced by hypoxia, so that 
immediately upon reoxygenation, HIF-1 a is rapidly degraded (Masson, Ratcliffe 
2003). Furthermore, the hypoxic-induction of PHD2 is through HIF-1 a-mediated 
transcription of the PHD2 gene. That PHD2 is a HIF-1 responsive gene is intriguing, 
since these data demonstrate that xenon is capable of increasing EPO and VEGF, 
yet it does not have an effect on PHD2 expression. The reasons for this are, at 
present, unclear. A possible explanation may be due to the limitation of the end- 
point RT-PCR approach used in our experiments; although it is a suitable and 
commonly used technique for mRNA detection, this technique is relatively 
insensitive and produces semi-quantitative data and, as such, pales in reliability 
when compared to real-time RT-PCR, the most sensitive technique for mRNA 
detection and quantitation currently available. 
Alternatively, xenon's ability to differentially regulate HIF target genes may be due to 
the fact that xenon is capable of inducing other mechanisms, and EPO, VEGF and / 
or PHD2 may be additionally regulated by HIF-1-independent pathways. Firstly, this 
may be exemplified through the observations that HIF-la siRNA decreased 
expression of xenon-induced EPO, but it did not result in complete abrogation; this 
may be because of less than 100 % HIF-1a siRNA efficiency, and / or indicative of 
HIF-1-independent EPO expression. Secondly, xenon may be capable of inducing 
other members of the HIF system, including HIF-2a and HIF-3a, since all the HIF 
isoforms are biologically active and play non-redundant roles, as demonstrated by 
mouse knockouts; to achieve this, xenon may be regulating other signalling 
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pathways that results in the coordinated activity of each of these isoforms, inducing 
a different phenotype to that induced by hypoxia. Thirdly, the different phenotypes 
produced by hypoxia or xenon may be due to effects wider than their effects on the 
HIF system, where the HIF system may form just a partial contribution to their 
overall phenotype. Lastly, HIF-1 transcriptional activity is also dependent on 
recruitment of other molecules to the HRE of genes, such as p300 (Gray et al. 
2005), to form a transcription complex; xenon may cause the differential recruitment 
of these other molecules to the EPO, VEGF or PHD2 gene, that may result in their 
distinct expression profiles. Although the differential regulation of xenon-induced 
PHD2 and other HIF-1 target genes is currently enigmatic and requires further 
investigation, the current study corroborates findings from other laboratories, that 
normoxic HIF-1 a induction occurs, not through degradation, but through protein 
synthesis. 
4.2.2.2 VHL-mediated HIF-1 a degradation 
Another essential component of the HIF-1 a degradation pathway is VHL. 
VHL recognises PHD2-mediated hydroxylated HIF-1a that results in formation of an 
E3 ubiquitin ligase complex and hydroxylated HIF-1a polyubiquitination (Kallio et al. 
1999). To further understand the role of xenon in HIF-1 a degradation, the effect of 
xenon-induced HIF-1 a was explored using two RCC4 cell lines that were either 
VHL-deficient (RCC4-), or stably transfected with VHL (RCC4+). Experiments 
described in this thesis demonstrated that HIF-la induction by xenon occurs at a 
similar rate in the absence or the presence of VHL. Therefore, the finding that xenon 
does not affect PHD2 expression and increases HIF-la through VHL-independent 
mechanisms, suggests that xenon does not regulate HIF-1a at the post-translational 
degradation level. This is further supported by the observation that xenon increases 
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HIF-1 a in normoxic conditions, and HIF-la expression continues to rise, in the 
pý F; sence of oxygen, after the withdrawal of exposure to xenon. 
4.2.3 Xenon preconditioning and HIF-1 a translation 
The results of the current study demonstrated that xenon exposure induces 
-xpression of the mammalian target of rapamycin (mTOR) in an in vitro model, 
using RCC4+ cells. mTOR expression occurs from 2 hours after xenon exposure, 
vwith striking induction occurring after 24 hours. This result is important as mTOR is 
a possible upstream regulator of HIF-la protein expression and may be the signal 
t. arisducer for xenon's effect on HIF-1a. Accordingly, these experiments also 
demonstrated that the specific mTOR inhibitor rapamycin was able to abrogate 
expression of xenon-induced HIF-1 a, thereby showing an essential role for mTOR in 
i ! fr 1a induction. These results are in line with a recent investigation demonstrating 
that isoflurane preconditioning increases HIF-la in the rabbit heart, through a 
rapamycin sensitive pathway; interestingly, rapamycin administration also resulted 
in abolishing the isoflurane-mediated cardioprotection (Raphael et al. 2008). 
Although our study is the first to demonstrate xenon preconditioning induces HIF-1a 
through mTOR, the recent elucidation from these isoflurane preconditioning studies 
lends support for the involvement of HIF-1 a as a key mediator, not only in hypoxic 
preconditioning, but in other preconditioning paradigms also. The results obtained 
on our current study, however, are relevant to RCC4+ cells. Renal cell carcinomas 
ire thought to be neoplastic due to VHL deficiency (Krieg et al. 2000), and therefore 
stable transfection of VHL (to form RCC4+) should restore the wild-type phenotype. 
However, the use of any cancer cell line still raises issues of translatability to the 
physiological mechanisms involved, because the processes occurring in neoplastic 
cells differ in many respects to normal primary cells in culture. Therefore, the 
involvement of mTOR was validated in the mouse brain and kidney, where 
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rapamycin administration to mice was also found to abrogate expression of HIF-1a 
following xenon exposure. Although these results cannot be directly extrapolated to 
the mechanisms involved in humans, this is a more clinically relevant model. 
4.2.3.1 mTOR-mediated HIF-1 a protein translation 
Although evidence has begun to gather in the last couple of years, very little 
is still known about the molecular targets involved in xenon preconditioning. The 
serine-threonine protein kinase, mTOR, is a key component of the P13K / Akt / 
mTOR pro-survival signalling pathway, where it plays a regulatory role in integrating 
signals from growth factors, nutrients and cellular energy levels, to stimulate cell 
growth and proliferation, through mRNA translation initiation and protein synthesis 
(Gingras, Raught & Sonenberg 2001). Through the inhibitory effects of rapamycin, 
the current study demonstrated that HIF-1a is a downstream target of mTOR 
signalling. Several preconditioning studies have demonstrated the recruitment and 
activation of mTOR in mediating protection, for example, in ischaemia- (Kis, Yellon 
& Baxter 2003) or insulin- (Jonassen, Mjos & Sack 2004) induced preconditioning; 
furthermore, rapamycin inhibited their protective effects. 
4.2.3.2 Rapamycin inhibition of mTOR-mediated HIF-la protein 
translation 
Rapamycin, also known as sirolimus, is a macrolide compound obtained 
from Streptomyces hygroscopicus (Sehgal 2003), and is a relatively new 
immunosuppressant drug, clinically approved for use in prevention of organ 
rejection after transplant surgery. Additionally, it also possesses both anti-fungal 
and anti-neoplastic properties (Sehgal 2003), and has more recently been 
associated with anti-depressive-like effects in mice and rats (Cleary et at. 2008) . 
Mechanistically, however, rapamycin acts as the specific inhibitor of the serine- 
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threonine protein kinase, mTOR; to achieve its inhibition, rapamycin combines to 
the FK506 binding protein-12 (FKBP-12), that associates directly with the mTOR / 
p70 S6 kinase complex, and prevents downstream activity of mTOR (Asnaghi et al. 
2004). The inhibitory effect of rapamycin on HIF-1 a expression, as described in this 
thesis, is also exemplified in its recent approval for use as an anti-cancer treatment, 
in HIF-la-expressing tumours(Belozerov, Van Meir 2005). 
Curiously, a recent paper by Khan et al. have reported that rapamycin can itself 
confer preconditioning-like protection against ischaemia-reperfusion injury in 
isolated mouse myocytes (Khan et al. 2006). These findings are difficult to reconcile 
with data from other investigators (Hausenloy, Yellon 2006, Jonassen, Mjos & Sack 
2004, Kis, Yellon & Baxter 2003) including ourselves. Although our study did not 
investigate the effect of rapamycin on xenon-mediated protection, we did 
demonstrate that rapamycin abrogates xenon-induced HIF-la, and that HIF-la 
plays an important role in xenon-mediated protection; this latter finding 
demonstrated that HIF-la siRNA results in the loss of xenon's protective effects, 
and would suggest that rapamycin would worsen, rather than confer, xenon- 
mediated protection against injury. Khan's results may reflect differences in 
experimental models, where they used isolated mouse hearts rather than the intact 
animal. The results may also be dependent on the preconditioning and injury 
paradigm used: rapamycin was administered 30 minutes prior to removal of the 
heart, exposed to ischaemia for 20 minutes, and reperfused for 30 minutes before 
infarct size was assessed. Administering rapamycin 30 minutes prior to injury is an 
atypical preconditioning paradigm, as is the time used for reperfusion; as such, the 
observed reduction in infarct size does not reflect any later expansions of the infarct. 
Although these results are enigmatic, they are worth considering as they may 
provide insight into, as yet, novel and unexplored mechanisms of protection. 
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4.2.3.3 Administration of rapamycin 
Several caveats need to be considered. Rapamycin at 25,50 and 100 nM 
concentrations were used in the in vitro model because these doses have been 
shown to inhibit mTOR. However, the dose-response relationship to rapamycin in 
RCC4+ cells was not performed in this study, and these data suggest that lower 
concentrations of rapamycin may still be effective at inhibiting HIF-la expression. 
Although rapamycin is described as a specific inhibitor of mTOR activity, it cannot 
be excluded that it may interact with the activity of other protein kinases that may 
also have an effect on HIF-1 a expression. In the mouse model, rapamycin 1.5 mg / 
Kg, IP, significantly reduced xenon-induced HIF-1a expression in the brain and 
kidney. However, other preconditioning studies have observed mTOR inhibitory 
effects with rapamycin doses of 0.25 mg / Kg (Raphael et al. 2008). At this lower 
dose, our study observed a trend towards decreased HIF-1 a expression, but without 
significance. Explanations for these differences may be related to the animal model 
and species, the organ of study, differing effects of preconditioning agents and 
paradigms, as well as the route of drug administration. Firstly, our study has used 
C57BL6 mice to investigate the effects of xenon preconditioning in the brain and 
kidney, whereas other studies demonstrating a role for mTOR in preconditioning 
have used rats or rabbits to study the effects of isoflurane in the heart. Furthermore, 
taking into consideration that the half-life of rapamycin in mice is 4.5 hours (Rivera 
et al. 1999) and over 5 hours in rats (Trepanier et al. 1998), the time course of our 
investigation, from rapamycin administration to organ harvesting was 26.5 hours 
(rapamycin administration, 30 minutes of stabilisation, 2 hours of xenon exposure, 
24 hours rest, organ harvesting), compared to much shorter time courses employed 
by others, such as 5 to 6 hours (Raphael et al. 2008). Additionally, other 
preconditioning studies have administered rapamycin intravenously, compared to 
the intraperitoneal route chosen for use in experiments described in this thesis. 
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Doses of rapamycin 0.5 - 1.5 mg / Kg, IP, have previously been used and 
demonstrated effective at inhibiting mTOR (Lang et al. 2007). Nonetheless, these 
pharmacological data do suggest an important requirement for mTOR signalling in 
xenon-induced HIF-1 a. 
4.2.3.4 Effects of DMSO in vivo 
Surprisingly, the current study observed the ability of the rapamycin solvent, 
DMSO, to increase expression of HIF-1a in a concentration-dependent manner, a 
finding that has not yet been reported by other investigators. The nanomolar 
concentrations of rapamycin used in the in vitro setting, with 0.0025 % DMSO, was 
not enough to alter expression of HIF-1 a. However the higher concentrations of 
rapamycin used in mice, necessitated the use of higher concentrations of DMSO 
(0.1 %), which may account for the constitutively higher background expression of 
HIF-1a, observed in the Western blots of the rapamycin-treated mouse samples. 
Although DMSO-induced HIF-1a expression was a confounding factor, the ability of 
rapamycin to inhibit xenon-induced HIF-la was still evident, occurring 
independently to the DMSO-induced HIF-la expression. Another solvent of 
rapamycin, ethanol, was not chosen, as it may itself contribute to preconditioning 
(Wang et al. 2007) and induction of the HIF target gene, VEGF (Gu et al. 2001). 
Furthermore, rapamycin is less soluble in ethanol than DMSO, which would 
necessitate the use of even greater concentrations. 
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4.23,5 Upstream of the mTOR pathway 
Importantly, it is still not known at what upstream juncture in the mTOR 
,,, away xenon converges on. However, putative molecular targets may be gleaned 
from the increasing number of studies in hypoxic or ischaemic preconditioning. 
Activation of P13K and Akt, molecules that are upstream of mTOR and stimulated 
via tyrosine kinase receptors, have been suggested to play protective roles in 
, _. riaemic preconditioning of 
the myocardium (Raphael, Rivo & Gozal 2005), as well 
is the brain, where the P13K inhibitors LY294002 or wortmannin have been shown 
to reverse the protective effects of ischaemic preconditioning; these P13K inhibitors 
J, .; ked the reduction 
in myocardial infarct size in rats as well as the increase in 
phosphorylation and thus activation of Akt (Mocanu, Bell & Yellon 2002). 
Fca, `"ýh(, rmore, consistent with the role of the P13K / Akt / mTOR pathway in 
pri vcAnditioning, tyrosine kinase receptor agonists, such as insulin and IGF-1, are 
able to induce preconditioning-mediated protection (Fukuda et al. 2002). P13K / Akt / 
mTOR signalling is thought to contribute to protection through inhibition of the pro- 
ipc)ptotic proteins Bad, Bax and caspase-9 (Raphael et al. 2006), as well as 
t. nrough mediating eNOS-derived NO production (Zaugg et al. 2003). However, 
recent elucidations reveal that mTOR activity may also be mediated through P13K- 
independent pathways including one that may involve ATP. 
4236 mTOR-independent pathways 
Further adding to the complexity of preconditioning, HIF-1 a may be 
regulated through mTOR-independent mechanisms, which instead relies on 
iý iiolvement of members of the MAPK family, such as ERK (Roux, 
Blenis 2004). 
ERK takes part in intracellular transduction pathways to relay extracellular signals 
within cells. It has been reported to contribute to ischaemic preconditioning 
(Fryer, 
ý 1su & Gross 2001) and interestingly, both ERK and p38 MAPKs are demonstrated 
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to play a time-dependent role in xenon preconditioning of the rat heart. Furthermore, 
the role of ERK in isoflurane preconditioning of the rat heart was demonstrated to 
influence HIF-1a protein expression, where isoflurane-induced HIF-1o was 
abolished in the presence of the ERK inhibitor PD098059 (Wang et al. 2006). A 
more recent investigation studying both ERK and Akt, has demonstrated that 
hypoxic preconditioning results in phosphorylation and activation of both of these 
kinase pathways in mesenchymal stem cells, which is also associated with an 
increase in VEGF expression (Wang et al. 2008a); however, the effect of inhibition 
of either of these kinases on VEGF expression was not ascertained by these 
investigators. Alternatively, mTOR-independent yet P13K-dependent pathways may 
also exist. P13K / Akt signalling may additionally activate PKC, another protein 
kinase that is implicated in ischaemic (Chachami et al. 2004). and anaesthetic 
(Bergeron et al. 2000) preconditioning; moreover, PKC has also been shown to 
increase HIF-1 a (Page et al. 2002). 
It is believed that these different intracellular pathways are complementary to each 
other through cross-talking mechanisms, and preconditioning exerts its protection 
by manipulating multiple stress responsive pathways. However, the pathways 
employed and their actions on HIF-1 a may be cell type-and-stimulus specific; 
furthermore, different cell types may express distinct combinations of each of these 
signalling proteins. Continued investigation will be required to unravel the intricacies 
of these intracellular signalling pathways and to ascertain their relevance to xenon 
preconditioning. 
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4.3 NECESSITY OF HIF-1 a IN XENON 
PRECONDITIONING VERSUS RENAL ISCHAEMIC - 
REPERFUSION INJURY 
The ability of xenon to precondition and protect the neonatal rat brain from 
acute neuronal injury has previously been demonstrated (Ma et al. 2006) but the 
mechanism of protection remains to be elucidated. It is known that the 
heterodimeric transcription factor HIF-1 plays an essential role in mediating tissue 
adaptation and tolerance to hypoxia, and is an important mediator of hypoxic 
preconditioning. This is by virtue of its ability to regulate transcriptional activity of 
over a hundred genes that take part in prosurvival mechanisms. Notably, it is the 
expression and stabilisation of the HIF-l a subunit that is the determinant of 
transcriptional activity of HIF-1. As such, the experiments aimed to explore whether 
HIF-1a is necessary for xenon preconditioning. Recently, HIF-la has been shown to 
be upregulated by another anaesthetic gas, isoflurane, in a Hep3B cell line (Li et al. 
2006) as well as by isoflurane preconditioning in the rabbit heart (Raphael et al. 
2008). However, to the best of our knowledge, this current study is the first to 
demonstrate, under normoxic conditions, the capability of xenon to induce sustained 
expression of HIF-la and its downstream effectors, EPO and VEGF compared to 
nitrogen controls, in vitro as well as in vivo, in the mouse brain and kidney. 
Furthermore, we have investigated the necessity of HIF-1 a in xenon preconditioning 
against ischaemia-reperfusion injury, through the use of siRNA technology. SiRNA 
was chosen to knockdown HIF-la in mice, as HIF-1a knockout mice are not 
available, owing to embryonic lethality. Conditional HIF-la knock-out mice are 
available, but were not chosen, due to unknown compensatory mechanisms that 
these mice may display. Additionally, siRNA technology is a relatively cost-effective 
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technique that results in specific knockdown of its putative target. The current study 
explored the necessity of HIF-la participation in xenon preconditioning; as a proof 
of concept experiment we have addressed this question in the mouse kidney, in a 
previously established model of renal ischaemia-reperfusion injury. 
4.3.1 Delivery and function of in vivo siRNA 
Our experiments showed that administration of 3'-fluorescein-labelled 
nonsense siRNA through a single hydrodynamic tail vein injection in the mouse 
results in the presence of siRNA in the renal parenchyma 24 hours later, thereby 
demonstrating the efficient delivery of siRNA to the desired tissue under 
investigation. Furthermore, 24 hours following administration of HIF-1 a siRNA, 
mRNA expression of both HIF-1a and its downstream target EPO were significantly 
decreased, when compared to non-treated control mice, as well as nonsense siRNA 
or PBS -injected control mice. This demonstrated that upon efficient siRNA delivery 
into the renal parenchyma, HIF-1a siRNA is capable of silencing HIF-1a gene 
expression. Additionally, the silencing of HIF-la results in attenuation of EPO 
mRNA expression, thereby demonstrating that EPO is, at least in part, dependent 
on HIF transcriptional activity. 
4.3.2 Necessity of HIF-1 a in xenon-mediated erythropoietin 
As described in discussion 4.1, xenon preconditioning increases expression 
of EPO at both the transcriptional and translational level, over a time course that is 
relevant to xenon-induced HIF-1a. Additionally however, the use of siRNA directed 
against HIF- la further enhances knowledge, by showing that HIF-la siRNA 
attenuates the xenon-induced expression of both HIF-1 a and EPO, providing 
evidence that xenon-induced EPO occurs, at least in part, through HIF-1 
transcriptional activity in the mouse kidney. 
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4.3.3 Necessity of HIF-1 a in xenon preconditioning against 
renal ischaemia-reperfusion injury 
In the context of renal ischaemia-reperfusion injury, xenon preconditioning 
resulted in a 4-fold reduction in the degree of ischaemic damage, according to 
histological data; importantly, HIF-1 a siRNA injection prior to xenon preconditioning 
resulted in ischaemic damage that was not significantly different to the PBS- 
injected, untreated injury group. Similarly, renal function, as measured by urea and 
creatinine levels, showed significant improvement with xenon-mediated protection, 
but this functional protection was lost with HIF-1a knockdown. Furthermore, xenon 
preconditioning decreased apoptosis of renal tubular cells following injury, detected 
through TUNEL staining, whereas HIF-1a siRNA resulted in apoptosis to the same 
degree as non-preconditioned injured mice. In the more severe injury model of renal 
failure, xenon preconditioning not only improved the survival of these mice, but renal 
function was significantly better, as measured by urea and creatinine levels; HIF-1 a 
siRNA also removed the xenon-mediated protection in this severe injury model. 
Overall, this current study demonstrated that the necessary contribution of HIF-la 
is, at least in part, responsible for the phenomenon of protection induced by xenon 
preconditioning. 
4.3.4 Regulation of erythropoietin 
Attenuation of HIF-1 a or EPO mRNA by HIF-la siRNA is not absolute and 
several caveats must be considered. As previously mentioned, oxygen-sensitive 
induction of erythropoiesis, via the prosurvival growth factor EPO, led to the 
discovery of HIF-1 a (Semenza 1994). At the time this study was initiated, EPO was 
considered a canonical HIF-la target gene and evidence of EPO expression is still 
used by many investigators as a credible representative of HIF-1a activity. However. 
since the initiation of these studies, it has come to light that the regulation of EPO 
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may riot be exclusively under the control of HIF-1a. HIF-1a and HIF-2a are both 
t ir. to bind to the HRE of the EPO (Ratcliffe 2007), and indeed, recent studies 
::; rig conditional knockouts of HIF-1 a or HIF-2a have shown that EPO is 
predominantly dependent on HIF-2a in the hepatocytes of these mice (Rankin et al. 
2( (', 7). The mechanisms driving either HIF-la or HIF-2a -mediated EPO production, 
or perhaps even both, are not fully understood. The incomplete attenuation of 
; -ion-induced EPO through HIF-la siRNA may be due to xenon mediating HIF-la- 
independent mechanisms, which have not yet been explored. Indeed, it is clear that 
xenon does not regulate HIF-1a in the same way as hypoxia-regulated HIF-1a; 
furthermore, hypoxia exerts distinct responses in the different HIF-a isoforms, which 
is h irt: her dependent on cell type and disease state of the tissue. Therefore, the 
me ` dnism of xenon-mediated protection is likely to extend beyond its effects on 
HIF -1 a and the relevance of these interesting findings to xenon preconditioning 
requires further investigation. Nonetheless, these results show that xenon 
preconditioning induces EPO, at least in part, through HIF-1a dependent 
mechanisms, in the intact kidney. 
4 705 Apoptosis and HIF isoforms 
The results from the current study demonstrate the capability of xenon 
preconditioning to reduce the occurrence of apoptosis in renal ischaemia- 
reperfusion injury in mice; this requires HIF-la activity, since HIF-la siRNA 
#ýy, »gates the protective effect afforded by xenon. However, the role of HIF-2a has 
riot been addressed in these studies, and a few remarks are worth considering. 
Interestingly, HIF-1 a appears capable of playing a dichotomous role in the response 
to hypoxia, between pro-survival and proliferation on the one hand, and pro- 
: ipoptosis and anti-proliferation on the other (Aminova et al. 2005). It may be that 
inese responses are not mediated by HIF-1a alone, but by a more complex, yet 
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coordinated, interaction between the different HIF-a isoforms, as non-redundancy of 
each isoform has been demonstrated in knockout mice. How these isoforms 
coordinate together is unclear, but examples from tumour biology may aid in better 
understanding. Non-cancerous renal tubular cells predominantly express HIF-1 a; 
yet, in clear-cell renal carcinoma, hypoxia appears to drive, not HIF-1 a. but HIF-2a 
to promote expression of anti-apoptotic proteins and proliferation for tumour growth 
(Rosenberger et al. 2002); conversely, HIF-la in these advanced tumours, appears 
to promote apoptosis (Raval et al. 2005). These observations, and other findings, 
suggest for the existence of cell, condition, and disease -specific alterations in HIF- 
1a and HIF-2a activity that is, as yet, not well understood. 
4.3.6 siRNA technology 
RNA interference through siRNA is a powerful technique for post- 
transcriptional knockdown of a specific mRNA. Due to the properties of nucleic 
acids, siRNA is subject to rapid degradation by nucleases, and do not naturally 
cross cell membranes. However, the development of techniques, such as 
hydrodynamic injection, has greatly facilitated the use of siRNA in in vivo 
experimental models. Although delivery of the siRNA may be challenging, it results 
in gene silencing with greater specificity when compared to other techniques, such 
as small molecule inhibitors or anti-sense DNA oligonucleotides. 
The use of siRNA in small mammals is relatively recent. In murine models of renal 
IRI, siRNA techniques have furthered the understanding of renal pathophysiology. 
For example, siRNA against Fas was shown to reduce renal tubular apoptosis and 
overall mortality from 90 % to 20 % (Hamar et al. 2004), and siRNA against caspase 
3 and 8 also attenuated renal IRI (Zheng et al. 2006). Interestingly, PHD2 inhibition 
increased HIF-1 a expression and activity and improved renal function (Bernhardt et 
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al. 2006). To date, no studies have investigated the effect of HIF-la siRNA in 
preconditioning against HI or IR injury of any organ. However, a study on 
intermittent hypoxia in tumours, arising from disorganised tumour vasculature, 
demonstrated that the resistance of tumours to pro-apoptotic stress could be 
attenuated using HIF-1a siRNA; this underscores the role of HIF-la in promoting 
cell survival (Martinive et al. 2006). Therefore, this current study using HIF-la 
siRNA is the first to explore and provide evidence for the necessity of HIF-1 a, in 
xenon preconditioning versus ischaemic organ injury. 
Several caveats must be considered. A major barrier in in vivo RNAi experiments is 
the difficulty in delivering the siRNA to the tissue of interest; this is due to both the 
practical expertise required as well as the need for refinement of the manufactured 
reagents. It is known that naked siRNA, as used in these studies, is more prone to 
degradation by nonspecific proteases and, therefore, less effectively delivered 
compared to coated siRNA varieties. This may account for the incomplete 
suppression of HIF-1a and EPO expression that was observed after HIF-la siRNA 
treatment. However, it may be argued that the reduction in expression, although 
incomplete, was enough to result in attenuation of HIF-la function and activity; for 
example, the renoprotection afforded by xenon preconditioning was lost (despite 
incomplete HIF-la suppression) in the presence of HIF-la siRNA resulting in 
abrogation of the protective effect of xenon. Coated siRNAs constructs also have 
their disadvantages, where they are more likely to contribute to toxicity than naked 
varieties, due to "off-target" gene silencing (Jackson et al. 2003), and have been 
reported to induce components of the host's immune response, such as activation 
of the interferon system (Hornung (2005). This naturally raises concerns over their 
unknown and unanticipated effects. 
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4.3.7 The requirement of anaesthesia for surgical 
experiments 
Anaesthesia was induced and maintained with 5% and 2% isoflurane 
respectively, in surgical experiment procedures; these included cannula 
implantation for hydrodynamic tail vein injection, clamping of the renal pedicle for 
induction of renal IRI, as well as nephrectomy. Isoflurane is one of a number of 
anaesthetic gases that is capable of inducing preconditioning, and protecting 
against ischaemic-reperfusion injury (Julier et al. 2003). It is possible that isoflurane 
may have contributed to the renoprotection observed with xenon preconditioning; 
however, animals in all experimental groups each received equipotent doses of 
isoflurane during surgery and as such, the observed differences in renal injury 
between the experimental groups is likely to be due to the effect of xenon 
preconditioning. 
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CHAPTER 5 
FINAL CONCLUSION 
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5.1 OVERVIEW OF FINDINGS 
By definition, aerobic organisms are entirely dependent on oxygen, for all 
rr, mabolic processes, including ATP formation through oxidative phosphorylation. A 
disparity between oxygen supply and oxygen demand may result in deleterious 
consequences due to hypoxia and/or ischaemia. Interestingly, cells have evolved 
highly sensitive oxygen sensors and adaptive mechanisms to respond to hypoxic- 
ischaemic (HI) challenge, through increased HI tolerance and restoration of oxygen 
homeostasis. These mechanisms, termed preconditioning, are characterised by 
iniLiry-induced protection from a subsequent more severe injury. Preconditioning is 
F ko inducible through pharmacological agents, including some anaesthetics, and as 
such, exploitation of this endogenous protective phenomenon may be applicable to 
hý ians and is putatively clinically important. 
The noble anaesthetic gas xenon displays many of the hallmarks of the ideal 
anaesthetic agent, and its neuroprotective potential, through a preconditioning 
phenomenon, has been demonstrated in an in vivo model of acute neuronal HI 
injury (Ma et al. 2006). The mechanism for xenon-mediated adaptation to HI 
nq)V prance remains unclear. The transcription factor HIF-1 plays an important role in 
hypoxia, acting as a molecular switch for adaptation to a more hypoxia-resilient 
phenotype. HIF-1 a activity induces expression of at least one hundred genes, of 
which several are capable of mediating the cytoprotective responses of 
preconditioning. Given the important roles of HIF-1 a and its target genes for 
tolerance to HI injury, this current study investigated whether xenon preconditioning 
may be exerting its protective effects through HIF-1 a. 
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Aim 1 of the experiments demonstrated the ability of xenon to induce the 
time-dependent expression of HIF-la over a 24 hour time period in normoxic 
conditions, in vitro and in vivo, and in different tissues, such as the brain and kidney. 
Greatest HIF-1 a induction occurred 8- 24 hours after exposure to xenon, a time 
course that parallels that of xenon-mediated preconditioning. This provided 
evidence that HIF-la accumulation may be a necessary component of the 
endogenous adaptation required for the protection conferred through xenon. 
Furthermore, this is different from the effect of acute hypoxia on HIF-1 a expression, 
which rapidly returns to baseline levels on removal of the hypoxic stimulus. 
Xenon exposure also time-dependently increased expression of EPO, firstly at the 
transcriptional level and subsequently at the translational level, over a time course 
that is relevant to xenon's induction of HIF-1a. This HIF target gene is itself a 
powerful neuroprotectant that is modulated by the binding of HIF to the EPO 
hypoxia-responsive element (HRE), and represents a candidate protein for 
transducing the preconditioning effects of xenon. Moreover, xenon exposure 
increased expression of VEGF, another HIF-1 target gene, providing further 
evidence that xenon-induced HIF-1a expression is functionally active and able to 
transcribe its target genes. 
Plausible mechanisms of protection by xenon-induced EPO may be through a 
phosphorylation cascade of the JAK/STAT pathway, as reported by (Sola et al. 
2005), the PI3K/Akt pathway (Ruscher et al. 2002), and/or the Ras/Raf/MEK/ERK 
pathway (Arai, Kanda & Miura 2002). Dirnagl and colleagues postulate an 
interwoven combination of these pathways to ultimately converge on end-effectors, 
such as the Bcl protein family, that inhibit apoptosis and promote cell survival, 
(Dirnagl, Simon & Hallenbeck 2003). 
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Exposure to nitrous oxide, another gas with anaesthetic properties through NMDA 
receptor antagonism, did not induce HIF-la expression at any of the time points 
studied. This suggests that xenon's effects on HIF-1a are not simply due to its 
anaesthetic properties or to its blocking activity at the NMDA receptor alone. 
Aim 2 explored the mechanism of xenon-induced HIF-1a, by investigating 
the effect of xenon on HIF-1a transcription, translation and degradation. 
Accumulation of HIF-la may occur if its rate of synthesis is superior to its rate of 
degradation, either through increased transcription and/or translation, or decreased 
degradation. 
Whereas hypoxia increases HIF-1 a through PHD2 and VHL -dependent inhibition of 
its degradation, xenon does not affect PHD2 expression at any of the time points 
studied, and is able to induce HIF-1a by the same order of magnitude in the 
presence or absence of VHL. Therefore, unlike hypoxia, xenon does not inhibit HIF- 
1a degradation, and increases HIF-la through PHD2 and VHL -independent 
mechanisms. 
The possibility that xenon may induce HIF-la expression through transcription was 
rejected, because of the lack of effect of xenon on HIF-1 a mRNA expression in both 
in vitro and in vivo models. These data corroborate the finding in the hep3B cell line 
that isoflurane, another anaesthetic preconditioner, does not affect HIF-la at the 
transcript level (Li et al. 2006). Furthermore, although there is discrepancy as to 
whether hypoxia, the major inducer of HIF-la protein expression, may or may not 
induce HIF-la mRNA expression, it primarily regulates HIF-1a through degradative 
mechanisms. 
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The best described regulator of translation of HIF-la protein synthesis is the 
mammalian target of rapamycin (mTOR), where mTOR activation results in 
downstream phosphorylation, which activates as well as disinhibits translation 
initiation proteins, of which the HIF-1 a mRNA is a target. Xenon is capable of 
increasing mTOR expression with a detectable, but not significant, increase 
occurring 2 hours after xenon exposure; 8 hours after, xenon significantly increases 
mTOR expression, with greatest expression after 24 hours. Additionally, rapamycin 
administration abrogates xenon's HIF-la inducing capability, providing evidence 
that xenon increases HIF-la through mTOR-mediated translation-dependent 
mechanisms. 
Aim 3 investigated the necessity of HIF-1 a in xenon preconditioning versus 
renal ischaemic-reperfusion injury in mice, through the use of siRNA technology 
directed against HIF-1a. First delivery of siRNA by hydrodynamic tail vein injection 
into the renal parenchyma was verified, and the functional effect of HIF-1a 
demonstrated, through the attenuation of both HIF-1a and EPO mRNA following 
siRNA treatment. Secondly, the necessity of HIF-1a in xenon-induced EPO was 
established; HIF-1a siRNA pre-treatment prevented xenon from inducing HIF-la, as 
well as EPO, providing evidence that the induction of EPO by xenon occurs through 
a HIF-dependent mechanism. 
Finally, a necessary role for HIF-1a in xenon preconditioning against renal IR injury 
as well as renal failure was elucidated. Xenon preconditioning ameliorates the 
detrimental effects of renal IR injury, both morphologically and functionally. Its anti- 
apoptotic effect following renal IR injury, measured by TUNEL staining, provides 
further evidence of xenon's powerful protective capabilities. Furthermore, xenon 
preconditioning significantly improves survival and function following renal 
failure. 
The role that HIF-la plays in xenon preconditioning is an essential one. siRNA 
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directed against HIF-1 a detrimentally attenuates the renoprotection afforded by 
xenon preconditioning, with morphological and functional outcome similar to injury 
alone. HIF-la siRNA also abrogates the anti-apoptotic effects of xenon 
preconditioning against injury, and decreases survival after renal failure. 
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5.2 FUTURE DIRECTION 
Several preconditioning mechanisms of organ protection have been postulated. 
The study into the role of HIF-1 a in xenon preconditioning is novel and contributes 
to the knowledge that is gathering in this large field. The results of this body of work 
have suggested for a number of possible subsequent experiments in which to 
further explore the mechanisms of xenon preconditioning. Some questions that 
remain to be answered include: 
" What is the effect of xenon on mTOR and HIF-1 a beyond 72 hours? 
" At what molecular juncture upstream of mTOR does xenon exert its effect? 
0 What is the effect of xenon on other HIF-a isoforms? 
0 What effect does xenon have on other signalling kinases and transcription 
factors, such as MAPKs and NFKB, and how do these pathways coordinate 
with xenon-induced HIF-1 a? 
" What are the similarities and differences in xenon preconditioning compared 
to postconditioning? 
9 What are the similarities and differences in xenon-mediated preconditioning 
compared to preconditioning by other agents, such as hypoxia or isoflurane? 
0 Is the administration of xenon in combination with other preconditioning 
agents additive or synergistic? 
" Would the use of microarrays reveal molecules pertinent to the mechanism 
of xenon preconditioning? How would this compare to hypoxic 
preconditioning? 
" What is the minimum exposure of xenon required, in terms of length of time 
as well as concentration, for the organ protective effect? 
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5.3 CLINICAL IMPLICATIONS 
Despite intensive research over several decades, there are no satisfactory 
clinical strategies to diminish the vulnerability of tissues to injury. Mitigating the 
consequences of HI, IR injury with a safe, efficacious and non-toxic agent 
represents an unmet healthcare need. 
Other than timely reperfusion, ischaemic preconditioning is acknowledged to be the 
most powerful mechanism for limiting ischaemic injury (Riksen, Smits & Rongen 
2004), providing strong impetus to identify pharmacological agents capable of 
mimicking ischaemic preconditioning. Xenon is one such agent. Xenon has been 
used safely in the clinical setting as an anaesthetic in patients of all ages for more 
than 50 years and its potent preconditioning properties combined with its powerful 
organ protective capabilities, could be put to great use in several fields of medicine, 
where there is an anticipated risk of HI or IR organ injury. Applications may include 
the use of xenon intra-operatively for procedures that carry a substantial risk of HI 
injury, such as cardiopulmonary bypass surgery, renal transplantation surgery or 
neurosurgery. Xenon may also be pre-emptively administered to expectant mothers 
in labour who have a high risk of neonatal hypoxia, such as pre-term labour. In 
addition, it has a safety profile that is unrivalled (Sanders, Franks & Maze 2003). 
Xenon, therefore, represents a promising new therapeutic strategy for reducing the 
incidence of disorders arising through HI or IR injury. Elucidation of the organ 
protective mechanism of xenon as a preconditioner is essential if it is to progress for 
safe and efficacious use in the clinical setting. 
Until recently, the high cost and scarcity of xenon have prevented its widespread 
clinical application; with refinements in production of xenon and the advent of 
xenon-conserving ventilation systems, such as closed-loop or low-flow systems, 
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financial concerns have been alleviated to a large extent. It is still probable at first, 
however, that its use will have to be reserved for high risk patients. 
Clinical translation of findings from this project will facilitate the use of xenon in 
preventing hypoxia-related injury. By understanding the mechanisms involved in 
xenon's preconditioning action, it will be possible to prioritise the clinical settings 
that are most likely to benefit from this safe and efficacious anaesthetic agent. 
Moreover, results from these experiments have established a necessary role for 
HF-1a in mediating xenon's preconditioning action; data from these studies will 
enhance our understanding of the interactions of the putative signalling cascades 
that are involved. 
Even if xenon itself were not to be clinically exploited, date from the current study 
may facilitate the discovery and development of novel chemical entities for action at 
newly identified therapeutic targets to protect against impending injury, while 
avoiding those that may promote toxicity. 
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5.4 CONCLUSION 
Xenon preconditioning time-dependently increases expression of HIF-1 a and 
its target genes, EPO and VEGF, over a time course that is relevant to xenon- 
mediated protection against acute neuronal hypoxic-ischaemic injury. The xenon- 
induced accumulation of HIF-la is sensitive to rapamycin, and occurs through an 
mTOR-mediated protein translation pathway. Xenon preconditioning is also capable 
of protecting against renal ischaemic-reperfusion injury as well as renal failure, 
reducing apoptosis, improving function after injury, as well as improving long term 
survival. HIF-la plays a necessary role in this xenon-mediated protection. The 
sufficiency of HIF-1 a alone in mediating xenon preconditioning remains to be seen. 
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